Dietary factors and low-grade inflammation in relation to overweight and obesity

Philip C. Calder1, Namanjeet Ahluwalia2, Fred Brouns3,21, Timo Buetler4,22, Karine Clement5, Karen Cunningham6, Katherine Esposito7, Lena S. Jönsson8, Hubert Kolb9, Mirian Lansink10, Ascension Marcos11, Andrew Margioris12, Nathan Matusheski13, Herve Nordmann14, John O’Brien4, Giuseppe Pugliese15, Salwa Rizkalla5, Casper Schalkwijk16, Jaakko Tuomilehto17, Julia Wärnberg11,18, Bernhard Watzl19 and Brigitte M. Winklhofer-Roob20

1. School of Medicine, University of Southampton, Southampton SO16 6YD, UK
2. INSERM U557, University of Paris, 93017 Bobigny Cedex, France
3. Cargill R&D Centre Europe, 1800 Vilvoorde, Belgium
4. Nestlé Research Centre, Vers-chez-les-Blanc, 1000 Lausanne, Switzerland
5. Department of Nutrition, INSERM U872, Research Center on Human Nutrition, Pitie Salpetriere Hospital, 75013 Paris, France
7. Division of Metabolic Diseases, University of Naples, 80138 Naples, Italy
8. ILSI Europe a.i.s.b.l., Avenue E. Mounier 83, Box 6, 1200 Brussels, Belgium
9. Research Group Immunobiology, Medical Faculty, University of Dusseldorf, 40225 Dusseldorf, Germany
10. Danone Research, Centre for Specialised Nutrition, 6700, CA, Wageningen, The Netherlands
11. Department of Metabolism and Nutrition, CSIC, Spanish National Research Council, 28040 Madrid, Spain
12. School of Medicine, University of Crete, 71409 Heraklion, Greece
13. Nutrition Research, Kraft Foods, Inc., Glenview IL 60025, USA
14. Ajinomoto Europe, 75817 Paris, France
15. Department of Clinical and Molecular Medicine, “La Sapienza” University of Rome, 00161 Rome, Italy
16. Internal Medicine, University of Maastricht, 6202 AZ Maastricht, The Netherlands
17. University of Helsinki, 00014 Helsinki, Finland
18. Department of Preventive Medicine and Public Health, University of Navarra, 31080- Pamplona, Spain
19. Max-Rubner Institut, Federal Research Centre for Nutrition and Food, 76131 Karlsruhe, Germany
20. Institute of Molecular Biosciences, Human Nutrition and Metabolism Research and Training Center, Karl-Franzens University of Graz, 8010 Graz, Austria
21. Department of Nutrition, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands
22. XeRR, Institute of Pharmacology and Toxicology, University of Zürich, 8057, 8057 Zürich, Switzerland

Commissioned by the
ILSI Europe Metabolic Syndrome and Diabetes Task Force

Correspondence: ILSI Europe a.i.s.b.l. - Avenue E. Mounier 83, Box 6 – 1200 Brussels, Belgium, fax +32 2 762 00 44, email publications@ilsieurope.be
Table of Contents

Preamble S5
Concept and markers of low-grade inflammation S5–S11
Chronic low-grade inflammation and insulin resistance S11–S13
Postprandial inflammatory response S13–S14
Ageing and low-grade inflammation S14–S15
Exercise and low-grade inflammation S15–S18
A consideration of different approaches to identify relationships between diet and its components and markers of chronic low-grade inflammation S18
Dietary patterns and low-grade inflammation S18–S28
Process-related compounds: advanced glycation end products and advanced lipoperoxidation end products S28–S37
Macronutrients and low-grade inflammation S37–S46
Micronutrients and phytochemicals S46–S52
Other factors S52–S53
Summary, conclusions and research gaps S53–S54
Acknowledgements S54–S55

(Received 20 January 2011 – Revised 8 August 2011 – Accepted 7 September 2011)

Key words: Inflammation: Cytokines: Adipose: Obesity: Diet

Correspondence: ILSI Europe a.i.s.b.l., Avenue E. Mounier 83, Box 6 – 1200 Brussels, Belgium, fax +32 2 762 00 44, email publications@ilsieurope.be

Abbreviations: AGE, advanced glycation end products; AGE-R, advanced glycation end product receptor; AHEI, alternate healthy eating index; ALE, advanced lipoxidation end products; CCL, chemokine (C–C motif) ligand; CCR, CC chemokine receptor; CFU, colony forming units; CLA, conjugated linoleic acids; CRP, C-reactive protein; DQI, Diet Quality Index; DQI-R, revised Diet Quality Index; GI, glycaemic index; GL, glycaemic load; HEI, healthy eating index; IFN, interferon; IL-1ra, IL-1 receptor antagonist; IRS, insulin receptor substrate; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MCP, monocyte chemoattractant protein; MIF, macrophage migration inhibitory factor; MIP, macrophage inflammatory protein; MRP, Maillard reaction products; NHANES, National Health and Nutrition Examination Survey; PAI-1, plasminogen activator inhibitor 1; Q, quintile; RAGE, receptor for advanced glycation end products; RANTES, regulated on activation, normal T expressed and secreted; ROS, reactive oxygen species; SAA, serum amyloid A; sE-selectin, soluble E-selectin; sICAM-1, soluble intercellular adhesion molecule-1; sP-selectin, soluble P-selectin; STAMP, six-transmembrane protein of prostate; sTNFR, soluble receptors of TNF; sVCAM-1, soluble vascular cell adhesion molecule-1; TGF, transforming growth factor; TLR, Toll-like receptors.

© ILSI Europe [2011]
Low-grade inflammation is a characteristic of the obese state, and adipose tissue releases many inflammatory mediators. The source of these mediators within adipose tissue is not clear, but infiltrating macrophages seem to be especially important, although adipocytes themselves play a role. Obese people have higher circulating concentrations of many inflammatory markers than lean people do, and these are believed to play a role in causing insulin resistance and other metabolic disturbances. Blood concentrations of inflammatory markers are lowered following weight loss. In the hours following the consumption of a meal, there is an elevation in the concentrations of inflammatory mediators in the bloodstream, which is exaggerated in obese subjects and in type 2 diabetics. Both high-glucose and high-fat meals may induce postprandial inflammation, and this is exaggerated by a high meal content of advanced glycation end products (AGE) and partly ablated by inclusion of certain antioxidants or antioxidant-containing foods within the meal. Healthy eating patterns are associated with lower circulating concentrations of inflammatory markers. Among the components of a healthy diet, whole grains, vegetables and fruits, and fish are all associated with lower inflammation. AGE are associated with enhanced oxidative stress and inflammation. SFA and trans-MUFA are pro-inflammatory, while PUFA, especially long-chain n-3 PUFA, are anti-inflammatory. Hyperglycaemia induces both postprandial and chronic low-grade inflammation. Vitamin C, vitamin E and carotenoids decrease the circulating concentrations of inflammatory markers. Potential mechanisms are described and research gaps, which limit our understanding of the interaction between diet and postprandial and chronic low-grade inflammation, are identified.

Preamble

Inflammation is a normal defence mechanism that protects the host from infection and other insults; it initiates pathogen killing as well as tissue repair processes and helps to restore homeostasis at infected or damaged sites. It is typified by redness, swelling, heat, pain and loss of function, and involves interactions among many cell types and the production of, and responses to, a number of chemical mediators. Self-regulation of the inflammatory response involves the activation of negative feedback mechanisms such as the secretion of anti-inflammatory cytokines, inhibition of pro-inflammatory signalling cascades, shedding of receptors for inflammatory mediators and activation of regulatory cells. As such, and controlled properly, regulated inflammatory responses are essential to remain healthy and maintain homeostasis. Pathological inflammation involves a loss of tolerance and/or of regulatory processes. Where this becomes excessive, irreparable damage to host tissues and disease can occur. Such diseases are characterised by markedly elevated concentrations of inflammatory markers and of activated inflammatory cells at the site of tissue damage and in the systemic circulation. While the existence of inflammatory diseases has been long recognised, it is only more recently that the condition of chronic low-grade inflammation has received attention, particularly in relation to obesity, the metabolic syndrome and CVD. Chronic low-grade inflammation is characterised by raised concentrations of inflammatory markers in the systemic circulation. This article sets out to explain the nature of chronic low-grade inflammation in the context of overweight and obesity, and to describe the factors that might influence it, in particular those related to diet. The literature in the areas of adipose tissue, obesity and inflammation, and dietary components and inflammation is vast, and it is not possible to mention all studies here. In particular, the review of diet and its components and inflammation is not exhaustive, although the main studies of relevance are included.

Concept and markers of low-grade inflammation

Obesity and low-grade inflammation

The concept of systemic, chronic, but low-grade inflammation as a risk factor for the metabolic syndrome and for type 2 diabetes is based on the observation of elevated blood levels of inflammation-associated markers in people with incident type 2 diabetes or with the metabolic syndrome. The up-regulation of systemic indicators of inflammation such as leucocyte count, and serum and plasma concentrations of acute-phase proteins, pro-inflammatory cytokines, chemokines, soluble adhesion molecules and prothrombotic mediators is modest, usually less than 2-fold above what is observed in controls. Diagnostic criteria for low-grade inflammation have not been precisely defined, but the phenotype per se is not disputed. Systematic concentrations of pro-inflammatory mediators are higher in obese (BMI > 30 kg/m^2) than in normal-weight persons. Serum or plasma concentrations of TNF-α or IL-6 in healthy adults are typically 0.01–2 pmol/l. Other inflammatory mediators, such as monocyte chemoattractant protein (MCP)-1, interferon (IFN)-γ-induced protein-10 and IL-18, may reach mean concentrations of 10 pmol/l; macrophage migration inhibitory factor (MIF) and regulated on activation, normal T expressed and secreted (RANTES) concentrations may get close to the nanomolar range; and C-reactive protein (CRP) concentration is often above 10 nmol/l. The variation in concentrations of most mediators among non-obese or obese individuals is at least 10-fold. Hence, there is a substantial overlap between non-obese and obese persons. However, there is a positive relationship between BMI and other measures of obesity such as waist circumference and circulating concentrations of CRP and other inflammatory markers.

A mechanistic link between obesity and low-grade inflammation was first proposed by Hotamisligil et al. who showed that white adipose tissue synthesises and releases the pro-inflammatory cytokine TNF-α. The expression of TNF-α is elevated in adipocytes of obese and insulin-resistant mice, while insulin sensitivity is improved following administration of anti-TNF-α antibodies. Based on these data, it was suggested that adipose tissue plays an important immune role and may be a major...
source of pro-inflammatory mediators which initiate the development of chronic inflammation, insulin resistance and atherosclerosis, all of which are characteristics of the metabolic dysregulation associated with obesity. The discovery of leptin modified the view of adipose tissue as being an 'inert' energy store to being the largest endocrine gland in the body. Leptin is produced and secreted by white adipose tissue. The discovery of leptin introduced the concept of ‘adipocytokines’ or ‘adipokines’, substances produced by adipose tissue and which circulate in the bloodstream, so exerting systemic effects as hormones\(^\text{(9)}\). Some adipokines are produced within adipose tissue exclusively by adipocytes (e.g. leptin, adiponectin, serum amyloid A (SAA)), while others are produced by both adipocytes and other cell types of the non-adipocyte fraction of adipose tissue. It is now recognised that macrophages accumulate in the adipose tissue in obesity\(^\text{(10,11)}\) (Fig. 1) and that these may represent major contributors to the production of adipokines\(^\text{(12,13)}\).

**Adipose tissue as a source of inflammatory mediators**

Adipose tissue expresses and secretes into the systemic circulation a growing list of hormones, inflammatory mediators and immune system effectors. The products of adipose tissue can be categorised into several groups (Table 1):

1. **Hormones**: many of the hormones produced by adipose tissue affect the immune system and insulin sensitivity. Leptin appears to be pro-inflammatory\(^\text{(14)}\), while adiponectin appears to be anti-inflammatory and insulin-sensitising\(^\text{(15)}\). Similarly, visfatin\(^\text{(16)}\) and resistin\(^\text{(17)}\) contribute to the development of insulin resistance, while omentin\(^\text{(18,19)}\) appears to be an insulin sensitizer.

2. **Acute-phase proteins**: these proteins are secreted in the acute phase of inflammation and include plasminogen activator inhibitor 1 (PAI-1)\(^\text{(22)}\), pentraxin-3, lipocalin 24p3, haptoglobin, SAA\(^\text{(23)}\) and α1-glycoprotein.

3. **Cytokines**: these are the classic peptide mediators of inflammation and include IL-1, IL-1 receptor antagonist (IL-1ra)\(^\text{(24–26)}\), IL-6, IL-7, IL-18\(^\text{(27–30)}\), IL-10\(^\text{(31,32)}\), MIF\(^\text{(33)}\) and TNF-α.

4. **Chemokines**: these include IL-8\(^\text{(34,35)}\), MCP-1, -3, -4, RANTES (now known as chemokine (C–C motif) ligand (CCL) 5), angiopoietin, metallothioneins, macrophage inflammatory protein (MIP)-1α and -1β (now known as CCL3 and CCL4, respectively)\(^\text{(36)}\), and induced protein-10\(^\text{(37)}\).

5. **Growth factors**: transforming growth factor (TGF)-β\(^\text{(38)}\).

6. **Components of the alternative complement system**: adipin and factors C2, C3, C4, C7, B and D (these are expressed more highly in omental compared with subcutaneous adipose tissue\(^\text{(39,40)}\)).

7. **Retinol-binding protein 4** which is linked with insulin resistance\(^\text{(41,42)}\), although its precise role has been debated\(^\text{(43)}\).

**Adipose tissue distribution and its impact on inflammation**

Obesity is characterised by an expansion of the mass of adipose tissue and dramatic changes in its distribution in the body. Simplistically speaking, accumulation of adipose tissue in the thorax and abdomen (variably termed abdominal, central, visceral, splanchnic or android obesity) results in an increased risk for diabetes and atherosclerosis, while excess adipose tissue in the lower part of the body (termed gynoid obesity) does not appear to be associated with major metabolic consequences\(^\text{(44,45)}\). The increase in abdominal fat mass is associated with a chronic elevation of the circulating concentrations of inflammatory mediators including several acute-phase inflammatory proteins such as CRP\(^\text{(46,47)}\), pro- and anti-inflammatory cytokines, adhesion molecules and pro-thrombogenic molecules\(^\text{(42,47−49)}\). It should be noted that the liver and the lymphoid organs are usually the major production sites of these inflammatory mediators but in obesity, adipose tissue becomes a major producer resulting in a chronic and constant local and systemic inflammatory milieu (Table 2).

Abdominal obesity is a risk factor for type 2 diabetes, hypertension, dyslipidaemia and CVD\(^\text{(50)}\), and also probably obesity-associated hepatic diseases (non-alcoholic fatty liver disease and non-alcoholic steatohepatitis). Glucose intolerance is significantly more common in subjects with abdominal obesity compared with those with fat mass accumulation in their lower part of the body. Plasma TAG concentrations are also significantly more elevated in individuals with abdominal obesity. It appears that the anatomical localisation of adipose tissue is of paramount importance in relation to its physiological function, i.e. handling of lipids (lipogenesis, lipolytic activity), expression of multiple genes, and response to insulin, catecholamines, sex hormones and cortisone\(^\text{(51)}\). In addition, the profile of adipokines produced is dissimilar between the subcutaneous and abdominal adipose tissues. Thus, leptin is preferentially expressed and secreted by subcutaneous adipose tissue\(^\text{(52)}\), while the expression of adiponectin, visfatin, omentin, resistin, PAI-1, IL-8, IL-7, IL-1α, MCP-1, TGF-β, growth-related oncogen-α, CCL5 and MIP-1B is higher in abdominal fat. In contrast to such distributions, there are reports that IL-6 and TNF-α seem to be equally synthesised by the different sites\(^\text{(28,56,55−59)}\). It is important to mention that in severe obesity, the part played by the abdominal or the very abundant subcutaneous adipose tissue in the systemic delivery of inflammatory mediators is still not well understood. Nevertheless, the distinct profile of adipokine secretion between the abdominal and subcutaneous adipose tissues probably contributes to the increased risk of metabolic and cardiovascular complications and to the development of other complications such as hepatic steatosis and non-alcoholic steatohepatitis in obese individuals. Finally, other adipose tissue depots in so-called ‘ectopic sites’, such as within the liver, heart or skeletal muscle, may contribute to the production of inflammatory mediators in the absence of obesity. In this regard, the local production of the inflammatory molecules by adipose tissue within the heart may be important; the amount of this tissue and its proximity to the coronary vessels could contribute to the development of coronary pathologies\(^\text{(60,61)}\).
Cell populations of adipose tissue

Adipose tissue is a heterogeneous tissue composed of several cell types: mature adipocytes, pre-adipocytes, fibroblasts, endothelial cells, mast cells, granulocytes, lymphocytes and macrophages. Cells within adipose tissue, apart from mature adipocytes, are collectively termed the stroma-vascular fraction. The various cell types have not been precisely characterised, nor has the relative change of their quantitative contributions to the tissue in obesity. Because of the heterogeneity of cells in the adipose tissue, the cellular source of the inflammatory factors secreted by the tissue into the systemic circulation remains unknown. In vitro studies have demonstrated that mature adipocytes express inflammatory factors such as TNF-α. SAA is overexpressed and secreted in abundance by isolated adipocytes from obese subjects, as is leptin, while secretion of adiponectin is suppressed. SAA and leptin production by adipose tissue depends on adipocyte size. Adipocyte size also influences the expression of other inflammatory mediators as demonstrated by fractionation studies of adipocytes coupled with studies of gene expression profiles. Adipocyte size, for example, determines the production of IL-6, IL-8, MCP-1 and granulocyte colony-stimulating factor. Although adipocyte hypertrophy precedes the development of type 2 diabetes, a growing number of studies indicate that the principal site of production of inflammatory mediators appears to be the stroma-vascular fraction. More recent studies in mice have suggested that the infiltration of obese adipose tissue by macrophages is accompanied or even preceded by an influx of T-lymphocytes and that T-cells have a key early role. Early work indicated the presence of CD3-positive T-lymphocytes in human adipose tissue, and more recent studies have shown high numbers of T-cells in the adipose tissue of obese adipose tissue during weight gain leads to the recruitment of macrophages through various signals (e.g. chemokines such as chemokine (C–C motif) ligand 2 (CCL2)) released by adipocytes. Macrophages accumulate around apoptotic adipocytes. Mediators synthesised by adipocytes and resident macrophages contribute to local and systemic inflammation. Reproduced with permission from Tilg & Moschen.
Table 1. Cytokines expressed or secreted by human adipose tissue

<table>
<thead>
<tr>
<th>Family</th>
<th>Example(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemokines</td>
<td>MCP-1 (known as CCL2), MCP-3, MCP-4, RANTES (known as CCL5), MIP-1α (known as CCL3)</td>
</tr>
<tr>
<td>IL</td>
<td>IL-6, IL-8 (acts as a chemokine), IL-1α, IL-10, IL-1β</td>
</tr>
<tr>
<td>Interferons</td>
<td>IP-10</td>
</tr>
<tr>
<td>TNF</td>
<td>TNF-α</td>
</tr>
<tr>
<td>Growth factors</td>
<td>Vascular endothelial growth factor, TGF-β, hepatocyte growth factor</td>
</tr>
<tr>
<td>Others</td>
<td>Leptin</td>
</tr>
</tbody>
</table>

MCP, monocyte chemoattractant protein; CCL, chemokine (C–C motif) ligand; RANTES, regulated on activation, normal T expressed and secreted; MIP, macrophage inflammatory protein; IL-1α, IL-1 receptor antagonist; IP, interferon-γ-induced protein; TGF, transforming growth factor.

diet-induced obese insulin-resistant mice. Furthermore, Wu et al. demonstrated the presence of CD3-positive T-lymphocytes in human adipose tissue and described the expression of RANTES, a T-cell-specific chemokine, and its respective receptor CCR5 in the visceral adipose tissue of morbidly obese patients. A recent study in mice reported mainly CD8-positive lymphocyte infiltration in hypoxic areas within the adipose tissue. MCP-1 is a strong chemoattractant and it increase significantly in the adipose tissue of subjects with morbid obesity. MCP-1 and its receptor CCR2 are major players in the macrophage accumulation within the adipose tissue. However, contradictory data suggest that MCP-1 might not be such a crucial candidate. The role of MCP-1 in the macrophage accumulation in human obesity needs to be established. Other candidate molecules and other mechanisms continue to be explored. Local hypoxia could also play an important role in the attraction and retention of macrophages within the adipose tissue. Hypoxia-inducible factor-1α, a transcription factor normally induced by hypoxia, is overexpressed in the subcutaneous adipose tissue of obese subjects and its expression is decreased during weight reduction. Tissue hypoxia induces macrophage attraction into solid tumours as well as into atherosclerotic plaques. Adipose tissue of obese subjects could be hypoxic in some areas and a local expression of chemokines could be induced. It should be noted that leptin, which possesses indirect chemoattractant properties, is induced by hypoxia.

It is generally considered that macrophage accumulation in adipose tissue is detrimental. However, macrophage accumulation could be related to an adaptation process associated with the augmentation of fat mass, and macrophage accumulation could be necessary for the upkeep of the tissue and perhaps to limit its expansion. It appears that macrophage aggregates within the adipose tissue are localised around apoptotic adipocytes (Figs. 1 and 2). Although these macrophages express activation markers, they could be pro- or anti-inflammatory depending on the degree of obesity and its evolution as suggested by studies in mice showing that weight gain is accompanied by transformation from a macrophagic M2 (anti-inflammatory) phenotype towards an M1 (pro-inflammatory) profile. Consequently, secretion profiles of the adipose tissue can change depending on the phenotype of the cell population infiltrating it during the different stages of obesity (initiation, aggravation, maintenance and weight loss; Fig. 4).

Adipose tissue macrophages may contribute to the maintenance of the low-grade inflammatory state linked to obesity. Factors that induce the infiltration and activation of macrophages in the adipose tissue are probably multifactorial. Paracrine, autocrine and endocrine signals, as well as mechanical modifications (hypertrophy and adipocyte hyperplasia), could play a role in this phenomenon. Many adipokines synthesised by the adipose tissue are candidates to attract inflammatory cells. In vitro studies have suggested that leptin itself (at supra-physiological levels) induces adhesion proteins, hence facilitating the migration of monocytes. Conversely, adiponectin may inhibit this process. Very little is known about the role of selectins, integrins and elements of adhesion to the extracellular matrix, in the process of macrophage attraction to the adipose tissue. Gene expression studies with human adipose tissue have demonstrated that the levels of expression of MCP-1, colony-stimulating factor-3 and the urokinase plasminogen activator CD87 increase significantly in the adipose tissue of subjects with morbid obesity. MCP-1 is a strong chemoattractant and it acts via its receptor CCR2. MCP-1 is synthesised predominantly by macrophages and endothelial cells and, to a lesser extent, by adipocytes. In one study, CCR2 gene knockout mice showed a reduction of macrophage infiltration in the adipose tissue and improvement of insulin sensitivity. This led to the suggestion that MCP-1 and its receptor CCR2 are major players in the macrophage accumulation within the adipose tissue. However, contradictory data suggest that MCP-1 might not be such a crucial candidate. The role of MCP-1 in the macrophage accumulation in human obesity needs to be established. Other candidate molecules and other mechanisms continue to be explored. Local hypoxia could also play an important role in the attraction and retention of macrophages within the adipose tissue. Hypoxia-inducible factor-1α, a transcription factor normally induced by hypoxia, is overexpressed in the subcutaneous adipose tissue of obese subjects and its expression is decreased during weight reduction. Tissue hypoxia induces macrophage attraction into solid tumours as well as into atherosclerotic plaques. Adipose tissue of obese subjects could be hypoxic in some areas and a local expression of chemokines could be induced. It should be noted that leptin, which possesses indirect chemoattractant properties, is induced by hypoxia.
These cellular alterations are induced in co-cultures without direct cellular contact, suggesting the key role of soluble factors, although it cannot be excluded that a direct cell–cell interaction also plays a role in modifying pre-adipocyte or adipocyte biology. The mature adipocyte also endures profound modifications of its biology in culture systems with a medium from activated macrophages. Other than the pro-inflammatory state, increased lipolysis and resistance to insulin have been observed (89,90). TNF-α has been proposed to mediate these effects. From the molecular point of view, the NF-κB pathway, implicated in the primary regulation of inflammatory responses (91–93) (Fig. 5) (94), is induced in the pre-adipocyte (87) and in the adipocyte in the presence of a medium from macrophages (95). The NF-κB pathway is also brought into play in macrophages in contact with a medium from adipocytes. TLR appear to be important players which lead to the induction or suppression of genes orchestrating the inflammatory response. TLR-4 is the bacterial lipopolysaccharide (LPS) receptor, but data have shown that the NEFA produced by adipocytes after adrenergic stimulation are also strong inducers of the TLR-4/NF-κB system (95). The NF-κB pathway is also expressed by adipocytes and is overexpressed during obesity (96). TLR-4 knockout mice are protected from insulin resistance induced by lipid infusions (97).

Based on these different studies, a dual effect of macrophages of the adipose tissue could be expected: first, a local ‘beneficial’ effect in clearing out old adipocytes, and in the control and of the development of fat mass and second, a deleterious local and systemic effect via the increase in the production and secretion of adipokines, promoting the progression of complications of obesity and the induction of insulin resistance.

### Adipokines and chronic low-grade inflammation

**Adipokines and the complications of obesity.** Inflammatory molecules are likely candidates exerting a molecular link between the adipose tissue and the metabolic, cardiovascular, hepatic and thrombotic complications, and certain cancer types occurring in conjunction with or as a consequence of human obesity. A myriad of candidate adipokines are proposed to play this role (98–100). In the cardiovascular field, they can be considered as risk factors, and even directly play a pathophysiological role favouring the initiation and progression of atherosclerosis. Relationships between abnormalities of cardiac function in obese subjects, the accumulation of abdominal fat and low-grade inflammation have been suggested (101,102). Among the candidates secreted by the adipose tissue, the increase in IL-6, IL-8 and MCP-1 and the decrease in adiponectin are considered to be particularly important (101,102). The studies of the pathophysiological links between adipokines and cardiovascular health can be illustrated by the analysis of the effects of adiponectin in rodents. Overexpression of adiponectin results in diminished size of the lesions observed following acute ischaemic myocardial infarction, increased angiogenic properties and reduced size of atheromatous plaques in the genetically predisposed apoE/−/− mouse (103).

### Table 2. Modification of circulating inflammatory marker concentrations in relation to obesity and weight loss

<table>
<thead>
<tr>
<th></th>
<th>Effect of obesity</th>
<th>Effect of weight loss</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute-phase proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Orosomucoid</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Haptoglobin</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Serum amyloid A</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td><strong>Cytokines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>IL-8</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>IL-10</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>IL-1 receptor antagonist</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Increase</td>
<td>None or decrease</td>
</tr>
<tr>
<td>Monocyte chemoattractant protein-1</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Monocyte chemoattractant protein-4</td>
<td>Increase</td>
<td>Not known</td>
</tr>
<tr>
<td>Macrophage migration inhibitory factor</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td><strong>Other adipokines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leptin</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Visfatin</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Resistin</td>
<td>Decrease</td>
<td>None or increase</td>
</tr>
<tr>
<td>Adiponectin</td>
<td>Decrease</td>
<td>Increase</td>
</tr>
<tr>
<td>Omentin</td>
<td>Decrease</td>
<td>Not known</td>
</tr>
<tr>
<td><strong>Adhesion proteins/extracellular matrix remoulding proteins/prothrombotics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matrix metalloproteinase 9</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Soluble intercellular adhesion molecule-1</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Soluble vascular cell adhesion molecule-1</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Soluble E-selectin</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Hepatocyte growth factor</td>
<td>Increase</td>
<td>Not known</td>
</tr>
<tr>
<td>Plasminogen activator inhibitor 1</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td>Cathepsin S</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
</tbody>
</table>

*Table 2. Modification of circulating inflammatory marker concentrations in relation to obesity and weight loss.*
Several inflammatory mediators produced by adipose tissue, such as CCL5, IL-1β and IL-8, as well as markers of oxidative stress, are increased in diabetic or glucose-intolerant patients, and the amelioration of hyperglycaemia by insulin therapy reduces circulating concentrations of these molecules\(^{(104,105)}\). The increase in the concentrations of TNF-α, IL-6, IL-1β, IL-8, resistin and many other factors produced by macrophage activation could contribute to the deterioration of insulin sensitivity (Fig. 6)\(^{(106)}\). The precise relationship between the importance of macrophage and T-cell accumulation in adipose tissue depots, adipokine secretion and the modifications of insulin sensitivity needs to be further addressed in humans.

Macrophage accumulation is more abundant in the abdominal adipose tissue\(^{(65)}\) than in the subcutaneous tissue, and this could explain some of the risks associated with the accumulation of intra-abdominal fat. For example, a relationship between the increase in macrophages in the abdominal adipose tissue and hepatic inflammation and fibrosis has been reported\(^{(65)}\). In another study, the expression of the MCP-1 and colony-stimulating factor-1 genes and proteins was associated with macrophage accumulation in obese subjects\(^{(107)}\). Since the abdominal adipose tissue is partly drained by the portal system, it cannot be excluded that some adipokines, together with high NEFA fluxes and hormones delivered by the adipose tissue, could contribute to the alteration of hepatic function observed in obese subjects, the mechanism of which needs to be better dissected.

**Adipokines and weight loss.** Even modest weight reduction improves the metabolic and cardiovascular risks associated with human obesity. Measures of endothelial activation also improve after weight reduction\(^{(108–110)}\). Many studies have shown that weight loss induced by a decrease in energy intake, and sometimes an increase in exercise, reduces systemic inflammation. A reduction in concentrations of numerous inflammatory molecules and endothelial risk factors, and an increase in adiponectin concentration have been observed during weight-loss programmes, and these are sometimes associated with improvement of insulin sensitivity\(^{(111)}\). Such changes have been described for CRP\(^{(112)}\), IL-6\(^{(113)}\), IL-1β\(^{(114)}\), IL-1ra\(^{(26)}\), PAI-1\(^{(115)}\), SAA\(^{(23,116)}\), cathepsin S\(^{(117)}\), matrix metalloproteinase-9\(^{(118)}\), soluble adhesion molecules (soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1))\(^{(119)}\), tissue factor\(^{(119)}\), MIF\(^{(120)}\), MCP-1\(^{(121)}\), soluble receptors of TNF (sTNFR) and for eotaxin, an inflammatory factor implicated in asthma, another complication of obesity\(^{(122)}\).

Weight loss induced by gastric bypass reduced the circulating concentrations of visfatin\(^{(123)}\) and TNF-α\(^{(124,125)}\). One study followed sixty obese patients during the course of weight loss induced by bariatric surgery and reported a reduction of 30% of initial weight, a decrease in CRP, SAA, orosomucoid protein, IL-6, TNF-α and fibrinogen concentrations, and an increase in adiponectin concentration\(^{(126)}\). After the surgery, the concentration of IL-6 dropped slowly while the concentrations of SAA and CRP dropped more quickly\(^{(126)}\).

There was a significant modification in the expression of inflammatory genes in the subcutaneous adipose tissue of obese women following a hypoenergetic diet\(^{(127)}\). The expression of 100 genes linked to inflammatory processes was modified after 4 weeks (41% increased and 59% decreased). These genes belonged to at least twelve functional families including cytokines, the complement factor cascade, acute-phase proteins of inflammation, and molecules involved in cellular adhesion and in the remodelling of the extracellular matrix. The improvement of the inflammatory profile (at the level of gene expression) involved both the decreased expression of pro-inflammatory factors and the increased expression of anti-inflammatory factors such as IL-10 and IL-1ra. The modification of the inflammatory gene expression profile was very similar in subjects following bariatric
surgery and was associated with a reduction of macrophage infiltration. In this study, the protein expression of IL-10 increased, suggesting a possible M1 to M2 (pro-inflammatory to anti-inflammatory) switch of macrophage phenotypes.

Overall, the mitigation of the systemic inflammatory profile observed during weight loss is associated with modifications of adipose tissue inflammatory gene expression, and this may be linked with altered profiles of inflammatory protein secretion. The eventual consequence of this phenomenon on the local biology of the adipose tissue remains to be identified.

Chronic low-grade inflammation and insulin resistance

Experimental model systems in vitro

In obesity and the metabolic syndrome, key organs displaying increased insulin resistance are the liver, skeletal muscle, adipose tissue and the endothelium (Fig. 6). Experimental model systems in vitro have shown that hepatocytes as well as muscle cells, adipocytes and endothelial cells respond to exposure to the pro-inflammatory cytokines TNF-α, IL-6 and/or IL-1β with impaired insulin signalling. Overall, the mitigation of the systemic inflammatory profile observed during weight loss is associated with modifications of adipose tissue inflammatory gene expression, and this may be linked with altered profiles of inflammatory protein secretion. The eventual consequence of this phenomenon on the local biology of the adipose tissue remains to be identified.

In vivo models

The impairment of insulin signalling by TNF-α has also been observed in vivo after infusion of the cytokine into rodents. A critical mediator downstream of TNF-α appears to be MIF, since mice with a disrupted MIF gene preserve normal insulin signalling. In this context, it is of interest that adipocytes are able to secrete MIF. The latter finding demonstrates that there are still substantial gaps in our understanding of the pro-inflammatory cytokine signalling.
cascade leading to insulin resistance. Most importantly, it remains unclear where other known regulators of insulin sensitivity fit into the chain of events. There is convincing evidence that reactive oxygen species (ROS) are critical to the effects of TNF-α on insulin signalling (136), and also that mitochondrial dysfunction is involved (137). The impact of insulin on cellular metabolic activity, proliferation and differentiation can also be impaired by inflammatory mediators via an indirect pathway, i.e. by enhancing or suppressing the production of hormones that modulate cellular responses to insulin. These effects include the up- or down-regulation of the synthesis of resistin (138), leptin, adiponectin (139), lipocalin 2 (140), osteopontin (141), and of insulin itself. When considering the subnanomolar systemic concentration of many pro-inflammatory mediators (see section ‘Obesity and low-grade inflammation’), it is possible that only a few of them contribute to the metabolic derangements seen in obesity and the metabolic syndrome.

A different situation emerges when paracrine effects of inflammatory mediators are considered. As described above, there is substantial local production of inflammatory mediators in organs affected by insulin resistance. Hepatocytes, adipocytes, muscle cells and the endothelium are sites of inflammatory mediator synthesis, but local activated macrophages appear to be the dominant site of synthesis and secretion, which leads to spillover into the general circulation (66,67,142). Paracrine concentrations of inflammatory mediators are sufficient to induce insulin resistance (128). Indeed, co-culture of adipocytes with macrophages caused impairment of insulin signalling (75). In addition to paracrine effects, it is conceivable that the functions of liver cells are affected by inflammatory mediators released from the abdominal adipose tissue because of their blood link.

**Evidence supporting the link between inflammatory mediators and insulin resistance**

In human subjects, the most direct approach to assess the contribution of low-grade inflammation to the development of insulin resistance and the metabolic syndrome is to analyse the consequences of anti-inflammatory pharmacotherapy. The longest experience is with the use of salicylates which are weak inhibitors of IκB kinase and of serine phosphorylation of IRS proteins (143,144). Early clinical trials with high doses of salicylates, notably aspirin, yielded both positive and negative effects on glycaemia and insulin resistance. Later studies have revealed that only very high doses are effective in improving glucose metabolism (145). A randomised placebo-controlled pilot trial of salicylate treatment for 1 month in twenty non-diabetic obese individuals found decreased...
blood glucose and insulin responses to an oral glucose challenge consistent with improved insulin sensitivity\(^{(146)}\). A secondary analysis of a prospective multicentre observational study of 4905 adults with rheumatoid arthritis, of whom 1808 had taken hydroxychloroquine, indicated a reduced risk of diabetes in patients using this drug\(^{(147)}\). More specific anti-inflammatory intervention is possible through the use of recombinant proteins antagonising pro-inflammatory mediators. A first controlled double-blind trial was performed with daily injections of recombinant human IL-1ra for 13 weeks. This resulted in decreased glycated Hb levels and enhanced endogenous insulin production\(^{(148)}\). However, although there was a significant decrease in systemic CRP and IL-6 concentrations in response to anti-inflammatory treatment, there was no change in insulin resistance (homeostasis model assessment index and euglycaemic–hyperinsulinaemic clamp studies). It is difficult to judge the extent of inflammation persisting during therapy because absolute serum concentrations of CRP and IL-6 were not reported. There was no significant decrease in circulating TNF-α, MCP-1 or IL-8 concentrations, which indicates that there was no general down-regulation of pro-inflammatory cytokines. Another target-specific approach is the neutralisation of TNF-α by injections of recombinant antibodies or sTNFR. In animal models of insulin resistance, infusion of TNF-α antibodies has been reported to ameliorate insulin signalling\(^{(149)}\). In obese non-diabetic or diabetic individuals, several studies have observed improvement of insulin sensitivity after prolonged treatment with neutralising TNF-α antibodies\(^{(150,151)}\), whereas other trials did not report such effects of TNF-α antibody injections, despite dampening of systemic inflammation\(^{(152)}\). Possible explanations are that the recombinant antibodies do not reach sufficiently high concentrations in target tissues, or that TNF-α neutralisation is effective only in skeletal muscle tissue but not in adipose tissue as has been observed in rats\(^{(153)}\). The overall conclusion is that results of studies of anti-inflammatory therapy generally support the concept of inflammatory mediators as contributors to the pathogenesis of insulin resistance, but have as yet not provided clear evidence of a critical pathogenic role of TNF-α or IL-1.

**Postprandial inflammatory response**

The foregoing discussion has dealt with chronic changes in concentrations of inflammatory mediators but a rise in inflammation also appears to take place acutely following meals. The postprandial inflammatory response lasts for only few (4–8) h but it recurs several times a day following eating. Although the postprandial inflammatory response has been known for several years\(^{(154)}\), it is only recently that its probable importance in the generation of insulin resistance and atherosclerosis has been appreciated\(^{(155–157)}\). Several cells in the body associated with the innate immune system, including abdominal adipocytes and monocytes/macrophages, respond to acute postprandial elevation of several components of a meal by mounting a transient inflammatory response. The most efficient triggers of the postprandial inflammatory response appear to be TAG, SFA, oxysterols and glucose\(^{(158–161)}\). The pathophysiological significance of a postprandial inflammatory response in causing insulin resistance, the metabolic syndrome and atherosclerosis is currently under investigation, and this response appears to play a much more crucial role than previously thought\(^{(162)}\).

**Non-dietary factors influencing the magnitude of the postprandial inflammatory response**

**Body weight.** Obesity is considered an important determinant of the magnitude of the postprandial inflammatory response\(^{(163)}\), perhaps being more important than any specific component of a meal inducing the response. The exaggerated postprandial inflammatory response of the obese is reversible upon reduction of body weight\(^{(155,156)}\).

**Hyperglycaemia and type 2 diabetes.** Patients with type 2 diabetes exhibit a higher postprandial inflammatory response than non-diabetics, irrespective of their body weight\(^{(165,166)}\).
The magnitude of the postprandial inflammatory response appears to correlate with the degree of insulin resistance[165].

**Drugs.** Certain medications including statins and angiotensin II receptor antagonists ameliorate the postprandial inflammatory response in obese patients[167].

**Pathophysiology of the postprandial inflammatory response**

The daily influx of TAG, SFA, glucose and other food components initiates an acute innate immune (i.e. inflammatory) response that lasts for a few hours. Meals or food components may contain LPS which directly triggers systemic inflammation. Related to this effect, the absorptive process may allow translocation of LPS from gut bacteria into the systemic circulation[168]. Meals may contain oxidised components which initiate oxidative stress and/or inflammatory responses upon absorption. Postprandial hyperglycaemia can suppress antioxidant capacity[169] and thus its ability to curb an inflammatory reaction. Hyperglycaemia induces the production of free radicals which themselves initiate an inflammatory reaction. A six-transmembrane protein of prostate 2 (STAMP2) has been proposed as a major determinant of the postprandial inflammatory response[170], acting to block activated inflammatory signalling pathways in adipocytes and possibly in macrophages. In vivo, feeding induces STAMP2 expression in visceral white adipose tissue[170]. Furthermore, the visceral tissue of *STAMP* gene knockout mice is resistant to insulin action[170,171].

**Ageing and low-grade inflammation**

Ageing is associated with complex changes in, and a dysregulation of, the immune system, including its inflammatory component. The ageing of the immune system, immunosenescence, has been suggested to be a consequence of continuous attrition caused by chronic antigenic overload[172]. Ageing is accompanied by a low-grade, chronic inflammatory state clearly shown by 2- to 4-fold increases in serum levels of several inflammatory mediators in older persons[173]. Studies have reported increased plasma/serum levels of the pro-inflammatory cytokine IL-6 in healthy subjects with advanced age (55–75 v. 26–54 years)[174], an increase of 0.016 pg/ml per year of life[175] and a significant increase with overall age (from 20 to 102 years)[176], and in elderly diabetic subjects (65–80 years)[177]. Ageing is also associated with increased concentrations of TNF-α[178,179], CRP[180] and IL-1ra[176,181]. It is hypothesised that failure of anti-inflammatory mechanisms to neutralise inflammatory processes that are continuously triggered lifelong plays a role in chronic low-grade inflammation in the elderly[182]. In line with this, it has recently been shown that ageing (two groups with a mean age of 77.9 and 102.5 years, respectively v. a group with a mean age of 43.5 years) is characterised by a profound reduction in anti-inflammatory lipoxin A4 levels[183].

The effect of ageing on the immune system, however, cannot be completely separated from the contribution of co-morbidity, medication use or malnutrition[184,185]. Since several inflammatory markers act as disease markers, it is possible that some of the chronic low-grade inflammation patterns found in the elderly may be related to the presence of co-morbidities[180,186]. Interestingly, however, successful ageing (ageing without co-morbidities) has also been associated with chronic low-grade inflammation[173]. Other factors that may affect and modulate circulating levels of inflammatory mediators, including obesity, infections, physical activity, age-related decline in sex hormones and altered host–microbiota interaction at the gut level, may also be involved in the age-associated increase in low-grade inflammation[172,187–189]. Furthermore, high plasma
levels of IL-6 (and TNF-α) in the elderly were associated with truncal fat mass (177), suggesting that some of this effect might be mediated with age-associated increase in fat mass.

There is strong evidence that low-grade elevations of circulating inflammatory mediators are associated with the development of age-related conditions such as atherosclerosis, cognitive decline and frailty. This may in part reflect the inflammatory nature of these conditions which involve local or generalised inflammation (e.g. neuroinflammation in cognitive decline), with the increase in circulating concentrations of inflammatory mediators reflecting overspill from the inflammatory lesion(s). Additionally, the increased inflammatory burden could make a contribution to the ongoing pathology and to a worsening clinical situation. Increases in the levels of circulating TNF-α, IL-6, IL-2R and CRP are also strong predictors of all-cause mortality risk in longitudinal studies of several elderly cohorts (190–193). However, whether increased inflammatory activity causes age-associated pathology or reflects the sum of ongoing pathological processes (173,194) remains uncertain. Survival analyses in studies from the USA and Europe with several populations (healthy, non-disabled, ≥65-year-old subjects (191), high-functioning subjects aged 70–79 years (192), disabled women aged ≥65 years (193) and relatively healthy 80-year-old people (190)), however, show that effects of inflammatory mediators were independent of pre-existing morbidity and other traditional risk factors for death. This indicates that these inflammatory mediators influence pathological processes or act as very sensitive markers of subclinical disorders in the elderly (173).

Exercise and low-grade inflammation

**Influence of acute and regular physical activity and fitness on low-grade inflammation**

The health benefits of a physically active lifestyle are well recognised. Physical inactivity and obesity are also increasingly recognised as modifiable behavioural risk factors for a wide range of chronic diseases, and in particular for CVD (195). Physical fitness, physical exercise and physical activity are often used as interchangeable concepts, but it is important to point out the differences among these. Physical activity is any body movement that increases energy expenditure (196).
Self-reported data of physical activity are easy and feasible to ask in a questionnaire or interview in large populations but are a measurement subject to recall and reporting biases. Exercise is planned, structured and repetitive physical activity, while physical fitness is the capacity to perform physical activity, and makes reference to a full range of physiological and psychological qualities. To eliminate reporting bias that could be present in self-reported physical activity measurement, several studies have examined the relationship between cardiorespiratory fitness and inflammatory markers. Maximal oxygen consumption (VO₂max) attained during a graded maximal exercise to voluntary exhaustion is considered as the single best indicator of cardiorespiratory fitness (197). There are excellent reviews of the evidence addressing the influence of physical activity and fitness on low-grade inflammation from epidemiological studies as well as clinical trials on the general adult population (198–202), athletes (203,204), and in children and adolescents (205).

**Acute v. regular exercise.** IL-6 and other cytokines that are produced and released by skeletal muscles have been suggested to be involved in mediating the health-beneficial effects of exercise and to play important roles in the protection against diseases associated with low-grade inflammation. The following chain of events is based on observations by Pedersen and colleagues and has been excellently reviewed elsewhere (206–208).

1. Contracting skeletal muscle is a major source of circulating IL-6 in response to acute exercise. Plasma IL-6 increases in an exponential fashion with exercise and is related to exercise intensity, duration, the mass of muscle recruited and endurance capacity. During heavy exercise, such as a marathon, there is up to a 60-fold increase in plasma IL-6 concentration (209), with the duration of the event explaining more than 50% of the variation in concentration (210). Interestingly, IL-6 shows a markedly lower response to acute exercise in trained subjects.

2. Physiological concentrations of IL-6 stimulate the appearance in the circulation of the anti-inflammatory cytokines IL-1ra and IL-10 and inhibit the production of the pro-inflammatory cytokine TNF-α. The health benefits of long-term regular exercise are ascribed to the anti-inflammatory response elicited by an acute bout of exercise, which is partly mediated by muscle-derived IL-6.

3. The anti-inflammatory effects of exercise may therefore offer protection against TNF-induced insulin resistance. Moreover, IL-6 stimulates lipolysis as well as fat oxidation. The increase in IL-6 at the end of exercise is responsible for the increased CRP levels during late recovery.

In response to regular physical activity, basal as well as post-exercise plasma concentrations of IL-6 will decrease by mechanisms that might include increased glycogen content, improved antioxidant capacity and improved insulin sensitivity. The lower concentrations of IL-6 in the circulation will subsequently result in lower CRP levels.

Few studies have prospectively examined the effect of exercise training on low-grade inflammatory status, and the data obtained from intervention studies are less consistent when compared with cross-sectional population studies. A lower number of subjects or a good physical condition in the start of some intervention studies may explain a part of this inconsistency. Nevertheless, two longitudinal studies in athletes show that regular training induces a reduction in CRP concentration (211,212). Conflicting findings exist in clinical trials that have involved exercise only. Several training interventions have not produced changes in basal IL-6 or CRP concentrations (213–216), while significant reductions in inflammatory markers have been observed following training without changes in BMI or body fat in elderly participants (217,218). The largest trial was performed in 652 sedentary healthy, young and middle-aged, white and black women and men in the HEalth, RIsks factors, exercise Training And Genetics (HERITAGE) Family Study (219). They were subjected to a 20-week standardised exercise training programme; there was no control group, and each subject served as its own control. A non-significant reduction in CRP concentration was consistent across all groups and varied between 1·2 and 2·2 mg/l. Considering that the over-time variation in CRP in healthy individuals with stable lifestyle is small (220), the reduction, although not significant, could nevertheless reflect the true effect of exercise training. Further stratification according to basal CRP levels showed a reduction by about 1·5 mg/l in subjects with initial CRP levels above 3·0 mg/l.

**Effects of exercise in elderly people.** Elderly people have higher basal levels of inflammation independently of disease status, and a considerable number of studies have been carried out in this population to assess associations between physical activity and inflammatory markers (199,223–230). Rather consistent inverse, BMI-independent, associations are found and the associations are suggested to be dose-dependent; the more physically active the person, the lower the inflammatory markers (208,224). Also subjects over 80 years of age show consistent inverse associations between inflammation and physical activity (199). Functional fitness was inversely associated with IL-6 and IL-1ra concentrations (but not with CRP, TNF-α, IL-10 or IL-1β) in a prospective population-based study of 1020 participants aged 65 years and older (225,251). Muscle strength was also evaluated in this study and low hand-grip strength was associated with high levels of CRP and IL-6 (231,251). Other studies have also shown a negative association of CRP, IL-6 and TNF-α with muscle strength (228,252).

Exercise intervention in elderly people or in patients with CVD shows consistent anti-inflammatory effects. After a 6-month individualised, supervised exercise programme for forty-three subjects at high risk of IHD, a 35%, albeit non-significant, reduction in CRP concentration was observed. The subjects exercised for a mean of 2·5 (range 0·3–9·4) h/week (235). One reason for the lack of a significant effect despite the fairly large reduction in CRP concentration is the small size of the study. Another study reported a decrease in basal plasma IL-6 concentration after aerobic training in patients with coronary artery disease (236). A randomised trial of thirty-nine patients with intermittent claudication demonstrated that both serum CRP and SAA concentrations were significantly reduced after 3 and 6 months of supervised
exercise compared with controls (255). In a relatively large intervention study of exercise training on cardiac rehabilitation patients, the median CRP concentration was reduced by 41%, while CRP concentrations did not change in subjects who did not exercise (256). Again, the exercise training seemed to be more effective in those with the highest initial CRP concentrations, independently of changes in body weight or percentage of body fat, indicating that baseline levels of low-grade inflammation may be an important factor.

Studies in patients with diabetes (257) or the metabolic syndrome (238, 239) have consistently demonstrated inverse associations between fitness and inflammation, independently of fatness. In one study, the independent associations of fitness were in fact more prominent among metabolic syndrome patients compared with healthy participants (238, 239).

**Effects of exercise in middle-aged and younger adults and in children.** Several studies of large population cohorts, such as the British Regional Heart Study (225), the Greek ATTICA study (240), the Third National Health and Nutrition Examination Survey (NHANES) (241, 242), the Men’s Health Professionals’ Follow-Up Study (243), the Nurses’ Health Study (244) and the Women’s Health Study (245) provide evidence for an inverse, independent dose-response relationship between plasma CRP concentration and level of physical activity in both men and women, but the consistency is less than in elderly subjects, or in disease states. In contrast, the associations found between self-reported physical activity and TNFR1, TNFR2, IL-6 and CRP concentrations in a study including healthy men from the Men’s Health Professionals’ Follow-Up Study and healthy women from the Nurses’ Health Study (246) were no longer significant when adjusting for BMI and leptin. Thus, the effect of physical activity on circulating markers of low-grade inflammation appears to be mediated by weight loss. In another study in healthy men and women, BMI, but not previous year or current physical activity, predicted CRP concentration (247). Similarly, a cross-sectional study (248) in men found no relationship between leisure-time physical activity and CRP, fibrinogen and SAA concentrations, after correction for BMI and current smoking status. CRP levels in 2120 Finns were associated with obesity indices and physical activity among both sexes (249); in multivariate analyses, the determinants of CRP concentration included obesity and smoking in men, and obesity, oral contraceptive use and physical activity in women. The study showed that, among one in three of healthy women who used oral contraceptives had a CRP concentration exceeding 3 mg/l, which should be taken into account when studying younger females. Cross-sectional studies in men from the Aerobics Center Longitudinal Study have demonstrated that cardiorespiratory fitness levels are inversely associated with CRP concentration and also the prevalence of elevated CRP concentrations (249). Analyses with fibrinogen and white blood cell count showed similar results (249). The competing effect of weight and fitness (assessed by submaximal graded exercise treadmill testing) on cardiorespiratory fitness levels was studied in the NHANES, which included 2112 US adults without previously diagnosed CVD (250). Both fitness and BMI were independently associated with increased fasting insulin and CRP concentrations. However, when patients with low, moderate and high fitness were further stratified as normal, overweight or obese, weight remained significantly associated with CRP, but fitness did not. This study concludes that ‘fat but fit’ subjects require weight-loss interventions to improve their CRP levels. Future interventions should emphasise weight control, even for those with high cardiorespiratory fitness.

In disease-free young populations, studies have assessed the interaction between inflammatory markers (CRP, IL-6 and TNF-α), physical activity and cardiorespiratory fitness and fatness (247, 251–256). Organised leisure-time exercise (assessed by a questionnaire) in children has shown negative correlations with serum IL-6 concentrations, independently of adiposity and fat localisation (256), and in 10-year-old children, a borderline significant negative association was observed between CRP and self-reported physical activity, independently of ponderal index (257). US children and young adults (aged 6–24 years) from the Columbia University BioMarkers Study showed an inverse correlation between cardiovascular fitness and CRP concentration but only in boys, which remained after adjustment of confounders including BMI (251). Only one study has used accelerometry (an objective measure of total physical activity compared with leisure-time physical activity or exercise) instead of questionnaires as well as cardiovascular fitness (257). In this study of 9-year-old Swedish children, total physical activity was unrelated to CRP, fibrinogen, C3 or C4 concentrations, but exercise was. Nevertheless, once body fat was entered into the regression models, no associations with cardiovascular fitness or physical activity and the inflammatory markers measured were observed (257). Similarly, no associations were found between cardiorespiratory fitness or self-reported physical activity and CRP concentration in 12-year-old healthy Welsh children (259).

CRP, C3 and ceruloplasmin (but not C4) concentrations were negatively associated with muscle strength after controlling for sex, age, pubertal status, weight, height, socio-economic status and cardiorespiratory fitness, but did not remain when adjusting for body fat. Nevertheless, when stratifying according to overweight status, CRP (but not C3, C4 or ceruloplasmin) concentration was associated with muscle strength in overweight, but not in normal-weight, adolescents after controlling for potential confounders, including body fat and fat-free mass (260).

**Conclusions for effects of physical activity and fitness on low-grade inflammation**

Most research on this topic hypothesised that the association between fitness and inflammatory factors is independent of fatness. Given that physical activity and obesity are often inversely related, it is not clear as to whether the anti-inflammatory health benefits of a physically active lifestyle are due to exercise per se or result from favourable changes in body composition. Related anti-inflammatory effects could be mediated by increased insulin sensitivity and/or improved concentrations of HDL-cholesterol, ROS or endothelial function, which all demonstrate anti-inflammatory actions (261), and are related to both body fat and exercise. A systematic
review addressed whether fitness or fatness has the greatest impact on inflammatory factors. The review concluded that both fitness and fatness are associated with systemic inflammatory status, although the relative contributions of both may be dependent on age, disease status and sex. These determinants do most probably involve a strong background of low-grade inflammatory status, which consistently is shown to determine any possible inverse association. Although increasing physical activity may be an effective therapy for weight loss and may also emerge as a promising treatment for reducing overall inflammation, the magnitude of the effect to produce clinically meaningful results in the general population requires further research. Nevertheless, exercise is uniquely positioned to reduce inflammation, and even small non-significant reductions in CRP levels may contribute to clinical benefits by reducing cardiovascular and metabolic risk.

A consideration of different approaches to identify relationships between diet and its components and markers of chronic low-grade inflammation

The following sections review the effects of dietary factors, including dietary patterns, whole foods, individual nutrients and other bioactive components on the markers of low-grade inflammation described above. Due to the physiological complexities detailed above, assessment of effects requires careful attention to treatment interventions and study designs, in the context of the endpoints described. Here, important aspects of study design are briefly mentioned.

Epidemiological studies

Epidemiological studies, where available, are discussed for each of the dietary factors. As mentioned above, body-weight changes and exercise may have profound effects on biomarkers of low-grade inflammation; therefore, adjustments for BMI and activity level are critical. An accurate assessment of the analysed dietary parameter is also necessary. Although difficult to rectify, it is important to consider cultural differences in food consumption habits, for example differences in coffee preparation procedure and brew strength between the USA and Europe. Attention should also be paid to the assessment of dietary patterns. For example, the Mediterranean diet has been variously defined and scored as inclusive or exclusive of fish, poultry, dairy, eggs, moderate alcohol consumption and ratio of monounsaturated:saturated fat. However, it is not clear whether these differences in scoring would result in alternative conclusions being drawn, and as such, this body of literature is best viewed in totality.

Intervention studies

Intervention studies, where available, are also discussed for each of the dietary factors. The studies presented here typically fall into three design categories: (1) chronic dietary interventions in individuals with some degree of existing low-grade inflammation, based on changes in markers measured in fasting blood, sometimes in the context of weight loss; (2) acute dietary interventions in which the acute effect of a putative anti-inflammatory dietary treatment is assessed against some background level of low-grade inflammation; (3) challenge studies in which inflammation is induced by either a dietary or exercise challenge, in the presence or absence of a putative anti-inflammatory dietary treatment. As with epidemiological studies, body weight and activity levels require careful control and monitoring because of their possible impact on low-grade inflammation. Chronic interventions are most commonly either parallel-arm designs or cross-over designs, and may be most relevant since they directly evaluate the effect of the dietary component on low-grade inflammation. However, acute intervention and postprandial challenge studies may also provide valuable insight, and postprandial inflammation has recently been hypothesised to play an aetiological role in the progression of CVD. Additionally, between-subject variations in biomarkers of the inflammatory response can be controlled for statistically in cross-over designs. In contrast to epidemiological studies, which often have a large sample size and may evaluate outcomes over a long duration, intervention studies are most often relatively small and of short duration (hours for acute studies; weeks to months for chronic studies). Small studies can limit power to identify significant effects. Another difficulty with intervention studies can be compliance among subjects; although an ideal study design would include actions to ensure compliance and would monitor this, such approaches are not always considered. Lack of compliance may limit the effectiveness of an intervention.

Dietary patterns and low-grade inflammation

For the purposes of this article, low-grade inflammation was defined as elevated circulating concentrations of pro-inflammatory cytokines, acute-phase proteins and adhesion molecules, and low circulating concentrations of adiponectin.

Eating patterns

Studies on diet and disease have traditionally examined the associations of individual nutrients, foods or food groups with risk factors and health outcomes. However, this approach has certain limitations: many nutrients are highly correlated, and have synergistic or interactive effects; examination of nutrients or foods singly may not provide enough statistical power due to the small effect size; and the possibility of finding significant associations by chance alone, due to multiple testing, is large. In response to the challenges of the traditional approach to understanding diet–disease relationships, more recently, nutrition epidemiologists have studied dietary or eating patterns that examine combinations of foods and nutrients, in relation to health and disease. Dietary pattern research is generally based on two kinds of methods: a priori using diet scores; or a posteriori using data-driven techniques such as factor analysis and cluster analysis.

Hypoenergetic diet. One diet-dependent but apparently quite non-specific way of decreasing low-grade inflammation
Diet and low-grade chronic inflammation

...is energy restriction\(^{(267)}\). Weight loss is accompanied by decreased concentrations of circulating mediators of inflammation, such as CRP, TNF-α, IL-6 and sICAM-1\(^{(155,268–270)}\), although it is difficult to dissect whether this effect is due to the weight loss per se or to the nature of the diet used to induce weight loss. On the other hand, it seems likely that reduced secretion of pro-inflammatory mediators from adipocytes or activated macrophages of adipose tissue contributes to the effect of weight loss\(^{(31,36,65,67,142)}\). However, energy restriction itself may also play an anti-inflammatory role, with key mediators of the effect being proteins of the sirtuin and Forkhead box, sub-group O (FoxO) families which are induced/activated during states of limited energy supply. The sirtuins are NAD\(^+-\)dependent deacetylases of substrates ranging from histones to transcriptional regulators. As a consequence, metabolic efficiency is improved, cell defences against stress are strengthened and inflammatory activities are dampened, notably by decreasing the activation of NF-κB\(^{(271–274)}\). FoxO proteins are transcription factors which regulate the expression of genes involved in energy homeostasis, cell survival and inflammatory responses including NF-κB\(^{(271–274)}\). Early studies have shown that reduced energy intake is paramount compared with the nature of low-energy food, i.e. decreased concentrations of inflammatory markers are observed with a low-energy, fat-rich as well as with a low-energy, carbohydrate-rich diet\(^{(279)}\). However, it is conceivable that some dietary components are better regulators of sirtuin or FoxO activity than others. Resveratrol, present in red wine, was found to directly or indirectly interact with sirtuins and promote their deacetylase activity. This led to increased lifespan in model organisms and in animal models\(^{(280,281)}\). It is likely that dietary components will be identified that mimic or counteract the anti-inflammatory effects of energy restriction.

**Mediterranean diet.** The term Mediterranean diet refers to a traditional dietary pattern characteristic of many parts of Greece, Southern Italy, Southern Spain and elsewhere in the Mediterranean region. The traditional Mediterranean diet is rich in fruit, vegetables, whole-grains, legumes (beans), nuts, fish and low-fat dairy products, with moderate consumption of wine, and whose principal source of fat is olive oil\(^{(282–286)}\). Most studies have assessed the adherence to the Mediterranean diet by assigning a score in relation to the consumption of these foods. Others\(^{(284,285)}\) have used modified versions of this score by not considering certain food groups, i.e. dairy products.

Observational studies have examined the association of the Mediterranean diet with inflammatory markers in healthy persons\(^{(282,285,285)}\), and they generally report inverse correlations. In a recent study\(^{(282)}\) investigating psychological, behavioural and biological risk factors for subclinical CVD in 345 middle-aged male twins, an inverse association between adherence to the Mediterranean diet and inflammation, as measured by plasma IL-6 concentration, was noted. This association was independent of several known cardiovascular risk factors, and persisted when twins within pairs were compared, suggesting that the results were not confounded by shared environmental and genetic factors. Although a marginal relationship between CRP concentration and the Mediterranean diet was observed, this association was no longer significant when other cardiovascular risk factors were considered in the models. It is likely that IL-6 is a more sensitive marker of chronic low-grade inflammation and that CRP reflects a more downstream effect associated with IL-6. In a subsample of the Nurses’ Health Study\(^{(285)}\), a Mediterranean diet index score was inversely associated with markers of inflammation (circulating IL-6 and CRP) as well as markers of endothelial dysfunction (the adhesion molecules sICAM-1, sVCAM-1 and soluble E-selectin (sE-selectin)); these associations persisted upon adjustment for traditional CVD risk factors. Similar findings were reported in the ATTICA study, involving 1514 men and 1528 women; specifically, subjects with greater adherence to the Mediterranean diet (those in the highest tertile) had 17% lower IL-6 and 20% lower CRP concentrations, compared with those in the lowest tertile in analyses that adjusted for other cardiovascular risk factors\(^{(285)}\). Although a marginal association was noted between TNF-α and the Mediterranean diet, it was not significant in adjusted models\(^{(285)}\). In another observational study with obese subjects (625 men and 712 women with abdominal adiposity), those with high CRP levels (>3 mg/l) were less likely to adopt the Mediterranean diet\(^{(287)}\). The authors reported that adoption of the Mediterranean diet in conjunction with moderate physical activity was associated with a reduced likelihood of having high CRP levels by 72%, highlighting the potential importance of the Mediterranean diet in diminishing inflammation. In subjects at high risk for CVD, those with diabetes or with multiple CHD risk factors, however, no association between the Mediterranean diet and CRP or adhesion molecule (sICAM-1 and sVCAM-1) concentrations was seen\(^{(288)}\). However, a significant relationship between higher consumption of some typical Mediterranean diet components (cereals, fruit, nuts and virgin olive oil) and circulating inflammatory markers (IL-6) and markers of endothelial function was noted in these at-risk subjects.

Few intervention studies have been conducted to examine the effect of consuming the Mediterranean diet on markers of low-grade inflammation. In two cross-over studies involving short-term interventions (1–3 months) with healthy subjects, differential effects of the Mediterranean diet on markers of inflammation (and endothelial dysfunction) were observed. In the study by Ambring et al.\(^{(289)}\), healthy subjects received their typical Swedish diet for about 4 weeks, and a Mediterranean-inspired diet for about 4 weeks in a randomised cross-over design, with 4 weeks of washout in-between. A marked reduction in the number of leucocytes, including monocytes, neutrophils and lymphocytes, and in the number of platelets after 4 weeks of the Mediterranean diet was noted, suggesting a lower inflammatory activity than during the Swedish diet period. On the other hand, IL-6 and CRP concentrations did not change with the Mediterranean diet; the authors speculated that the study may not have been powered to detect those effects. In another study\(^{(290)}\), twenty healthy young males were provided three dietary interventions, each lasting 4 weeks. First, all subjects consumed a diet high in saturated fat, next they were randomly assigned to either...
of the two intervention diets: a Mediterranean-style diet (MUFAtagged diet, 22% energy from MUFAs) or a low-fat, high-carbohydrate diet (<30% energy from fat and 55% from carbohydrates). LDL was isolated and oxidised. Oxidised LDL from subjects on either the Mediterranean diet or the high-carbohydrate diet decreased TNF-a-induced VCAM-1 and E-selectin expression in human umbilical endothelial cells in vitro. A consistent decline in inflammatory markers has been observed in intervention studies involving obese subjects or those with the metabolic syndrome. In a randomised controlled study with 120 pre-menopausal obese women, the effects of a multidisciplinary approach (aiming at 10% weight reduction with a combination of a low-energy, Mediterranean-style diet and increased physical activity) were evaluated compared with a control group (given general information about healthy choices and exercise)(111). The intervention group received regular sessions (18 over a 2-year period) with a nutritionist to ensure compliance. Significant reduction in several markers of inflammation (CRP, IL-6 and IL-18) and an increase in adiponectin concentration were noted in the Mediterranean diet group compared with the control group. In a randomised controlled trial lasting 2 years, 180 subjects with the metabolic syndrome were assigned either to a Mediterranean-style diet (instructions were provided on increasing daily consumption of whole grains, fruit, vegetables, nuts and olive oil) or to a control group (prudent diet, with same macronutrient composition as the Mediterranean diet)(284). After 2 years, body weight decreased more in the intervention group and inflammatory markers (CRP, IL-6, IL-7 and IL-18) decreased and endothelial function improved, compared with the control group. Interestingly, even after controlling for weight loss, the inflammatory markers declined more in subjects following the Mediterranean-style diet. In other related studies involving individuals with the metabolic syndrome, a consistent reduction in CRP concentration in the intervention group receiving the Mediterranean diet has been shown(291,292). In the Prevençión con Dieta Mediterránea study, 772 asymptomatic subjects at high cardiovascular risk (diabetes or more than three CHD risk factors) were randomly assigned to a low-fat diet or one of two Mediterranean diets(293). Those allocated to the Mediterranean diets received nutritional education and either free virgin olive oil, or free nuts for 3 months. Both Mediterranean diets were beneficial in terms of significant reductions in serum IL-6, sICAM-1 and sVCAM-1 concentrations, while CRP concentration was reduced only in the Mediterranean diet supplemented with olive oil. Taken together, the results from these often large intervention studies strongly suggest that Mediterranean diets can lead to reductions in chronic low-grade inflammation and improvement in endothelial function, thereby offering cardioprotective effects.

**Vegetarian diets.** Observational studies have compared vegetarian with non-vegetarian diets in healthy subjects in relation to inflammatory markers. Dietary patterns consistent with vegetarianism were associated with lower concentrations of markers of chronic low-grade inflammation and endothelial function when compared with non-vegetarian diets(294–296). In one study comparing a group of thirty Taoist adults who had been vegetarian for 5–55 years (average 22 years) with a group of thirty age- and sex-matched non-Taoist adults consuming a non-vegetarian diet, lower CRP concentrations were noted in the former group(295). Specifically, plasma CRP concentration averaged 0.77 and 1.30 mg/l in vegetarians and non-vegetarians, respectively. Another study with a similar design comparing vegetarians with non-vegetarians also found that the average CRP concentration was significantly lower in the vegetarian group (0.72 vs. 1.62 mg/l)(293). Similarly, lower levels of the adhesion molecules sICAM-1 and sE-selectin have been reported in those following a vegetarian v. a non-vegetarian diet(296). Thus, these cross-sectional studies suggest that a vegetarian-style diet can lead to lower chronic low-grade inflammation than an omnivorous diet. However, it is important to recognise that vegetarians may differ from non-vegetarians in aspects of lifestyle other than diet such as physical activity, smoking behaviour and socio-economic class. Studies considering vegetables and fruits are described in section Vegetables and fruits.

**Eating patterns.** The healthy eating index (HEI) was developed by the US Department of Agriculture, based on the Dietary Guidelines for Americans and the Food Guide Pyramid(277). It has ten subcomponents: grains, fruits, vegetables, dairy, meats, fats, saturated fat, cholesterol, Na and dietary variety. Individuals are assigned scores for each of the ten components (from 0 to 10) based on their typical intakes; the maximum value for the HEI being 100. Recently, the HEI was revised as the Alternate HEI (AHEI) to focus on healthier items in the Food Guide Pyramid food groups(298) such as protein source, ratio of polyunsaturated:saturated fats and cereal fibre, as well as cis-v. trans-fat. Additionally, moderate alcohol consumption and long-term multivitamin use are also considered in the AHEI. The Diet Quality Index (DQI) is a composite score of an overall healthy diet that reflects an individual’s adherence to the eight diet and health recommendations of the National Academy of Science. The revised DQI (DQI-R) is based on similar guidelines but also includes Fe and Ca intakes(299).

Using the data from NHANES III on a representative sample of the US population, Ford et al.(300) found a negative correlation between the HEI and CRP concentration after adjustment for several CVD risk factors including BMI and waist:hip ratio; when stratified by sex this finding was significant in women only. The authors noted that this association was primarily driven by grain consumption. The authors speculated that because HEI score was determined based on dietary intake data collected by a 24h recall, the possibility of misclassification of individuals with respect to HEI status could have attenuated the associations. In a study by Fung et al.(295), the association of several diet-quality scores, such as the HEI, AHEI, DQI-R and an alternate Mediterranean diet index with various markers of inflammation, was evaluated in a subsample of the Nurses’ Health Study (n 690 healthy women). The key findings were that the AHEI and alternate Mediterranean diet index scores were negatively associated with CRP, IL-6, sE-selectin and sICAM-1 concentrations, and that these associations persisted upon adjustment for potential confounding variables including BMI. In contrast, the HEI and
DQI-R did not correlate with any of the inflammatory markers when potential confounders were taken into consideration in the regression models. A more recent study evaluated the impact of the AHEI among 1922 women from the Nurses’ Health Study (62% of whom were overweight) who had no history of diabetes or CVD on plasma inflammatory marker concentrations. After adjustment for age and energy intake, women with the highest adherence to the AHEI had 24% higher median total adiponectin and 32% higher median high-molecular-weight adiponectin concentrations, as well as 16% lower resistin, 41% lower CRP and 19% lower sE-selectin concentrations than did women with the lowest adherence to the AHEI. These associations remained significant after adjustment for potential confounders. Inverse associations between the AHEI and CRP, sTNFR2, IL-6, sICAM-1 and sVCAM-1 concentrations were evident, but they did not remain significant after adjustment for BMI. In a small cross-sectional study involving 114 ‘apparently healthy’ overweight or obese postmenopausal women, Boynton et al. found little evidence of an association between dietary quality, as measured by the HEI and DQI, and markers of inflammation (CRP and SAA). Marginal associations were noted between the DQI and these inflammatory markers. These associations were, however, attenuated and no longer significant, after adjusting for adiposity (percentage of body fat or BMI), suggesting that the decrease in CRP or SAA concentration seen with a higher-quality diet is most probably mediated by obesity. The authors speculated that consuming a healthier diet may lead to decreased adiposity, which in turn could result in less low-grade inflammation.

Several studies have examined the relationship between consuming a ‘prudent diet’ and markers of low-grade inflammation. In one study, in 732 healthy women from the Nurses’ Health Study aged 43–69 years, a prudent pattern was characterised by higher intakes of fruit, vegetables, legumes, fish, poultry and whole grains, and a Western pattern was characterised by higher intakes of red and processed meats, sweets, desserts, French fries and refined grains. The prudent pattern was inversely associated with plasma concentrations of CRP and sE-selectin after adjustment for age, BMI, physical activity, smoking status and alcohol consumption. The Western pattern showed a positive relationship with CRP, IL-6, sE-selectin, sICAM-1 and sVCAM-1 after adjustment for all confounders except BMI; with further adjustment for BMI, the coefficients remained significant for CRP, sE-selectin, sICAM-1 and sVCAM-1. Using data from the Nurses’ Health Study, Schulze et al. identified a dietary pattern that was significantly associated with increased concentrations of CRP, IL-6, sTNFR2, sE-selectin, sICAM-1 and sVCAM-1. This pattern, which was high in sugar-sweetened soft drinks, refined grains, diet soft drinks and processed meat but low in wine, coffee, cruciferous vegetables and yellow vegetables, was also associated with an increased risk of diabetes. Most recently, Hoebeeck et al. evaluated the relationship between adherence to food-based dietary guidelines and inflammatory markers among 2524 healthy Belgian men and women aged 35–55 years. The dietary index consisted of three subscores (dietary quality, diversity and equilibrium) according to adherence to the Flemish food-based dietary guidelines, using data from a semi-quantitative FFQ. Higher dietary scores were inversely associated with IL-6 concentration and leucocyte numbers in the bloodstream. Nettleton et al. examined relationships between dietary patterns and markers of inflammation and endothelial activation among 5089 non-diabetic participants in the Multi-Ethnic Study of Atherosclerosis. In this study, four dietary patterns were derived by using factor analysis. The fats and processed meats pattern (fats, oils, processed meats, fried potatoes, salty snacks and desserts) was positively associated with CRP and IL-6 concentrations. The beans, tomatoes and refined grains pattern (beans, tomatoes, refined grains and high-fat dairy products) was positively related to sICAM-1 concentrations. In contrast, the whole grains and fruit pattern (whole grains, fruit, nuts and green leafy vegetables) was inversely associated with CRP, IL-6 and sICAM-1 concentrations, while the vegetables and fish pattern (fish and dark-yellow, cruciferous and other vegetables) was inversely related to IL-6 concentration. There are few such studies using data from outside of the USA or Europe. A cross-sectional study of 486 healthy Iranian women aged 40–60 years identified dietary patterns by factor analysis and related these to circulating markers of inflammation. The healthy dietary pattern (high in fruits, vegetables, tomatoes, poultry, legumes, tea, fruit juices and whole grains) was inversely related to plasma CRP, sE-selectin and sVCAM-1 concentrations after controlling for potential confounders; with further adjustment for BMI and waist circumference, the associations remained significant for CRP and sVCAM-1. In contrast, the Western dietary pattern score (high in refined grains, red meat, butter, processed meat, high-fat dairy, sweets and desserts, pizza, potatoes, eggs, hydrogenated fats and soft drinks) was positively related to CRP, SAA, IL-6, sICAM-1 and sVCAM-1 concentrations; however, after additional control for BMI and waist circumference, the associations remained significant only for SAA and IL-6. The traditional dietary pattern (high in refined grains, potatoes, tea, whole grains, hydrogenated fats, legumes and casserole) was positively associated with the plasma IL-6 concentration after controlling for BMI and waist circumference. Nanri et al. investigated the relationship between dietary patterns and circulating CRP concentration in 7802 Japanese men and women with CRP < 3 mg/l. The dietary patterns were derived from principal component analysis of the frequency of consumption of forty-nine food items ascertained by the FFQ. The following four dietary patterns were identified: healthy, high-fat, seafood and Westernised breakfast patterns. The healthy dietary pattern, characterised by high intakes of vegetables, fruits, soya products and fish, was inversely related to CRP concentrations, even after adjustment for age, BMI, smoking, alcohol consumption and physical activity in both men and women. Neither the high-fat dietary pattern nor the Westernised breakfast pattern was related to CRP concentrations. Most recently, the relationship between two dietary patterns (Healthy and Western), which were derived by principal component analysis using data collected by a FFQ from subjects in the Atherosclerosis Risk in Communities Study
Study, and markers of inflammation has been described (309). The measures of inflammation were quantified by flow cytometry in fresh whole blood from 1101 white adults. After multivariable adjustment, monocyte LPS receptor (CD14), monocyte TLR-2 and platelet glycoprotein IIb (CD41) showed inverse associations with the healthy dietary pattern. In contrast, the Western dietary pattern was positively associated with CD41 and platelet-granulocyte aggregates. Taken together, these studies suggest that healthy eating patterns are associated with lower concentrations of markers of chronic low-grade inflammation.

Whole foods

Whole grains/refined grains. Published studies have so far investigated a narrow and low range of whole grain intakes, which limits the interpretation of associations between whole grain intake and markers of low-grade chronic inflammation. Observational studies (Table 3) (310–314) including data from NHANES III have suggested that a high intake of whole grain is inversely associated with plasma CRP concentration (quintile Q1 < 3.5 servings/d, Q5 > 9.7 servings/d) (310). In contrast, Jensen et al. (310) reported no association between a moderate whole grain intake (Q1 8.2 g/d, Q5 43.8 g/d) and markers of inflammation (CRP, IL-6 and fibrinogen) in the Health Professionals’ Follow-Up Study. However, bran intake correlated inversely with CRP concentration and germ intake with IL-6 concentration. Data from the Nurses’ Health Study showed lower CRP and sTNFR2 concentrations in diabetic women with a moderate intake of whole grain compared with those with a low intake (314). In another study with diabetic males (n 780; from the Health Professionals’ Follow-Up Study), Qi et al. (315) showed that cereal fibre was positively associated with adiponectin concentration after controlling for a number of confounding factors. A higher intake of whole grain (low < 0.8 servings/d, high ≥ 2 servings/d) within a Mediterranean diet in diabetic women was associated with increased adiponectin concentration (312). Data from the Multi-Ethnic Study of Atherosclerosis (MESA) showed a higher whole grain intake (Q1 0.02 servings/d, Q5 1.39 servings/d) to be associated with lower CRP concentration in elderly subjects (311).

Evidence from intervention studies (Table 4) (311,316–320) includes a study whereby overweight and obese subjects consumed a hypoenergetic diet with or without whole-grain foods. CRP concentration decreased by 38% (CRP at baseline 5.9–6.0 mg/l) in the whole-grain group independent of the observed weight loss (319). However, plasma concentrations of IL-6 and TNF-α and PAI-1 activity did not change within the 12-week-study period. Based on the outcome of this study, the authors concluded that the changes seen in CRP concentration with a whole-grain diet were not part of a systemic anti-inflammatory effect (319). In a study from Sweden with a similar design but only a 6-week intervention (whole-grain v. refined-grain products), the whole grain intake was not associated with changes in the concentrations of CRP and IL-6 or in PAI-1 activity of moderately overweight subjects (316). Baseline CRP concentration (2.03–2.86 mg/l) and BMI were much lower than in the previous study, which may explain the different outcomes between these studies. Recent intervention trials with whole grain (60–120 g/d) or wholemeal intake (30–40 g/d) and comparable CRP baseline concentrations also did not observe any changes in plasma markers of inflammation (317,320). In the study by Brownlee et al. (317), whole-grain products did not substitute refined-grain products but were consumed in addition to the refined products. Bioprocessing of whole wheat affected the anti-inflammatory potential in a human intervention study when compared with unprocessed whole wheat (323). Bioprocessing modulated the ratio of pro-inflammatory:anti-inflammatory cytokines during 24 h after the intake of 300 g whole wheat bread. This study suggests that subtle changes in the processing of whole grains may be relevant for their anti-inflammatory activity, which could in part explain the contradictory findings of the human intervention studies.

Replacing a refined-wheat flour pizza by a similar pizza prepared from whole-wheat flour resulted in a decreased postprandial concentration of the pro-inflammatory cytokine IL-1β in both non-diabetic and diabetic subjects (318).

In summary, whole grain intake appears to inversely associate with markers of low-grade inflammation. Processing status of whole-grain products should be more precisely defined in future studies. Potential mechanisms still have to be elucidated, as well as the active constituents which may include dietary fibre, minerals, vitamins and phytochemicals such as lignans and phenolic acids.

Vegetables and fruits. A number of cross-sectional studies have investigated the association between vegetable and fruit intake and biomarkers of inflammation (Table 5) (328,322–330). Study participants included healthy, normal-weight adults as well as overweight/obese adults with associated diseases. Each study applied different criteria to stratify the intake of vegetables and fruits which makes it difficult to compare the outcomes. Of the ten cross-sectional studies, seven reported an inverse association between a high intake of vegetables and fruits, either in combination or alone, and blood CRP concentrations (322–325,327–329). In one study, no association with CRP was observed (328), while in a second study, an inverse association was seen in men but not in women (327). For the other biomarkers reported, the outcome is less consistent. A recent study reported that a high intake of vegetables and fruits was associated with a lower peripheral blood mononuclear cell gene expression for several pro-inflammatory cytokines and adhesion molecules (326). An important observation is that besides the quantity of total intake of vegetables and fruits, the variety consumed in a given time has a significant impact on these biomarkers. A high number of varieties of vegetables and fruits were inversely correlated with blood CRP levels (322). This suggests that plant-specific constituents of vegetables and fruits such as the phytochemicals may contribute to the anti-inflammatory activities.

A number of intervention studies have investigated the impact of vegetables and fruits in total or of specific varieties on biomarkers of inflammation (Table 6) (331–340). Of the four studies focusing on vegetables and fruits as a food group, three reported a reduction in blood concentrations of different biomarkers of inflammation (318,312,345), while one study did...
not find any significant effect\(^\text{336}\). In twelve studies with a specific focus on a single variety of vegetable or fruit, inconsistent results were reported. Most studies have used fruits or fruit extracts high in polyphenols. Results from such studies suggest an anti-inflammatory effect; however, mostly, only a single biomarker was affected, and never the complete set of inflammation biomarkers investigated\(^\text{551–354,357–340,346}\). In conclusion, current evidence for specific effects of single vegetable and fruit varieties is not convincing, while a high overall intake of vegetables and fruits seems to be associated with a lower state of inflammation.

**Soya.** Several randomised controlled intervention trials have shown that supplementation with different quantities of soya protein did not affect markers of inflammation (CRP, IL-6, IL-18, sICAM-1, sVCAM-1 and sE-selectin) \((\text{Table 7})\). Variations in soya protein isoflavone contents did not modulate the outcome in these studies. In one study, reduced plasma CRP, TNF-\(\alpha\) and IL-18 concentrations were reported in postmenopausal Iranian women with the metabolic syndrome consuming soya nuts but not soya protein\(^\text{347}\). The major difference between soya protein and soya nuts (comparable contents of isoflavones) was a much higher content of PUFA in the soya nuts, suggesting that rather than soya-specific constituents, the increased intake of PUFA may be responsible for the reduction in biomarkers of inflammation\(^\text{347}\). The same group investigated in diabetic patients with nephropathy the anti-inflammatory effect of textured soya protein compared with animal protein after 4 years of intake. Consumption of soya protein significantly lowered plasma concentrations of CRP\(^\text{349}\). In another study investigating soya nuts in normotensive and hypertensive postmenopausal women, no effect on CRP, IL-6, sICAM-1 or matrix metalloproteinase-9 concentrations was observed compared with the control diet\(^\text{361}\). However, in hypertensive women, levels of sVCAM-1 were significantly lower after soya nut consumption\(^\text{361}\). Again, the increased PUFA intake may have caused this effect. Long-term soya exposure did not affect CRP, IL-6, leptin and adiponectin concentrations in postmenopausal women\(^\text{357}\), or CRP, IL-6, leptin, adiponectin, MCP-1 or MIP-1\(\beta\) concentrations in men\(^\text{356}\). Short-term soya intervention in postmenopausal women with or without exercise-induced inflammation had no effect on IL-1\(\beta\), IL-6 or TNF-\(\alpha\) concentrations\(^\text{349,350}\). Among men with prostate cancer undergoing androgen deprivation therapy, soya intervention had no effect on the concentrations of several inflammatory markers\(^\text{360}\). Overall, these data suggest that soya protein does not affect markers of inflammation, that soyabean processing may affect the anti-inflammatory potential of soyabean constituents and that the health status of the study subjects might determine the anti-inflammatory efficacy of specific foods.

**Nuts.** To date, only few studies have investigated the effect of nuts on inflammatory markers. The MESA reported that a high intake of nuts and seeds (\(\geq 5\) times/week) compared with a low intake (rarely or no consumption) was associated with lower plasma concentrations of CRP, IL-6 and fibrinogen\(^\text{367}\). In contrast, data from the Nurses’ Health Study suggest that nut intake is not associated with inflammatory

---

**Table 3.** Observational studies on the association between whole grain intake and markers of low-grade inflammation.

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Intake</th>
<th>Study type</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy</td>
<td></td>
<td>(\geq 20)</td>
<td>3.5–7 servings/d</td>
<td>Cross-sectional</td>
<td>300</td>
</tr>
<tr>
<td>Healthy</td>
<td></td>
<td>45–70</td>
<td>5.3–9.6 g/d</td>
<td>Cross-sectional</td>
<td>310</td>
</tr>
<tr>
<td>Healthy</td>
<td></td>
<td>57–60</td>
<td>4.8 v. 3.5 g/d</td>
<td>Cross-sectional</td>
<td>314</td>
</tr>
<tr>
<td>Healthy</td>
<td></td>
<td>Median 56((\pm) 7</td>
<td>3.5–7 servings/d</td>
<td>Cross-sectional</td>
<td>312</td>
</tr>
<tr>
<td>Healthy</td>
<td></td>
<td>40–60</td>
<td>1.39 servings/d</td>
<td>Cross-sectional</td>
<td>313</td>
</tr>
<tr>
<td>Healthy</td>
<td></td>
<td>902 (F)</td>
<td>0.8 v. 2.1 servings/d</td>
<td>Prospective</td>
<td>311</td>
</tr>
<tr>
<td>Healthy</td>
<td></td>
<td>1058 (F)</td>
<td>0.02 v. 1.39 servings/d</td>
<td>Cross-sectional</td>
<td>313</td>
</tr>
<tr>
<td>Healthy</td>
<td></td>
<td>Mean 941 (M/F)</td>
<td>0.04 v. 1 servings/d</td>
<td>Cross-sectional</td>
<td>313</td>
</tr>
</tbody>
</table>

M, male; F, female; 1, increased; CRP, C-reactive protein; fibrinogen. Table 3. Observational studies on the association between whole grain intake and markers of low-grade inflammation. Subject, subject; n, number; CRP, C-reactive protein; IL-6, interleukin-6; TNF-\(\alpha\), tumour necrosis factor-\(\alpha\); MCP-1, monocyte chemotactic protein-1; sICAM, soluble intercellular adhesion molecule-1; sE-selectin, soluble E-selectin; sVCAM, soluble vascular cell adhesion molecule-1; sTNFR2, soluble tumour necrosis factor receptor 2; sPAI-1, soluble plasminogen activator inhibitor 1. Table 3. Observational studies on the association between whole grain intake and markers of low-grade inflammation. Subject, subject; n, number; CRP, C-reactive protein; IL-6, interleukin-6; TNF-\(\alpha\), tumour necrosis factor-\(\alpha\); MCP-1, monocyte chemotactic protein-1; sICAM, soluble intercellular adhesion molecule-1; sE-selectin, soluble E-selectin; sVCAM, soluble vascular cell adhesion molecule-1; sTNFR2, soluble tumour necrosis factor receptor 2; sPAI-1, soluble plasminogen activator inhibitor 1.
Table 4. Intervention studies investigating the effect of whole grain intake on markers of low-grade inflammation

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Intake</th>
<th>Study design and duration</th>
<th>Effect on low-grade inflammation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderately overweight</td>
<td>111, 318</td>
<td>Mean 60(M/F)</td>
<td>High carbohydrate, low fibre</td>
<td>Randomised, unblinded, 6 weeks</td>
<td>IL-18 in diabetics and healthy</td>
</tr>
<tr>
<td>Obese with the metabolic syndrome</td>
<td>50(M/F)</td>
<td>Mean 26–63</td>
<td>Low fibre: whole wheat bread, high fibre: refined wheat bread</td>
<td>Randomised, unblinded, 12 weeks</td>
<td>CRP, IL-6, PAI-1</td>
</tr>
<tr>
<td>Normal weight, overweight, obese</td>
<td>226(M/F)</td>
<td>Mean 14–65</td>
<td>3 servings of refined cereal foods, 3 servings of whole wheat, 0·60 then 120 g whole wheat/white crude energy</td>
<td>Parallel arm; 12 weeks</td>
<td>CRP, IL-6, TNF-α</td>
</tr>
</tbody>
</table>

M, male; F, female; IL-18, IL-18; CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor-1; sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM-1, soluble intercellular adhesion molecule-1; sE-selectin, soluble E-selectin.

Fish. Increased frequency of fish consumption was associated with lower CRP and IL-6 concentrations in a cohort of 727 adults in the USA(373). sCAM-1 and sE-selectin concentrations also decreased but the effect of fish consumption was weaker than what was observed for CRP and IL-6. sTNFR2 concentrations were not associated with fish consumption. A study in 379 adults in Denmark reported a lack of association between fish consumption and CRP concentration, even though the subjects displayed a wide range of intakes including very high intakes (e.g. over 30% of subjects ate fish more than once per day)(374). Data from 5037 adults in the NHANES showed no association of fish consumption with CRP concentration after adjusting for a range of confounders(375). In this study, 25% of subjects consumed fish more than 3 times per month. Most recently, fish consumption among a cohort of 4077 Australian adults was reported not to be associated with CRP concentration before or after adjustment for confounders(376). In contrast to these findings, a study in 3102 Greek adults reported that fish consumption was ‘dose-dependently’ associated with lower CRP, IL-6, TNF-α and SAA concentrations and white blood cell counts; individuals consuming >300 g fish/week (n 259; 9%) had significantly lower concentrations of CRP (~33%), IL-6 (~33%), TNF-α (~21%), SAA (~28%) and leucocytes (~4%) than seen in individuals not consuming fish (n 319; 11%) (377). It is possible that the observations of Zampelas et al. may be due to greater fish consumption than in the other populations studied and/or to the type of fish consumed. No studies have discriminated between consumption of lean v. fatty fish. A 4-week intervention study with herring (150 g/d, 5 d/week) in overweight and obese adults in Sweden (n 13) reported a trend towards lower CRP concentration compared with the concentration seen when the subjects consumed a reference diet, but the 30% reduction in CRP was not significant(378). The lack of statistical significance of the effect seen may be due to the small sample size.
Observational studies on the association between vegetable and fruit intake and markers of low-grade inflammation

<table>
<thead>
<tr>
<th>Study type</th>
<th>Associations with low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross-sectional</td>
<td>High vegetable and fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age (years)</th>
<th>Intake level/frequency</th>
<th>Study type</th>
<th>Associations with low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overweight</td>
<td>69</td>
<td>fruit servings/d</td>
<td>Cross-sectional</td>
<td>High vegetable and fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Overweight</td>
<td>69</td>
<td>1.4</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Overweight</td>
<td>69</td>
<td>1.3</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy and overweight</td>
<td>19</td>
<td>0</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy and overweight</td>
<td>19</td>
<td>0</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy adolescents</td>
<td>15</td>
<td>0</td>
<td>Association with intake of vegetables or fruit</td>
<td>Cross-sectional</td>
<td>Increasing fruit intake: CRP</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable and fruit intake: Increased: IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High vegetable intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Healthy normal weight</td>
<td>Mean 21</td>
<td>0.66</td>
<td>Cross-sectional</td>
<td>High fruit intake: CRP, IL-1ra, IL-6, TNF, NF-κB</td>
<td>380–383,387</td>
</tr>
<tr>
<td>Subjects</td>
<td>n (sex)</td>
<td>Age (years)</td>
<td>Intake</td>
<td>Study design and duration</td>
<td>Effect on low-grade inflammation</td>
</tr>
<tr>
<td>----------</td>
<td>---------</td>
<td>-------------</td>
<td>--------</td>
<td>---------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>Healthy</td>
<td>13 (M)</td>
<td>23–40</td>
<td>High-fat meal</td>
<td>Single meal, short term</td>
<td>↓ PAI-1</td>
</tr>
<tr>
<td></td>
<td>12 (F)</td>
<td></td>
<td>v. high-fat meal + 400 g of vegetables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy</td>
<td>6 (M)</td>
<td>Mean 22</td>
<td>500 ml/d of high-pressure orange juice</td>
<td>Randomised, open label, uncontrolled; 14 d</td>
<td>= CRP</td>
</tr>
<tr>
<td></td>
<td>6 (F)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy</td>
<td>6 (M)</td>
<td>Mean 22</td>
<td>500 ml/d of vegetable soup</td>
<td>Randomised, open label, uncontrolled; 14 d</td>
<td>↓ MCP-1, PGE₂</td>
</tr>
<tr>
<td></td>
<td>6 (F)</td>
<td></td>
<td></td>
<td></td>
<td>= TNF-α, IL-6, IL-1</td>
</tr>
<tr>
<td>Healthy</td>
<td>5 (M)</td>
<td>19–52</td>
<td>196 g/10 MJ v. 810 g/10 MJ of vegetables + fruit</td>
<td>Randomised, controlled, parallel; 6 weeks</td>
<td>CRP, sICAM-1, sP-selectin</td>
</tr>
<tr>
<td></td>
<td>13 (F)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obese pre- and postmenopausal women</td>
<td>24 (pre-)</td>
<td>Mean 38 (pre-)</td>
<td>36 g/d of lyophilised grape powder</td>
<td>Randomised, controlled, parallel; 4 weeks</td>
<td>↓ TNF-α, = IL-6, CRP</td>
</tr>
<tr>
<td>Healthy</td>
<td>63 (M)</td>
<td>31–32</td>
<td>2, 5 or 8 servings/d of vegetables + fruit</td>
<td>Randomised, open label, parallel; 4 weeks</td>
<td>↓ CRP with high intake</td>
</tr>
<tr>
<td></td>
<td>50 (F)</td>
<td></td>
<td></td>
<td>= IL-12, TNF-α</td>
<td></td>
</tr>
<tr>
<td>Overweight</td>
<td>25 (M)</td>
<td>Mean 49</td>
<td>Garlic powder (2-1 g/d) ( = 5-2 g fresh garlic) v. placebo</td>
<td>Randomised, double blind, controlled; 3 months</td>
<td>= CRP, TNF-α, sICAM-1, sVCAM-1, sE-selectin, fibrinogen</td>
</tr>
<tr>
<td>Haemodialysis patients</td>
<td>4 (M)</td>
<td></td>
<td>100 ml/d of red grape juice</td>
<td>Randomised, open label, uncontrolled; 3 weeks</td>
<td>↑ MCP-1</td>
</tr>
<tr>
<td></td>
<td>6 (F)</td>
<td></td>
<td></td>
<td>= CRP, sICAM-1, sVCAM-1</td>
<td></td>
</tr>
<tr>
<td>Healthy</td>
<td>18 (M/F)</td>
<td>45–61</td>
<td>280 g/d of cherries</td>
<td>Randomised, open label, uncontrolled; 28 d</td>
<td>= IL-6</td>
</tr>
<tr>
<td>Healthy</td>
<td>61 (F)</td>
<td>40–74</td>
<td>300 mg/d of anthocyanins ( = 100 fresh bilberries) v. placebo</td>
<td>Randomised, controlled, parallel; 3 weeks</td>
<td>= RANTES, IL-8, IFN-α</td>
</tr>
<tr>
<td>Healthy</td>
<td>59 (M)</td>
<td>19–50</td>
<td>28 g/d of a frozen seabuckthorn puree v. placebo</td>
<td>Randomised, controlled, parallel; 3 months</td>
<td>= CRP, IL-1, IL-6, TNF-α, MCP-1</td>
</tr>
<tr>
<td>Patients with peripheral arterial disease</td>
<td>47 (M/F)</td>
<td>57–61</td>
<td>250 ml orange juice + 250 ml blackcurrant juice v. placebo</td>
<td>Randomised, open label, uncontrolled; 28 d</td>
<td>= CRP</td>
</tr>
<tr>
<td>Healthy postmenopausal women</td>
<td>52</td>
<td>Mean 58</td>
<td>500 mg/d of elderberry extract ( = 25 g/d elderberries) v. placebo</td>
<td>Randomised, controlled, parallel; 12 weeks</td>
<td>= IL-6, PAI-1</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>48 (M/F)</td>
<td>Mean 52 (M)/48 (F)</td>
<td>960 ml/d water with 50 g/d of freeze-dried blueberries ( = 350 g/d fresh blueberries) v. 960 ml/d water</td>
<td>Randomised, controlled, parallel; 8 weeks</td>
<td>= CRP, IL-6, TNF-α, sTNFR1 and 2, RANTES</td>
</tr>
<tr>
<td>Elevated risk for CVD</td>
<td>62 (M/F)</td>
<td>Mean 53</td>
<td>330 ml/d of bilberry juice diluted to 1 litre of water v. water alone</td>
<td>Randomised, controlled, parallel; 4 weeks</td>
<td>= CRP, IL-6, IL-15, MIG</td>
</tr>
<tr>
<td>Healthy overweight</td>
<td>24 (M)</td>
<td>Mean 56</td>
<td>500 ml/d of orange juice v. control drink</td>
<td>Randomised, controlled, parallel; 4 weeks</td>
<td>= WBC count, IL-1, IL-1ra, MCP-1, RANTES</td>
</tr>
</tbody>
</table>

M, male; F, female; ↓, decreased; PAI-1, plasminogen activator inhibitor-1; =, no effect on; CRP, C-reactive protein; MCP-1, monocyte chemoattractant protein-1; sICAM-1, soluble intercellular adhesion molecule-1; sP-selectin, soluble P-selectin; sVCAM-1, soluble vascular cell adhesion molecule-1; sE-selectin, soluble E-selectin; RANTES, regulated on activation, normal T expressed and secreted; IFN, interferon; sTNFR, soluble TNF receptor; MIG, monokine-induced by IFN-γ; WBC, white blood cell; IL-1ra, IL-1 receptor antagonist; ↑, increased.
<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Intake</th>
<th>Study design and duration</th>
<th>Effect on low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypercholesterolaemic and postmenopausal</td>
<td>24 (F)</td>
<td>55 (SD 5)</td>
<td>25 g/d of soya protein v. milk protein</td>
<td>Randomised, double blind, controlled; 6 weeks</td>
<td>sIL-2R, sE-selectin, sP-selectin, sICAM-1, sVCAM-1</td>
<td>351</td>
</tr>
<tr>
<td>Healthy postmenopausal</td>
<td>50 (F)</td>
<td>50–75</td>
<td>40 g/d of soya protein v. casein</td>
<td>Randomised, double blind, controlled; 6 weeks</td>
<td>CRP</td>
<td>363</td>
</tr>
<tr>
<td>Hypercholesterolaemics</td>
<td>32 (M/F)</td>
<td>57–59</td>
<td>25 g/d of soya protein v. milk protein</td>
<td>Randomised, double blind, cross-over; 6 weeks</td>
<td>CRP, IL-6</td>
<td>355</td>
</tr>
<tr>
<td>Healthy postmenopausal</td>
<td>55 (F)</td>
<td>47–72</td>
<td>40 g/d of soya protein low or high in isoflavones</td>
<td>Randomised, double blind, controlled; 6 weeks</td>
<td>CRP</td>
<td>354</td>
</tr>
<tr>
<td>Healthy and overweight</td>
<td>35 (M)</td>
<td>20–40</td>
<td>32 g/d of soya protein v. milk protein</td>
<td>Randomised, double blind, controlled; 57 d</td>
<td>CRP</td>
<td>359</td>
</tr>
<tr>
<td>Healthy postmenopausal</td>
<td>52 (F)</td>
<td>50–65</td>
<td>706 ml/d of soya milk v. cows’ milk</td>
<td>Randomised, double blind, controlled; 14 d</td>
<td>CRP, TNF-α</td>
<td>362</td>
</tr>
<tr>
<td>Postmenopausal with the metabolic syndrome</td>
<td>42 (F)</td>
<td>DASH diet with 1 serving/d of meat, or soya protein or roasted soya nuts</td>
<td>Randomised, double blind, controlled; 14 d</td>
<td></td>
<td>Soya protein: ↓ CRP, sE-selectin</td>
<td>347</td>
</tr>
<tr>
<td>Hypercholesterolaemic</td>
<td>34 (F)</td>
<td>47–69</td>
<td>26 g/d of soya protein v. milk protein</td>
<td>Randomised, double blind, cross-over; 6 weeks</td>
<td>CRP, IL-6, sICAM-1, sVCAM-1</td>
<td>353</td>
</tr>
<tr>
<td>Healthy postmenopausal</td>
<td>28 (M/F)</td>
<td>&gt; 50</td>
<td>37.5 g/d of protein from whole soyabean, soyafour, soyamilk or animal proteins</td>
<td>Randomised, double blind, cross-over; 6 weeks</td>
<td>CRP</td>
<td>358</td>
</tr>
<tr>
<td>Normotensive and hypertensive postmenopausal</td>
<td>60 (F)</td>
<td>Mean – 55</td>
<td>25 g/d of soya protein (nuts) v. non-soya protein</td>
<td>Randomised, double blind, cross-over; 8 weeks</td>
<td>Normotensives: = CRP, IL-6, sICAM-1, sVCAM-1</td>
<td>361</td>
</tr>
<tr>
<td>Healthy postmenopausal</td>
<td>75 (F)</td>
<td>46–74</td>
<td>20 g/d of soya protein v. milk protein</td>
<td>Randomised, double blind, controlled; 12 weeks</td>
<td>Hypertensives: = CRP, IL-6, sICAM-1, ↓ sVCAM-1</td>
<td>352</td>
</tr>
<tr>
<td>Normal weight and obese</td>
<td>183 (F)</td>
<td>Mean 43</td>
<td>2 servings/d of soya foods v. regular diet</td>
<td>Randomised, controlled; 2 years</td>
<td>CRP, IL-6, adiponectin</td>
<td>357</td>
</tr>
<tr>
<td>Healthy postmenopausal</td>
<td>31 (F)</td>
<td>Mean 54</td>
<td>3 cups/d of soya milk v. low-fat cows’ milk</td>
<td>Randomised, single blind, controlled; 4 weeks</td>
<td>TNF-α, IL-1β, IL-6</td>
<td>349, 350</td>
</tr>
<tr>
<td>Overweight and obese</td>
<td>20 (M/F)</td>
<td>Mean 31</td>
<td>3 servings/d of soya milk v. cows’ milk</td>
<td>Randomised, double blind, cross-over; 28 d</td>
<td>CRP, TNF-α, IL-6, IL-15, MCP-1, adiponectin</td>
<td>364</td>
</tr>
<tr>
<td>Type 2 diabetics with nephropathy</td>
<td>41 (M/F)</td>
<td>Mean 45</td>
<td>Soya protein diet v. animal protein diet</td>
<td>Longitudinal randomised; 4 years</td>
<td>CRP with soya protein diet</td>
<td>348</td>
</tr>
<tr>
<td>Obese with the metabolic syndrome</td>
<td>64 (M/F)</td>
<td>Mean 45</td>
<td>Walnut- or cashew nut-enriched diet v. control diet</td>
<td>Randomised, controlled; 8 weeks</td>
<td>Cashew nuts: ↑ plasma glucose, furosamine, blood pressure, uric acids, S-hs CRP</td>
<td>360</td>
</tr>
<tr>
<td>Healthy hyperlipidaemic</td>
<td>41 (M/F)</td>
<td>Mean 62</td>
<td>High- and low-isoisoflavone soya diet v. control diet</td>
<td>Randomised, cross-over; 3 months</td>
<td>Isoflavone: ↓ blood lipids, apolipoprotein B, homocysteine, systolic blood pressure in men, urinary levels of daidzein, glycin, genistein, equol, O-desmethylangolensin</td>
<td>356</td>
</tr>
</tbody>
</table>

F, female; ¼, no effect on; sIL-2R, soluble IL-2 receptor; sE-selectin, soluble E-selectin; sP-selectin, soluble P-selectin; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; CRP, C-reactive protein; M, male; ↓, decreased; ↑, increased; MCP, monocyte chemoattractant protein; S-hs CRP, serum high-sensitivity C-reactive protein; DASH, dietary approaches to stop hypertension.
and opposing effects on inflammatory cytokine production in vitro of low- and higher-degree of polymerisation flavanols have been reported\(^{412,413}\). Because of the focus on in vitro exploration of the effects of cocoa flavanols, there is a need for well-designed human studies, using cocoa properly characterised in terms of flavanol content. In an Italian study of over 10,000 people, of whom half were free of any chronic disease, 1317 people reported having eaten any chocolate during the past year; 824 ate chocolate regularly in the form of dark chocolate only\(^{414}\). Regular consumption of small doses of dark chocolate seemed to decrease inflammation: after adjustment for multiple confounders, dark chocolate consumption and serum CRP was observed; consumers of up to 1 serving (20 g) of dark chocolate every day had significantly lower serum CRP concentrations than non-consumers or those consuming more than 20 g chocolate per day. In a small uncontrolled intervention study, healthy subjects \((n = 25)\) consumed dark chocolate (36.9 g/d) and a cocoa powder drink (30.8 g powder/d) for 6 weeks; there was no change in concentrations of CRP, TNF-α, IL-1β, IL-6 or soluble P-selectin (sP-selectin)\(^{415}\). Another small \((n = 28)\), uncontrolled intervention study with dark chocolate for 1 week found a reduction in CRP concentration in women but not in men\(^{416}\). Most recently, Monagas et al:\(^{417}\) reported the effect of a 4-week randomised cross-over trial of 40 g cocoa powder in skimmed milk daily \(v.\) skimmed milk in forty-two older subjects: serum concentrations of sICAM-1 and sP-selectin were lower after the cocoa powder intervention. Thus, there is some evidence that cocoa and cocoa-rich foods reduce low-grade inflammation.

**Alcohol.** The regular consumption of alcohol-containing beverages such as wine or beer has been reported to be inversely associated with several markers of low-grade inflammation, in a dose-dependent manner: i.e. moderate daily intake \((1–2 \text{drinks/d})\) was often found to be associated with decreased concentrations of inflammatory markers, although this was not the case in all studies (Table 10)\(^{418–425}\).

The short-term effect of alcohol intake on markers of low-grade inflammation has been studied in intervention trials which either determined acute effects during the next hours following ingestion or changes compared with baseline after 2–4 weeks of daily alcohol consumption (Table 11)\(^{445–448}\). Although most studies were of small size, findings were quite consistent in that there was little change in low-grade inflammation in the hours following alcohol intake. In one study, a decrease in NF-κB activation was reported after consuming a fat-rich meal when red wine was also consumed compared with consuming the fat-rich meal\(^{449}\). In general, findings are fairly similar for trials with wine, beer, vodka or ethanol (see Table 11). After 2–4 weeks of daily intake of alcoholic beverages, changes in low-grade inflammation were noted in five out of eight trials, with decreases in concentrations of CRP, cytokines and soluble adhesion molecules, and an increased concentration of adiponectin (see Table 11).

These effects were seen in trials with white or red wine, or beer. The three ‘negative’ trials\(^{455–456}\) used red wine or beer. Some variation of outcome between trials is to be expected, notably because the lifestyle and characteristics of participants will not be identical between trials, in particular with regard to the local diet and the amount of daily physical activity. Nevertheless, when taken together, these studies suggest some beneficial long-term effects of moderate daily consumption of wine or beer on low-grade inflammation. It is not clear whether such effects are due to the alcohol content of the beverages tested, or to other components, such as phenolic compounds in these fermented beverages.

### Process-related compounds: advanced glycation end products and advanced lipoperoxidation end products

**Introduction**

Humans have been using fire to cook food for thousands of years. They used boiling, baking, broiling, roasting, grilling or frying to make food more hygienic, digestible, nutritious and durable, and particularly to improve its flavour, aroma and texture. Despite man’s long history of exposure to heated food, the demonstration that the Maillard reaction also occurs and is associated with ageing and age-related conditions, such as diabetic complications, atherosclerosis, Alzheimer’s disease and hypertension, has raised the question whether dietary Maillard reaction products (MRP) might represent a risk to human health. A plausible mechanism for adverse health effects of dietary MRP could be their potential promotion of a state of low-grade inflammation. In fact, consumption of a Western diet rich in these products was found to correlate with impaired glucose metabolism, insulin resistance and increased risk of cardiovascular and renal disease associated with the metabolic syndrome and related conditions\(^{449,450}\). However, although excellent work has been published in the past few years, it is still unresolved whether MRP are causally involved in the aetiology of these conditions\(^{451–455}\). In particular, whether the potential harm of a Western diet is mainly due to the increased intake of Maillard compounds produced by heating of carbohydrate- and/or lipid-rich food or rather to the excess intake of energy, refined sugars and saturated fats, together with the lower intake of fresh fruits and vegetables, can be debated. Alternatively, other factors generated by thermal treatment of food or the thermal destruction of vitamins, polyphenols and antioxidants during food processing could also contribute to adverse health effects.

### Advanced glycation end products and advanced lipoxidation end products

Advanced glycation end products (AGE) are a family of heterogeneous, partly uncharacterised compounds that encompass both pre-melanoids and melanoids. Pre-melanoids are not coloured and in general exhibit no fluorescence, whereas melanoids are yellow to brown and are often fluorescent. The pre-melanoids include uncoloured...
### Effect on low-grade inflammation

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Type of tea and intake</th>
<th>Study design and duration</th>
<th>Effect on low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with coronary artery disease</td>
<td>66 (M/F)</td>
<td>54</td>
<td>Black tea (450 ml) v. water</td>
<td>4 weeks of tea followed by 4 weeks water</td>
<td>CRP 389</td>
<td>CRP, TNF-α, sICAM-1, sVCAM-1. Water 4 weeks of tea followed by 4 weeks water. CRP, TNF-α, sICAM-1, sVCAM-1.</td>
</tr>
<tr>
<td>Patients with coronary artery disease</td>
<td>31</td>
<td>18–55</td>
<td>Black tea (450 ml) v. water</td>
<td>Randomised, controlled; 6 months</td>
<td>CRP, TNF-α, sICAM-1, sVCAM-1. Water 4 weeks of tea followed by 4 weeks water. CRP, TNF-α, sICAM-1, sVCAM-1.</td>
<td>389</td>
</tr>
<tr>
<td>Healthy</td>
<td>75 (M)</td>
<td>Mean 59 (SD 8)</td>
<td>Black tea (4 cups/d)</td>
<td>Randomised, controlled; 6 weeks</td>
<td>CRP, sP-selectin. Black tea (4 cups/d) v. 'caffeinated placebo tea'. CRP, sP-selectin. Black tea (4 cups/d) v. 'caffeinated placebo tea'.</td>
<td>387</td>
</tr>
<tr>
<td>Healthy</td>
<td>22 (M/F)</td>
<td>Mean 59 (SD 9)</td>
<td>Black tea (4 cups/d) v. water</td>
<td>Randomised, controlled; 6 weeks</td>
<td>CRP, sP-selectin. Black tea (4 cups/d) v. water. CRP, sP-selectin. Black tea (4 cups/d) v. water.</td>
<td>383</td>
</tr>
<tr>
<td>Impaired glucose control</td>
<td>60</td>
<td>Mean 54 (SD 8)</td>
<td>Black tea (3 cups/d) v. water</td>
<td>Randomised, controlled; 4 weeks</td>
<td>CRP, sP-selectin. Black tea (4 cups/d) v. water. CRP, sP-selectin. Black tea (4 cups/d) v. water.</td>
<td>388</td>
</tr>
<tr>
<td>Smokers</td>
<td>64 (M/F)</td>
<td>Mean 32 (SD 10)</td>
<td>Green or black tea (6 cups (3 g)) or 3.6 g green tea polyphenols per d v. control</td>
<td>Randomised, cross-over; 4 weeks</td>
<td>CRP, sP-selectin. Black tea (4 cups/d) v. water. CRP, sP-selectin. Black tea (4 cups/d) v. water.</td>
<td>384</td>
</tr>
<tr>
<td>Healthy</td>
<td>12 (M)</td>
<td>Mean 54 (SD 8)</td>
<td>Green tea (4 cups/d) v. water</td>
<td>Randomised, cross-over; 4 weeks</td>
<td>CRP, sP-selectin. Black tea (4 cups/d) v. water. CRP, sP-selectin. Black tea (4 cups/d) v. water.</td>
<td>386</td>
</tr>
<tr>
<td>Obese</td>
<td>35 (M/F)</td>
<td>Mean 43 (SD 12)</td>
<td>Green tea (4 cups/d) v. water</td>
<td>Randomised, cross-over; 4 weeks</td>
<td>CRP, sP-selectin. Black tea (4 cups/d) v. water. CRP, sP-selectin. Black tea (4 cups/d) v. water.</td>
<td>384</td>
</tr>
<tr>
<td>Non-smokers</td>
<td>35 (M/F)</td>
<td>Mean 43 (SD 12)</td>
<td>Green tea (4 cups/d) v. water</td>
<td>Randomised, cross-over; 4 weeks</td>
<td>CRP, sP-selectin. Black tea (4 cups/d) v. water. CRP, sP-selectin. Black tea (4 cups/d) v. water.</td>
<td>384</td>
</tr>
</tbody>
</table>

M. male; F. female; – = no effect on; CRP, C-reactive protein; sICAM-1, soluble intercellular adhesion molecule 1; sVCAM-1, soluble vascular cell adhesion molecule 1; 1, decreased; SAA, serum amyloid A.

(1) Enhanced carbohydrate (and/or lipid) substrate availability, such as in hyperglycaemia (and/or hyperlipidaemia), which favours the nucleophilic addition of a carbonyl group from a reducing sugar to a free amino group of a protein (protein glycation) to form a reversible Schiff’s base, which then rearranges to the more stable ketoamine or Amadori product and subsequently, through dicarbonyl intermediates such as 3-deoxyglucone-ses, to the irreversible AGE.

(2) Increased oxidative metabolism, such as in the presence of transition metals and oxidative stress, which cause auto-oxidation of glucose (auto-oxidative glycation) or Amadori products (gloxification) via formation of dicarbonyl compounds, such as glyoxal.

(3) Increased non-oxidative metabolism, with accumulation of reducing sugars other than glucose, such as in the case of increased glucose flux through the glycolysis and polyol pathway (intracellular glycation) and/or thiamin deficiency, which result in the formation of the AGE precursor methylglyoxal.

AGE may also be derived from food or tobacco. AGE are formed during cooking and food processing procedures, and could accumulate in the body after intestinal absorption. It has been suggested from experimental animal models and studies in both healthy and type 2 diabetic subjects that dietary AGE represent a significant source of circulating and tissue AGE, although the absorption of individual AGE from food is largely unknown. Little is known about possible tissue deposition of food-derived AGE but in healthy animals, it has been shown that AGE are rapidly and completely excreted. Finally, accumulation of both endogenous and exogenous AGE may be favoured by reduced kidney clearance as in the case of renal failure and by impaired detoxification caused by the utilisation of cofactors of detoxifying enzymes.
Table 9. Observational studies on the association between coffee intake and markers of low-grade inflammation

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Age (years)</th>
<th>Intake level/frequency</th>
<th>Association with low-grade inflammation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population based</td>
<td>30–42 (M/F)</td>
<td>Coffee (&gt;200 mL/day)</td>
<td>IL-6, CRP, SAA, TNF-α, leucocyte count with higher intake</td>
</tr>
<tr>
<td>Healthy</td>
<td>65–70 (F)</td>
<td>Coffee (caffeinated/decaffeinated)</td>
<td>Caffeinated: CRP, sE-selectin, sICAM-1, sTNFR2</td>
</tr>
<tr>
<td>Healthy</td>
<td>50–60 (F)</td>
<td>Coffee</td>
<td>CRP, sE-selectin, sICAM-1, sTNFR2</td>
</tr>
<tr>
<td>Type 2 diabetics</td>
<td>60–70 (F)</td>
<td>Coffee</td>
<td>CRP, sE-selectin, sICAM-1, sTNFR2</td>
</tr>
<tr>
<td>Healthy</td>
<td>60–70 (M)</td>
<td>Coffee</td>
<td>CRP, sE-selectin, sICAM-1, sTNFR2</td>
</tr>
</tbody>
</table>

The so-called advanced lipoxidation end products (ALE) are similar to AGE but, rather than originating from sugars and sugar breakdown products, ALE are derived from lipid oxidation\(^{467}\). Metal-catalysed oxidation of unsaturated lipids such as PUFA and cholesterol results in the formation of lipid hydroperoxides and oxysterols, respectively. Lipid hydroperoxides, in the presence of metal ions or at high temperature, form epoxyhydroperoxides, ketohydroperoxides and cyclic peroxides, which decompose to low-molecular-weight breakdown products such as aldehydes, ketones or alcohols, or condense to polymers. Malondialdehyde and 4-hydroxy-2-nonenal are the main aldehydes generated during lipid peroxidation of n-6 PUFA\(^{468}\), whereas 4-hydroxy-2-hexenal is the predominant compound derived from the oxidation of n-3 PUFA\(^{469}\). Reactive lipid peroxidation products can form ALE by reacting with amino groups of proteins to generate labile or stable adducts or cross-links in protein, some of which may be coloured or fluorescent. Some reaction products, such as carboxymethyllysine, can originate from both sugars and lipid oxidation products\(^{470}\), and have been called ‘either advanced glycation and lipoxidation end products’\(^{466}\).

**Advanced glycation end products/advanced lipoxidation end products receptors**

The putative deleterious effects of AGE may be attributed to direct physico-chemical effects such as modification of extracellular matrix proteins, resulting in cross-links, leading to increased vascular stiffness or modification of proteins resulting in altered function, as well as via binding to a variety of cell-surface receptors\(^{471}\). AGE receptors have a dual function and are involved in both AGE removal and AGE-induced cell activation\(^{440}\). Cell activation can occur via receptor-mediated generation of ROS through both mitochondrial and cytosolic pathways involving the electron transport chain and NAD(P)H oxidase, respectively\(^{472,473}\). ROS can trigger pro-inflammatory signalling pathways causing MAPK-dependent activation of transcription factors such as NF-κB\(^{474–476}\) and consequent modulation of the gene expression of several pro-inflammatory cytokines\(^{474–475,477}\).

Several AGE-binding proteins have been identified, including the 42–45 kD receptor for AGE (RAGE), a member of the Ig superfamily\(^{478}\), the 60 kD protein a 48-kDa member of the oligosaccharyltransferase complex (OST-48) or AGE-receptor (AGE-R)1, the 90 kD protein 80K-H or AGE-R2\(^{479}\), and the 32 kD protein galectin-3 or AGE-R3\(^{480}\). This redundancy could imply binding and/or functional specificity among AGE receptors; alternatively, not all these receptors might be relevant for AGE binding \(\text{in vivo}\) \(^{140,481}\). At present, RAGE seems to be the only receptor involved in cell activation \(^{140}\). On the other hand, AGE-R1, AGE-R2 and AGE-R3 seem to behave as an AGE-receptor complex rather than individual receptor molecules and exert a predominant scavenging function\(^{482,483}\).

In addition to the classical AGE receptors, AGE are cleared also by scavenger receptors, which share with AGE receptors the ability to bind modified lipoproteins such as oxidised LDL\(^{484}\). The scavenger receptor family can be broadly classified into eight classes (A–H), which are expressed on...
Table 10. Observational studies on the association between alcohol intake and markers of low-grade inflammation

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Association with low-grade inflammation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community based</td>
<td>2833 (M/F)</td>
<td>Adult</td>
<td>CRP (lowest for 5–7 drinks/week)</td>
</tr>
<tr>
<td>Alcohol abusers and moderate drinkers</td>
<td>530 (M)</td>
<td>Adult</td>
<td>CRP with higher intake</td>
</tr>
<tr>
<td>Population based</td>
<td>3697 (M/F)</td>
<td>18–90</td>
<td>CRP</td>
</tr>
<tr>
<td>Healthy</td>
<td>340 (F)</td>
<td></td>
<td>= CRP</td>
</tr>
<tr>
<td>Population based (type 2 diabetics)</td>
<td>600 (F)</td>
<td>Mean 64</td>
<td>IL-6 with higher intake</td>
</tr>
<tr>
<td>Population based</td>
<td>460</td>
<td>Adult</td>
<td>CRP, leucocyte count with higher intake</td>
</tr>
<tr>
<td>Blood donors</td>
<td>478 (M/F)</td>
<td>40–68</td>
<td>Adiponectin (&gt;9.2 g/d)</td>
</tr>
<tr>
<td>Population based</td>
<td>1776 (M/F)</td>
<td>18–88</td>
<td>IL-6</td>
</tr>
<tr>
<td>Population based</td>
<td>6739 (M/F)</td>
<td>25–74</td>
<td>CRP</td>
</tr>
<tr>
<td>Population based</td>
<td>5865 (M/F)</td>
<td>&gt; 65</td>
<td>= CRP</td>
</tr>
<tr>
<td>Healthy health professionals</td>
<td>1432 (M/F)</td>
<td></td>
<td>Leucocyte count, fibrinogen with higher intake</td>
</tr>
<tr>
<td>Type 2 diabetic health professionals</td>
<td>726 (M)</td>
<td>47–82</td>
<td>Albumin with higher intake</td>
</tr>
<tr>
<td>Population based</td>
<td>11572 (M/F)</td>
<td>&gt; 17</td>
<td>sTNFR1, sTNFR2 (1–2 drinks/d v. 0 drinks/d)</td>
</tr>
<tr>
<td>Healthy</td>
<td>2574 (M/F)</td>
<td>70–79</td>
<td>CRP, IL-6 (1–2 drinks/d v. 0 drinks/d)</td>
</tr>
<tr>
<td>Patients from general practices</td>
<td>3158 (M)</td>
<td>60–79</td>
<td>CRP, IL-6 (lowest for 1–7 drinks/week)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>= CRP (↑ for higher intake of wine)</td>
</tr>
</tbody>
</table>

M, male; F, female; U, U-shaped relationship; CRP, C-reactive protein; ↑, increased; =, no effect on; ↓, decreased; sICAM-1, soluble intercellular adhesion molecule-1; SAA, serum amyloid A; iU, inverse U-shaped relationship; sTNFR, soluble TNF receptor; sVCAM-1, soluble vascular cell adhesion molecule-1; PAI-1, plasminogen activator inhibitor 1.

macrophages but also on other cells, including endothelial, mesangial and vascular smooth muscle cells. Though the ability of AGE receptors and scavenger receptors to clear pro-inflammatory compounds such as AGE and oxidised LDL from the tissue or circulation would seem initially beneficial, the final net effect is dependent upon the balance between this scavenging function and several other functions of these receptors, including the clearance of other modified self and non-self ligands, downstream pathways with formation of cholesterol-laden cells, the initiation of pro-inflammatory signalling cascades, and the regulation of cellular lipid influx/eflux and synthesis/degradation. However, it should be emphasised that the ligand affinity of AGE proteins to scavenger receptors is dependent on their modification, with mildly modified AGE not showing significant affinity.

Among the AGE receptors, RAGE was shown to be implicated in atherogenesis, based on the observations that soluble RAGE, which is able to bind circulating AGE and other RAGE ligands, and therefore to prevent their pro-inflammatory effects, inhibited the development of atherosclerosis in diabetic apoE−/− mice, arrested its progression when treatment was started after establishment of lesions, and prevented experimental diabetic nephropathy, which was conversely accelerated by RAGE overexpression. In addition, RAGE ablation prevented diabetic nephropathy and neuropathy. Thus, the cell-surface RAGE appears to be involved in inducing pro-inflammatory signalling while the soluble form of RAGE appears to prevent this, by sequestering ligands away from the cell-surface RAGE. Conversely, galectin-3 was proposed to exert a prevailing protective role as indicated by reports that galectin-3 ablation resulted in (1) the acceleration of glomerulopathy induced by diabetes, (2) increased AGE levels and (3) accelerated ageing. In the vessel wall, galectin-3 was induced in proliferating vascular smooth muscle cells and particularly in foam cells from arteries of experimental animal models of atherosclerosis and human patients with advanced atherosclerotic lesions, and recent studies have shown that galectin-3 ablation accelerates lipid-induced atherogenesis. Also AGE-R1 seems to play a protective role, as indicated by reports that galectin-3 ablation resulted in increased AGE-R1 expression with AGE-binding receptors that can result in either clearance or cell activation would be determined by the relative expression of these different receptors on the respective cells.
<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Alcohol source and alcohol intake</th>
<th>Study design and duration</th>
<th>Effect on low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy</td>
<td>16 (M/F)</td>
<td>22–33</td>
<td>Red wine (two doses: 12 or 20 g/m² in men and 7·2 or 12 g/m² in women) or vodka (equivalent to high-dose red wine)</td>
<td>Acute; up to 9 h</td>
<td>↓ NFκB activation after a fat-enriched meal (only red wine – both doses)</td>
<td>438</td>
</tr>
<tr>
<td>Healthy</td>
<td>29</td>
<td>Adult</td>
<td>Red wine, white wine</td>
<td>Acute; 4 h</td>
<td>= sP-selectin, von Willebrand factor, thrombomodulin</td>
<td>439</td>
</tr>
<tr>
<td>Healthy</td>
<td>16</td>
<td>Adult</td>
<td>Vodka (1255·2 joules ~ 42 g)</td>
<td>Acute; 3 h</td>
<td>= NFκB activation</td>
<td>440</td>
</tr>
<tr>
<td>Healthy</td>
<td>16</td>
<td>Adult</td>
<td>Alcohol (15 g)</td>
<td>Acute; up to 6 h</td>
<td>= CRP (after a high-carbohydrate, high-fat meal)</td>
<td>442</td>
</tr>
<tr>
<td>Patients with coronary artery disease</td>
<td>13 (M)</td>
<td>White and red wine (2–3 glasses)</td>
<td>Randomised, controlled, cross-over, acute; 6 h</td>
<td>↑ IL-6</td>
<td>= sICAM-1, sVCAM-1</td>
<td>448</td>
</tr>
<tr>
<td>Healthy</td>
<td>6 (M)</td>
<td>Adult</td>
<td>Red wine (60 g)</td>
<td>Acute; 24 h</td>
<td>= TNF-α, IL-2, IL-4</td>
<td>435</td>
</tr>
<tr>
<td>Healthy</td>
<td>23 (M)</td>
<td>Adult</td>
<td>Alcohol (40 g)</td>
<td>Acute; 24 h</td>
<td>= TGF-β</td>
<td>443</td>
</tr>
<tr>
<td>Healthy</td>
<td>5 (M)</td>
<td>30–37</td>
<td>Red wine (60 g)</td>
<td>Acute; 36 h</td>
<td>↑ IL-6 in patients</td>
<td>441</td>
</tr>
<tr>
<td>Lean and overweight</td>
<td>20 (M)</td>
<td>18–25</td>
<td>Beer (40 g/d)</td>
<td>3 weeks</td>
<td>= Resistin, leptin, adiponectin, grehlin</td>
<td>433</td>
</tr>
<tr>
<td>Lean and overweight</td>
<td>20 (M)</td>
<td></td>
<td>Beer (40 g/d)</td>
<td>Randomised, controlled, cross-over; 3 weeks</td>
<td>= Resistin, adiponectin, fibrinogen, monocyte adhesion capacity (both), sCD40L, IL-6, MCP-1, monocyte chemoattractant protein-1, sCD40L, sCD40 ligand</td>
<td>444</td>
</tr>
<tr>
<td>Subjects with increased waist circumference</td>
<td>34 (M)</td>
<td>35–70</td>
<td>Red wine (40 g/d)</td>
<td>Randomised, controlled, cross-over; 4 weeks</td>
<td>= Resistin, adiponectin, fibrinogen</td>
<td>445</td>
</tr>
<tr>
<td>Healthy</td>
<td>87 (M/F)</td>
<td>Adult</td>
<td>Red wine (15 g/d)</td>
<td>Randomised, controlled, cross-over; 3 weeks</td>
<td>= CRP, sICAM-1, sCD40L, IL-6, MCP-1, monocyte chemoattractant protein-1, sCD40L, sCD40 ligand</td>
<td>446</td>
</tr>
<tr>
<td>Healthy</td>
<td>35 (F)</td>
<td>Adult</td>
<td>White or red wine (20 g/d)</td>
<td>Randomised, cross-over; 4 weeks</td>
<td>= CRP, fibrinogen, MCP-1, monocyte chemoattractant protein-1, sCD40L, sCD40 ligand</td>
<td>447</td>
</tr>
<tr>
<td>Healthy</td>
<td>20 (M/F)</td>
<td>45–64</td>
<td>Beer (40 g/d for male, 30 g/d for female)</td>
<td>Randomised, diet-controlled, cross-over; 3 weeks</td>
<td>= CRP, sICAM-1, sCD40L, IL-6, MCP-1, monocyte chemoattractant protein-1, sCD40L, sCD40 ligand</td>
<td>448</td>
</tr>
<tr>
<td>Healthy</td>
<td>20 (M)</td>
<td>Adult</td>
<td>Sparkling wine or gin (30 g/d)</td>
<td>Randomised, cross-over; 4 weeks</td>
<td>= TNF-α, IL-2, IL-4, TGF-β</td>
<td>436</td>
</tr>
</tbody>
</table>

M, male; F, female; ↓, decreased; =, no effect on; sP-selectin, soluble P-selectin; ↑, increased; CRP, C-reactive protein; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; TGF, transforming growth factor; MCP-1, monocyte chemoattractant protein-1; sCD40L, sCD40 ligand.
Significance of dietary advanced glycation end products/advanced lipoxidation end products

The nutritional properties of heated food were initially questioned because of the reduced availability of lysine due to the formation of Amadori-modified lysine. However, cooking was also shown to increase the bioavailability of some nutrients, especially proteins derived from some plant sources. Subsequently, the concern was raised that AGE (and ALE) formed during the Maillard reaction might exert adverse health effects in cells, tissues and organs. As a potential mechanism, a role of AGE/ALE binding to RAGE followed by triggering of RAGE-dependent downstream signalling events leading to transcription of pro-inflammatory genes has been postulated. This view is supported by a number of studies conducted in both experimental animal models and human subjects, showing that ingestion of diets containing high AGE levels results in increased levels of circulating AGE (see below). In addition, these high-AGE diets, generated by more severe thermal treatment than the control diets, also resulted in a series of metabolic and micro/macrovascular abnormalities related to diabetes and its long-term complications (see below). However, despite this body of experimental data, a cause–effect relationship between dietary AGE and development and progression of disease conditions related to Western-type lifestyle and dietary habits has not yet been conclusively demonstrated, and a number of issues remain to be solved.

Evidence supporting a potential harmful effect of dietary advanced glycation end products/advanced lipoxidation end products

Animal studies. In spontaneously diabetic db/db mice and in normal mice fed high-fat diets, feeding of a low-AGE diet reduced serum AGE levels and improved insulin sensitivity, compared with a high-AGE diet. In addition, in non-obese diabetic mice, a fetal or neonatal low-AGE environment prevented autoimmune diabetes, possibly by reducing antigenic stimulus for T-cell-mediated injury or by attenuating β-cell damage. In both type 1 and 2 diabetes models (i.e. non-obese diabetic and db/db mice, respectively) low dietary AGE content provided sustained protection towards the development of diabetic nephropathy. Likewise, in genetically hypercholesterolaemic apoE−/− mice, low AGE content in the diet attenuated the development of atherosclerosis after induction of diabetes with streptozotocin and neointimal formation after arterial injury. Finally, in db/db mice, wound healing was accelerated by a low-AGE diet, with predominant wound contraction, compared with animals on a high-AGE diet, which favoured the epithelialisation mode of wound closure.

Human studies. In healthy younger (aged < 45 years) and older (aged > 60 years) human subjects, dietary AGE, but not energy intake, correlated with serum AGE levels and markers of oxidative stress (8-isoprostanes), which in turn correlated with serum CRP concentration and insulin resistance. It is noteworthy that in this study, some healthy individuals showed AGE levels of similar magnitude as found in diabetic patients.

AGE-rich diets used for intervention studies in human subjects are usually generated by more severe thermal treatment of food, particularly by frying, broiling and baking, whereas AGE-poor food is prepared by steaming or simply without heating at all. Therefore, unless specified, these are the methods that were used for the preparation of test and control diets in the studies reviewed below. Taken together, these studies show that dietary AGE content correlates with circulating levels of AGE and with markers of inflammation, oxidative stress, endothelial dysfunction and renal function. One caveat that needs attention for future human studies is the significant contribution of smoking to the endogenous AGE load.

Diabetic subjects with and without nephropathy were given a single meal of egg-white, cooked with or without fructose, with the AGE-rich food containing about three times more AGE than a single meal of a regular diet. There was a significant increase in serum PAI-1 with the AGE-rich food containing about three times more AGE than a single meal of egg-white, cooked with or without fructose. In patients on haemodialysis or peritoneal dialysis randomly assigned to two groups consuming either a high- or low-AGE diet for 4 weeks, serum AGE levels were directly related to the degree of renal dysfunction, as estimated by the increase in albuminuria and the decrease in creatinine clearance, and renal AGE excretion was inversely correlated with the degree of renal dysfunction. The relationship between dietary AGE intake, serum AGE levels and renal AGE clearance was confirmed in a cross-sectional study performed in long-term haemodialysis and peritoneal dialysis patients with or without diabetes. This study showed that circulating AGE correlated significantly with the AGE content of a regular diet, as estimated by means of 3 d dietary records and food questionnaires, as well as with blood urea N level.

Likewise, in non-diabetic patients on maintenance peritoneal dialysis randomly assigned to two groups consuming either a high- or low-AGE diet for 4 weeks, serum AGE levels correlated with AGE consumption as well as with blood urea N, serum creatinine, total protein, albumin and P, with AGE restriction profoundly reducing circulating AGE. Finally, cross-sectional studies of healthy subjects and of patients undergoing haemodialysis showed a positive relationship between dietary AGE intake and plasma inflammatory markers.

A number of acute studies examining the effect of a single high-AGE meal on inflammatory markers have been conducted (see Table 12). Although these have been conducted in a variety of subject/patient groups, they show rather similar effects: typically, there is an elevation of various inflammatory markers (CRP, cytokines and soluble adhesion molecules) in the hours after consumption of a high-AGE meal, and this increase does not occur with a low-AGE meal (see Table 12). Furthermore, healthy and diabetic volunteers receiving a single dose of a high-AGE (caffeine-free) cola drink showed an increase in serum PAI-1.

In patients on haemodialysis or peritoneal dialysis randomly assigned to a 4-week high- or low-AGE diet, circulating levels of AGE as well as markers of inflammation and endothelial dysfunction (which were markedly elevated at baseline, although not correlated with AGE) decreased significantly in response to AGE restriction, i.e. the low-AGE diet.
The findings of this latter study are in accordance with earlier data in diabetic subjects with normal renal function who showed a decrease in several inflammatory markers following 2 or 6 weeks of a low-AGE diet[521].

**Arguments against potentially harmful effects of dietary advanced glycation end products/advanced lipoxidation end products**

In contrast to the aforementioned reports, circulating AGE levels could not be identified as an independent risk factor for cardiovascular or renal outcomes in diabetic subjects with diabetic nephropathy[524], and circulating AGE levels were even inversely correlated with mortality in haemodialysis patients, the latter most probably due to a better nutritional status[525]. In addition, a recent study in obese children found lower circulating AGE levels compared with lean controls while inflammatory markers were significantly elevated in obese children[517]. Several issues concerning the methodology and interpretation of published data have been raised that may question the alleged adverse health effects of dietary AGE/ALE[451,526,527].

A first issue is the large heterogeneity of AGE/ALE and their precursors, which would require examination of the effect of each of these compounds separately. In particular, the bioavailability and metabolic fate of individual AGE/ALE structures should be evaluated to assess whether and to what extent they are digested, absorbed and cleared by the body, and accumulate in tissues to produce any significant adverse health effect[451,527]. AGE, which are absorbed as free or short peptide-bound AGE, may be cleared more rapidly and efficiently by the kidney, except when renal function is significantly impaired, than those formed endogenously, which are usually protein-bound. Studies in experimental animals fed or injected with radiolabelled protein-bound AGE and human volunteers receiving diets enriched with MRP or specific AGE have shown that absorption of ingested MRP is variable and dependent on the MRP[464,465,527–529]. Highly cross-linked AGE and melanoidins were predominantly excreted in the faeces while absorbed MRP were in general rapidly excreted by the kidney, with limited accumulation in haemodialysis patients, the latter most probably due to a better nutritional status[525]. In addition, a recent study in obese children found lower circulating AGE levels compared with lean controls while inflammatory markers were significantly elevated in obese children[517]. Several issues concerning the methodology and interpretation of published data have been raised that may question the alleged adverse health effects of dietary AGE/ALE[451,526,527].

A first issue is the large heterogeneity of AGE/ALE and their precursors, which would require examination of the effect of each of these compounds separately. In particular, the bioavailability and metabolic fate of individual AGE/ALE structures should be evaluated to assess whether and to what extent they are digested, absorbed and cleared by the body, and accumulate in tissues to produce any significant adverse health effect[451,527]. AGE, which are absorbed as free or short peptide-bound AGE, may be cleared more rapidly and efficiently by the kidney, except when renal function is significantly impaired, than those formed endogenously, which are usually protein-bound. Studies in experimental animals fed or injected with radiolabelled protein-bound AGE and human volunteers receiving diets enriched with MRP or specific AGE have shown that absorption of ingested MRP is variable and dependent on the MRP[464,465,527–529]. Highly cross-linked AGE and melanoidins were predominantly excreted in the faeces while absorbed MRP were in general rapidly excreted by the kidney, with limited accumulation in haemodialysis patients, the latter most probably due to a better nutritional status[525]. In addition, a recent study in obese children found lower circulating AGE levels compared with lean controls while inflammatory markers were significantly elevated in obese children[517]. Several issues concerning the methodology and interpretation of published data have been raised that may question the alleged adverse health effects of dietary AGE/ALE[451,526,527].

A first issue is the large heterogeneity of AGE/ALE and their precursors, which would require examination of the effect of each of these compounds separately. In particular, the bioavailability and metabolic fate of individual AGE/ALE structures should be evaluated to assess whether and to what extent they are digested, absorbed and cleared by the body, and accumulate in tissues to produce any significant adverse health effect[451,527]. AGE, which are absorbed as free or short peptide-bound AGE, may be cleared more rapidly and efficiently by the kidney, except when renal function is significantly impaired, than those formed endogenously, which are usually protein-bound. Studies in experimental animals fed or injected with radiolabelled protein-bound AGE and human volunteers receiving diets enriched with MRP or specific AGE have shown that absorption of ingested MRP is variable and dependent on the MRP[464,465,527–529]. Highly cross-linked AGE and melanoidins were predominantly excreted in the faeces while absorbed MRP were in general rapidly excreted by the kidney, with limited accumulation in haemodialysis patients, the latter most probably due to a better nutritional status[525]. In addition, a recent study in obese children found lower circulating AGE levels compared with lean controls while inflammatory markers were significantly elevated in obese children[517]. Several issues concerning the methodology and interpretation of published data have been raised that may question the alleged adverse health effects of dietary AGE/ALE[451,526,527].

A first issue is the large heterogeneity of AGE/ALE and their precursors, which would require examination of the effect of each of these compounds separately. In particular, the bioavailability and metabolic fate of individual AGE/ALE structures should be evaluated to assess whether and to what extent they are digested, absorbed and cleared by the body, and accumulate in tissues to produce any significant adverse health effect[451,527]. AGE, which are absorbed as free or short peptide-bound AGE, may be cleared more rapidly and efficiently by the kidney, except when renal function is significantly impaired, than those formed endogenously, which are usually protein-bound. Studies in experimental animals fed or injected with radiolabelled protein-bound AGE and human volunteers receiving diets enriched with MRP or specific AGE have shown that absorption of ingested MRP is variable and dependent on the MRP[464,465,527–529]. Highly cross-linked AGE and melanoidins were predominantly excreted in the faeces while absorbed MRP were in general rapidly excreted by the kidney, with limited accumulation in haemodialysis patients, the latter most probably due to a better nutritional status[525]. In addition, a recent study in obese children found lower circulating AGE levels compared with lean controls while inflammatory markers were significantly elevated in obese children[517]. Several issues concerning the methodology and interpretation of published data have been raised that may question the alleged adverse health effects of dietary AGE/ALE[451,526,527].

A first issue is the large heterogeneity of AGE/ALE and their precursors, which would require examination of the effect of each of these compounds separately. In particular, the bioavailability and metabolic fate of individual AGE/ALE structures should be evaluated to assess whether and to what extent they are digested, absorbed and cleared by the body, and accumulate in tissues to produce any significant adverse health effect[451,527]. AGE, which are absorbed as free or short peptide-bound AGE, may be cleared more rapidly and efficiently by the kidney, except when renal function is significantly impaired, than those formed endogenously, which are usually protein-bound. Studies in experimental animals fed or injected with radiolabelled protein-bound AGE and human volunteers receiving diets enriched with MRP or specific AGE have shown that absorption of ingested MRP is variable and dependent on the MRP[464,465,527–529]. Highly cross-linked AGE and melanoidins were predominantly excreted in the faeces while absorbed MRP were in general rapidly excreted by the kidney, with limited accumulation in haemodialysis patients, the latter most probably due to a better nutritional status[525]. In addition, a recent study in obese children found lower circulating AGE levels compared with lean controls while inflammatory markers were significantly elevated in obese children[517]. Several issues concerning the methodology and interpretation of published data have been raised that may question the alleged adverse health effects of dietary AGE/ALE[451,526,527].

A first issue is the large heterogeneity of AGE/ALE and their precursors, which would require examination of the effect of each of these compounds separately. In particular, the bioavailability and metabolic fate of individual AGE/ALE structures should be evaluated to assess whether and to what extent they are digested, absorbed and cleared by the body, and accumulate in tissues to produce any significant adverse health effect[451,527]. AGE, which are absorbed as free or short peptide-bound AGE, may be cleared more rapidly and efficiently by the kidney, except when renal function is significantly impaired, than those formed endogenously, which are usually protein-bound. Studies in experimental animals fed or injected with radiolabelled protein-bound AGE and human volunteers receiving diets enriched with MRP or specific AGE have shown that absorption of ingested MRP is variable and dependent on the MRP[464,465,527–529]. Highly cross-linked AGE and melanoidins were predominantly excreted in the faeces while absorbed MRP were in general rapidly excreted by the kidney, with limited accumulation in haemodialysis patients, the latter most probably due to a better nutritional status[525]. In addition, a recent study in obese children found lower circulating AGE levels compared with lean controls while inflammatory markers were significantly elevated in obese children[517]. Several issues concerning the methodology and interpretation of published data have been raised that may question the alleged adverse health effects of dietary AGE/ALE[451,526,527].

A first issue is the large heterogeneity of AGE/ALE and their precursors, which would require examination of the effect of each of these compounds separately. In particular, the bioavailability and metabolic fate of individual AGE/ALE structures should be evaluated to assess whether and to what extent they are digested, absorbed and cleared by the body, and accumulate in tissues to produce any significant adverse health effect[451,527]. AGE, which are absorbed as free or short peptide-bound AGE, may be cleared more rapidly and efficiently by the kidney, except when renal function is significantly impaired, than those formed endogenously, which are usually protein-bound. Studies in experimental animals fed or injected with radiolabelled protein-bound AGE and human volunteers receiving diets enriched with MRP or specific AGE have shown that absorption of ingested MRP is variable and dependent on the MRP[464,465,527–529]. Highly cross-linked AGE and melanoidins were predominantly excreted in the faeces while absorbed MRP were in general rapidly excreted by the kidney, with limited accumulation in haemodialysis patients, the latter most probably due to a better nutritional status[525]. In addition, a recent study in obese children found lower circulating AGE levels compared with lean controls while inflammatory markers were significantly elevated in obese children[517]. Several issues concerning the methodology and interpretation of published data have been raised that may question the alleged adverse health effects of dietary AGE/ALE[451,526,527].
Table 12. Studies on the association between advanced glycation end products (AGE) intake and markers of low-grade inflammation

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Intake</th>
<th>Study design and duration</th>
<th>Effects on low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic and non-diabetic haemodialysis patients</td>
<td>189 (M/F)</td>
<td>Mean 61 (SD 14)</td>
<td>Dietary AGE</td>
<td>Cross-sectional</td>
<td>↑ CRP, sVCAM-1, TNF-α = PAI-1</td>
<td>515</td>
</tr>
<tr>
<td>Healthy stratified by age groups</td>
<td>172 (M/F)</td>
<td>Mean 50 (SD 14) 18–45 60–80</td>
<td>Dietary AGE</td>
<td>Cross-sectional</td>
<td>Correlation of AGE intake with CRP</td>
<td>520</td>
</tr>
<tr>
<td>Obese type 2 diabetics, smokers and non-smokers</td>
<td>13</td>
<td>Mean 57 (SD 10)</td>
<td>High-AGE meal</td>
<td>Acute; up to 4 h</td>
<td>↑ CRP, sICAM-1, sVCAM-1, sE-selectin = TNF-α, IL-6, IL-8, fibrinogen</td>
<td>518</td>
</tr>
<tr>
<td>Healthy and type 2 diabetics</td>
<td>10 Healthy + 44 type 2 diabetics (M/F) Mean 43 (SD 13) (Healthy) Mean 51 (SD 13) (Diabetics)</td>
<td>High-AGE cola drink</td>
<td>Acute; 90 min</td>
<td>↑ PAI-1 = sICAM-1</td>
<td>519</td>
<td></td>
</tr>
<tr>
<td>Healthy, non-smokers</td>
<td>9</td>
<td>Mean 32 (SD 8)</td>
<td>High- and low-AGE meal</td>
<td>Acute; 2 h</td>
<td>↑ NF-kB activation in both groups (effect of meal not of AGE?)</td>
<td>516</td>
</tr>
<tr>
<td>Overweight type 2 diabetics, smokers and non-smokers</td>
<td>20 (M/F)</td>
<td>Mean 55 (SD 10)</td>
<td>High- and low-AGE meal</td>
<td>Cross-over, acute; up to 6 h</td>
<td>High-AGE meal: ↑ IL-6, sICAM-1, sVCAM-1, sE-selectin = CRP, TNF-α, fibrinogen Low-AGE meal: ↑ TNF-α mRNA, sVCAM-1 with low-AGE diet = CRP</td>
<td>514</td>
</tr>
<tr>
<td>Non-smoking overweight diabetics</td>
<td>11 (M/F)</td>
<td>Mean 52 (SD 17)</td>
<td>High- and low-AGE diet</td>
<td>Cross-over; 2 weeks</td>
<td>↑ CRP with high-AGE diet and ↓ low-AGE diet</td>
<td>521</td>
</tr>
<tr>
<td>Non-smoking overweight diabetics</td>
<td>13 (M/F)</td>
<td>~ 62</td>
<td>High- and low-AGE diet</td>
<td>Randomised, parallel; 6 weeks</td>
<td>↑ TNF-α with high-AGE diet and ↓ low-AGE diet</td>
<td>521</td>
</tr>
<tr>
<td>Renal failure patients on dialysis</td>
<td>18 (M/F)</td>
<td>High- and low-AGE diet</td>
<td>Randomised, parallel; 4 weeks</td>
<td>CRP, TNF-α, sVCAM-1 and PAI-1 with low-AGE diet</td>
<td>515</td>
<td></td>
</tr>
<tr>
<td>Healthy obese children v. lean controls</td>
<td>18 (11 M/7 F) 18 (8 M/10 F)</td>
<td>5–18 4–17</td>
<td>Cross-sectional</td>
<td>Obese had lower plasma AGE and higher CRP and IL-6</td>
<td>517</td>
<td></td>
</tr>
</tbody>
</table>

M, male; F, female; ↑, increased; CRP, C-reactive protein; sVCAM-1, soluble vascular cell adhesion molecule-1; =, no effect on; PAI-1, plasminogen activator inhibitor-1; sICAM-1, soluble intercellular adhesion molecule-1; ↓, decreased.
food intake with postprandial inflammatory signalling. In fact, postprandial hyperglycaemia has been shown to be associated with increased NF-κB activation in patients with type 2 diabetes\(^{(549)}\). Moreover, an oral glucose load, or better the mean glucose excursions following an oral glucose load, were associated with urinary excretion of 8-iso PGF\(_2\alpha\) as a marker of oxidative stress within 2–3 h after the challenge\(^{(550)}\), and oral glucose and/or high fat additively increased inflammatory markers (CRP and IL-6) and oxidative stress (nitrotyrosine), while reducing flow-mediated dilatation\(^{(167,551)}\) in diabetic subjects\(^{(552)}\). This activation during postprandial hyperglycaemia or hyperlipidaemia may be due to acute changes in markers of glycoxidative and lipoxidative stress and may partly underlie the association of postprandial derangements and cardiovascular risk\(^{(553)}\). These observations have prompted the hypothesis that it is the sugar and lipid content of meals which is related to postprandial inflammation, oxidative stress and vascular dysfunction\(^{(157,167,551,554)}\). In addition, AGE precursors and AGE/ALE-rich diets may be different in healthy subjects and patients with diabetes, to humans. In addition, the effects of AGE/ALE-rich diets may be different in mice and rats, which are not accustomed to the intake of heated food, might result in outcomes that cannot be directly applied to humans. In addition, the effects of AGE/ALE-rich diets may be different in healthy subjects and patients with diabetes, other age-related disorders or renal insufficiency. The large variation in serum AGE levels detected in younger and older healthy subjects\(^{(520)}\), with some individuals showing values similar to those found in diabetic patients, would suggest that AGE might not be harmful unless a concomitant disease condition is present.

The argument that highly cooked or processed food may be responsible for adverse health effects because of their elevated AGE content may be countered by the findings that vegetarians consistently present with higher circulating AGE levels than individuals eating a Western diet\(^{(560)}\). Also, the recent report that obesity in children, while correlating with increased oxidative stress and inflammatory markers, showed an inverse correlation with circulating AGE levels is in disagreement with this argument\(^{(517)}\).

Another important issue is the reliability of methods for AGE/ALE quantification that are used by different groups\(^{(452,527,560)}\). In fact, the use of antisera for quantitative immunoassays of protein-bound AGE is questionable because the specificity of the antibodies is often difficult to ascertain and monospecific antibodies are not commercially available. Furthermore, proteins used to block non-specific binding in immunoassays may also contain AGE epitopes, and thus interact with the detection system. Finally, because of steric constraints, not all AGE epitopes on the protein may be available for interaction with the antibody, and factors competing for the reaction between the anti-AGE antibody and its antigen, including anti-AGE auto-antibodies and, possibly, complement, have been demonstrated in plasma\(^{(562,563)}\).

Thus, AGE measurements with immunoassays yield only semi-quantitative results and results obtained with immunoassays in both serum samples and foods should be interpreted with care. The indirect immunoassay used by Vlassara and coworkers only allows results to be expressed in units, thus making comparison with other analytical data impossible. A much better approach for the quantitative determination of specific AGE epitopes in proteins is the use of specific analytical techniques, such as liquid chromatography-MS–MS, for the analysis of specific AGE in protein hydrolysates\(^{(544)}\).

Application of this kind of analytical technique could lead to a more comprehensive understanding of the putative effects of AGE formed by the Maillard reaction in food as well as in the body of healthy and diabetic human subjects. In fact, conflicting carboxymethyllysine levels in different foodstuffs have been reported using either an indirect ELISA method\(^{(461)}\) or an ultra performance liquid chromatography-MS–MS method\(^{(546)}\).

A relevant objection to the hypothesis that dietary AGE/ALE have adverse health effects is the fact that the human organism is equipped with very effective and redundant defence mechanisms limiting the digestion and intestinal absorption of these compounds, which are also trapped in the gastrointestinal tract and detoxified in intestinal epithelia or, for those that are absorbed into the blood or lymph, in liver and other tissues. Based on the pivotal role of the gastrointestinal tract in the protection against ingested MRP, it would be important to assess whether AGE/ALE that are not absorbed have any adverse effects on the intestinal mucosa and/or colonic microflora. Preliminary studies have shown that a high-AGE diet did not affect the number or class of bifidobacteria and sulphate-reducing bacteria, which have beneficial and detrimental effects, respectively\(^{(451,564)}\). In addition, Morales \textit{et al.}\(^{(547)}\) recently summarised the beneficial health effects of melanoids generated during heat processing of food. Despite all these arguments, it might be prudent to advise renal failure patients to decrease their intake of highly heated food. This may not necessarily be due to the presence of AGE/ALE in thermally treated food but rather to other factors present/absent in thermally treated food.
Finally, there may even be a ‘chemoprotective’ role of individual dietary AGE/ALE due to antioxidant and anti-cancer properties, the former in part attributable to pronyllsine modification of lysine residues of proteins detected in certain foods including bread crust and malt.

Research gaps

Although there appears to be suggestive evidence for a potential role of dietary AGE in inducing low-grade chronic inflammation, insulin resistance and vascular dysfunction, the supporting proof so far has been weak, inconclusive and even contradictory. What the available studies have been able to consistently show is the relationship between dietary AGE/ALE exposure and postprandial circulating AGE levels. Whether the uptake of AGE/ALE from the diet is responsible for adverse biological consequences such as chronic low-grade inflammation, vascular dysfunction or insulin resistance will require further investigations.

The following research gaps have been identified:

1. There is a need for reliable analytical methods for food AGE with inter-laboratory cross-validations.
2. There is a need for a food AGE database based on reliable analytical methods.
3. There is a need for preclinical and clinical studies with pure and well-characterised AGE independent of food in both healthy individuals and diabetic patients.
4. There is a need to discriminate the biological effects induced by protein-bound v. free well-characterised AGE.
5. There is a need for toxicological evaluation of well-characterised AGE in animal studies.
6. There is a need to expand investigation of the (patho)physiological role of food-derived ALE and lipid peroxidation products.
7. There is a need to evaluate the (patho)physiological consequences of highly heated food beyond their AGE/ALE content.
8. There is a need to balance potentially adverse health effects of AGE with the potentially beneficial health effects of melanoids, both of which are generated by thermal treatment of food.

Macronutrients and low-grade inflammation

Fatty acids

Dietary fatty acids may affect inflammatory processes through modulation of eicosanoid metabolism, and by eicosanoid-independent mechanisms such as regulation of membrane and cytosolic signalling processes that influence the activity of transcription factors involved in inflammation. These latter transcription factors include NF-κB and PPAR-γ, both of which are sensitive to fatty acids. There is an intriguing interaction between these latter two transcription factors because PPAR-γ inhibits NF-κB activation. A number of different fatty acids including saturated, monounsaturated, trans, conjugated linoleic and polyunsaturated of both n-6 and n-3 families have been investigated in the context of inflammation. They have been examined in many model systems, typically with isolated cells in culture and in animal models of inflammatory conditions, as well as in studies in human volunteers and in various patient groups. In addition, associations between intake or status of various fatty acids and inflammatory markers have been examined in human studies.

SFA. In vitro studies have suggested that SFA may promote inflammatory processes. Exposure of myotubes or adipocytes to the SFA palmitic acid (16 : 0) increased IL-6 mRNA expression and subsequent protein production, possibly via activation of NF-κB. Monocytes are activated directly by SFA, especially lauric acid (12 : 0), via TLR-4 and through this mechanism induce NF-κB activity. A limited number of observational studies have investigated the relationship between SFA exposure and circulating markers of inflammation. Whether the uptake of AGE/ALE from the diet is responsible for adverse biological consequences such as chronic low-grade inflammation, vascular dysfunction or insulin resistance will require further investigations.

Fernandez-Real et al. did not see any relationship between serum SFA and CRP or IL-6 in lean individuals, while in overweight individuals, serum SFA were positively associated with IL-6 concentration, and the ratio of SFA:n-6 or n-3 PUFA was positively associated with IL-6 and CRP concentrations, respectively. A study in overweight adolescents showed positive relationships between total SFA in plasma phospholipids or cholesterol esters and IL-6, but not CRP, concentration. Thus, there is general agreement between two studies in overweight subjects that SFA exposure is associated with higher IL-6 concentration. A study in lean individuals does not show this. An intervention study feeding diets rich in stearic acid (18 : 0) or in lauric, myristic (14 : 0) and palmitic acids to men aged 25–60 years for 5 weeks showed higher concentrations of CRP, fibrinogen, IL-6 and sE-selectin compared with a diet enriched in oleic acid (18 : 1n-9). There are few other intervention studies chronically increasing SFA intake in human subjects and reporting inflammatory markers.

Trans-fatty acids. Using a subgroup of the Nurses’ Health Study, Lopez-Garcia et al. identified significant positive associations between the intake of trans-fatty acids in the diet and the concentrations of all six inflammatory markers assessed, including CRP, IL-6 and three soluble adhesion molecules. In a 5-week intervention in healthy men, a trans-fatty acid-enriched diet resulted in higher CRP and IL-6 concentrations than diets rich in oleic acid, stearic acid or the combination of lauric, myristic and palmitic acids. Furthermore, the concentration of sE-selectin was higher than in all other dietary groups including the stearic acid and lauric + myristic + palmitic groups. Thus, an association study and an intervention study both demonstrate that dietary trans-fatty acids elevate the concentrations of a range of inflammatory markers including CRP, IL-6 and adhesion molecules.

Conjugated linoleic acids. In vitro and animal feeding studies have suggested marked effects of conjugated linoleic acids (CLA) on inflammation. However, results from human intervention studies using CLA-rich capsules are equivocal (Table 1). For example, two studies demonstrate that CLA, especially the trans-10, cis-12 isomer, increases CRP
concentration, but not the concentrations of cytokines or soluble adhesion molecules. However, at least four other studies have failed to show an effect of CLA on CRP concentration (see Table 14). Duration of intervention is not likely to be an explanatory factor for differences in the findings, but, since most studies have used mixtures of CLA isomers in different proportions, the precise dose of the more potent isomer (perhaps the trans-10, cis-12 isomer) may be an explanation. The two studies showing increased CRP with CLA provided 2.1 and 2.7 g/d of trans-10, cis-12 CLA. The four studies showing no effect of CLA on CRP used between 0.4- and 2.5 g/d of this isomer (see Table 14). The question of whether CLA per se, or whether specific CLA isomers, increase low-grade inflammation requires further study.

Linoleic and α-linolenic acids. Linoleic (18:2n-6) and α-linolenic (18:3n-3) acids constitute the majority (>95%) of PUFA in most Western diets, with the former usually being present in an excess of approximately 10-fold over the latter. These two fatty acids are the parent n-6 and n-3 PUFA, respectively. Because of the role of linoleic acid as the precursor of arachidonic acid (20:4n-6), which is, in turn, the substrate for the synthesis of pro-inflammatory eicosanoids such as PGE2 and 4-series leukotrienes, it is widely considered that elevated n-6 and low n-3 fatty acids (i.e. a high n-6:n-3 PUFA ratio) in the diet will promote inflammation. However, available evidence does not support this contention.

Dietary intakes of linoleic acid were not associated with CRP, IL-6, sTNFR1 or sTNFR2 concentrations in subgroups of the Physicians’ Health Study and the Nurses’ Health Study. The concentration of linoleic acid in blood lipids or granulocytes was not associated with CRP or IL-6 concentration, although a large Swedish study reported an inverse association between linoleic acid in cholesteryl esters and CRP concentration. Linoleic acid makes a major contribution to the fatty acids within blood lipids, especially cholesteryl esters, where it is the predominant n-6 PUFA. Total n-6 PUFA in serum fatty acids in overweight, but not in lean, subjects were inversely associated with IL-6 but not CRP concentration. The ratio of SFA:n-6 PUFA in serum lipids or in plasma phospholipids was positively associated with IL-6 but not CRP concentration in overweight subjects. This suggests that decreasing SFA status while increasing n-6 PUFA status might reduce low-grade inflammation. An intervention study in thirty-eight healthy male and female volunteers (mean age 27 years) compared diets with 18% energy from oleic acid and 4% from linoleic acid or 4% energy from oleic acid and 12% from linoleic acid; plasma sICAM-1 concentrations were not different between these two groups, suggesting that exchange of oleic acid for linoleic acid, while keeping SFA intake constant, does not affect this marker of inflammation.

Dietary α-linolenic acid intakes were not associated with CRP, IL-6, sTNFR1 or sTNFR2 concentrations in one study on subgroups of the Physicians’ Health Study and the Nurses’ Health Study. In a second study on another subgroup of the Nurses’ Health Study, α-linolenic acid intakes were not associated with CRP, sICAM-1, sE-selectin or sTNFR2 concentrations but were associated with lower IL-6 and sVCAM-1 concentrations. The concentration of α-linolenic acid in blood lipids or granulocytes was not associated with CRP or IL-6 concentration. Data from an Italian study showed no association between α-linolenic acid in plasma fatty acids and several cytokines including IL-6 and TNF-α, but there was an inverse association with CRP. These association studies suggest a modest anti-inflammatory effect of α-linolenic acid.

Several intervention studies have involved high α-linolenic acid intakes usually by providing flaxseed oil in capsules or in liquid form or foodstuffs made using flaxseed oil. Frequently, these studies have used a control group with a high intake of linoleic acid, with the comparison essentially being replacement of linoleic acid with α-linolenic acid. Thus, the focus of these studies is essentially to explore the importance of the n-6:n-3 PUFA ratio of the diet. If linoleic and α-linolenic acids have similar effects on low-grade inflammation, then studies exchanging one of these fatty acids with the other would be likely to see little effect. Table 15 summarises intervention studies with α-linolenic acid that have measured markers of low-grade inflammation as an outcome. Findings are inconsistent with a number of studies identifying the effects of α-linolenic acid on some markers and not others, and some studies finding no effects. Many studies have used very high intakes of α-linolenic acid, relative to typical habitual intakes. The study of Paschos et al. is enlightening because it showed that α-linolenic acid (8.1 g/d for 12 weeks) was less effective (i.e. induced fewer and smaller effects) against a more healthy, than against a less healthy, background diet. Thus, dose, duration, sample size and the nature of the background diet are possible contributors to the varied findings of studies with α-linolenic acid. However, what is apparent from these observations is that a substantial increase in the intake of α-linolenic acid can decrease low-grade inflammation as indicated by circulating CRP, IL-6 or soluble adhesion molecules (see Table 15). The study of Zhao et al. provides further insight: the change in CRP and sVCAM-1 concentrations was correlated with the change in the concentrations of different serum n-3 PUFA (α-linolenic acid, EPA, docosapentaenoic acid (22:5n-6) and DHA) that had occurred. The only significant relationships were inverse and between the change in EPA status and the changes in CRP and sVCAM-1 concentrations. This suggests that the anti-inflammatory effect seen with the very high intake of α-linolenic acid in this study is due to the conversion of α-linolenic acid to EPA. A suitable conclusion may be that high intakes of α-linolenic are anti-inflammatory acting via the α-linolenic acid derivative, EPA.

Several of the intervention studies with α-linolenic acid have involved a group consuming a high intake of linoleic acid, frequently as the control for the high α-linolenic acid intake. These groups provide some information about the impact of linoleic acid on low-grade inflammation. The study of Rallidis et al. involved a control group consuming about 11 g/d of linoleic acid in addition to the dietary intake; this approximately doubled linoleic acid intake. The increase in linoleic acid intake did not alter the concentrations...
Table 13. Observational studies on the association between fatty acid intake or status and markers of low-grade inflammation

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Exposure</th>
<th>Association with low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Referrals for coronary angiography</td>
<td>269 (M/F)</td>
<td>Mean ~60</td>
<td>Granulocyte fatty acids</td>
<td>Linoleic acid, αLNA, arachidonic acid, docosapentaenoic acid: ↑ CRP EPA: ↓ CRP (trend) DHA: ↓ CRP Serum non-esterified arachidonic acid: ↓ sICAM-1, sE-selectin, thrombomodulin, tissue plasminogen activator antigen ↓ sVCAM-1, von Willibrand factor Serum non-esterified EPA: = thrombomodulin, tissue plasminogen activator antigen ↓ sVCAM-1, sICAM-1, sE-selectin, von Willibrand factor Serum non-esterified DHA: = sE-selectin, thrombomodulin, tissue plasminogen activator antigen, von Willibrand factor ↓ sVCAM-1, sICAM-1</td>
<td>374</td>
</tr>
<tr>
<td>At risk of CHD</td>
<td>152 (M)</td>
<td>Mean 70(± 3)</td>
<td>Serum non-esterified arachidonic acid, EPA and DHA</td>
<td></td>
<td>585</td>
</tr>
<tr>
<td>Healthy and overweight</td>
<td>109 Healthy (M/F) and 123 overweight (M/F)</td>
<td>Mean 38 (healthy) and mean 44 (overweight)</td>
<td>Serum fatty acids</td>
<td>Healthy subjects: Total SFA, n-6 PUFA, n-3 PUFA: = CRP, IL-6 Overweight subjects: Total SFA: ↑ IL-6, = CRP Total n-6 PUFA: = CRP, ↓ IL-6 Total n-3 PUFA: = IL-6, ↓ CRP Saturated:n-6 PUFA: ↑ IL-6, = CRP Saturated:n-3 PUFA: ↓ CRP, = IL-6</td>
<td>577</td>
</tr>
<tr>
<td>Healthy</td>
<td>405 (M) and 454 (F) Mean ~60 (men) and ~42 (women)</td>
<td>Dietary intakes of linoleic acid, αLNA, EPA + DHA as percentage of energy determined from FFQ</td>
<td>Linoleic acid: = CRP, IL-6, sTNFR1, sTNFR2 αLNA: = CRP, IL-6, sTNFR1, sTNFR2 EPA + DHA: = IL-6; ↓ CRP, sTNFR1, sTNFR2</td>
<td></td>
<td>583</td>
</tr>
<tr>
<td>Healthy</td>
<td>727 (F)</td>
<td>Mean ~56</td>
<td>Dietary intakes of αLNA, EPA + DHA, total n-3 PUFA as g/d determined from FFQ</td>
<td>αLNA: = CRP, sTNFR2, sICAM-1, sE-selectin; ↓ IL-6, sVCAM-1 EPA + DHA: = IL-6, sTNFR2; ↓ CRP, sICAM-1, sVCAM-1, sE-selectin Total n-3 PUFA: = sTNFR2; ↓ CRP, IL-6, sICAM-1, sVCAM-1, sE-selectin ↑ CRP, IL-6, sTNFR2, sICAM-1, sVCAM-1, sE-selectin</td>
<td>373</td>
</tr>
<tr>
<td>Healthy</td>
<td>730 (F)</td>
<td>Mean ~56</td>
<td>Dietary intake of trans-fatty acids as g/d determined from FFQ</td>
<td>Granulocyte EPA: = sICAM-1, sVCAM-1, sP-selectin</td>
<td>580</td>
</tr>
<tr>
<td>Patients with angina</td>
<td>291 (M/F)</td>
<td>Mean ~60</td>
<td>Granulocyte EPA and DHA Subcutaneous adipose tissue EPA and DHA</td>
<td>Granulocyte DHA: = sICAM-1, sVCAM-1, sP-selectin Granulocyte total n-3 PUFA: = sICAM-1, sVCAM-1, sP-selectin Adipose EPA: = sICAM-1, sVCAM-1, sP-selectin Adipose DHA: = sICAM-1, sVCAM-1, sP-selectin Adipose total n-3 PUFA: ↑ sVCAM-1; = sICAM-1, sP-selectin</td>
<td>576</td>
</tr>
</tbody>
</table>
## Table 13. Continued

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Exposure</th>
<th>Association with low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overweight</td>
<td>60 (M/F)</td>
<td>Mean ~12</td>
<td>Plasma phospholipid and cholesteryl ester fatty acids</td>
<td>Plasma phospholipids:</td>
<td>579</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total SFA: ↓ IL-6; = CRP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ratio of PUFA to SFA: = CRP; ↓ IL-6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Linoleic acid, αLNA, EPA, DHA: = CRP, IL-6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Plasma cholesteryl esters:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total SFA: ↓ IL-6; = CRP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ratio of PUFA to SFA: = CRP; ↓ IL-6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Linoleic acid, DHA: = CRP, IL-6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>αLNA, EPA: = IL-6; ↓ CRP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ratio of PUFA to SFA: = CRP; ↓ IL-6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Linoleic acid, DHA: = CRP, IL-6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>αLNA, EPA: = IL-6; ↓ CRP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EPA + DHA: ↓ CRP</td>
<td>581</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>αLNA: = CRP</td>
<td></td>
</tr>
<tr>
<td>Japanese general population</td>
<td>971 (M/F)</td>
<td>Mean 76(±4)</td>
<td>Dietary intake of n-3 fatty acids as g/d determined from FFQ</td>
<td>Linoleic acid: ↑ IL-6; = CRP, IL-6, TNF-α, IL-1β, IL-1ra, IL-10, TGF-β</td>
<td>578</td>
</tr>
<tr>
<td>aged &gt; 70 years</td>
<td></td>
<td></td>
<td></td>
<td>αLNA: = IL-6, TNF-α, IL-1β, IL-10, IL-6R, TGF-β; ↓ CRP, IL-1ra</td>
<td></td>
</tr>
<tr>
<td>General population aged &gt; 65 years</td>
<td>1123 (M/F)</td>
<td>Mean ~68</td>
<td>Plasma fatty acids</td>
<td>Arachidonic acid: ↑ TGF-β = CRP, TNF-α, IL-1β, IL-10, IL-6R; ↓ IL-6, IL-1ra</td>
<td>582</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EPA: ↑ IL-10, TGF-β; = CRP, TNF-α, IL-1β, IL-1ra, IL-6R; ↓ IL-6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arachidonic acid: ↑ TGF-β = CRP, TNF-α, IL-1β, IL-10, IL-6R; ↓ IL-6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EPA: ↑ IL-10, TGF-β; = CRP, TNF-α, IL-1β, IL-1ra, IL-6R; ↓ IL-6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DHA: ↑ IL-10, TGF-β; = CRP, IL-1β, IL-6R; ↓ IL-6, TNF-α, IL-1ra</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Radio of arachidonic acid to EPA = CRP, IL-6, TNF-α, IL-1β, IL-1ra, IL-6R, TGF-β</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>αLNA: = IL-6, TNF-α, IL-1β, IL-10, IL-6R, TGF-β; ↓ CRP, IL-1ra</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total n-6 PUFA: ↑ TGF-β = CRP, IL-6, TNF-α, IL-1β, IL-6R; ↓ IL-10, IL-1ra</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total n-3 PUFA: ↑ IL-6R, IL-10, TGF-β = CRP, IL-1β, IL-6R; ↓ IL-10, IL-1ra</td>
<td></td>
</tr>
<tr>
<td>Healthy</td>
<td>767 (M)</td>
<td>50 (fatty acids) and 70 (CRP)</td>
<td>Plasma cholesteryl ester fatty acids at age 50 years; ▲ CRP at age 70 years</td>
<td>Linoleic acid: ↓ CRP (men only)</td>
<td>582</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>αLNA: ↓ CRP (men only)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>αLNA: ↓ CRP (men only)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EPA, DHA, EPA + DHA: ↓ CRP (weak)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total n-6 PUFA: ↓ CRP (men only)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total n-3 PUFA: ↓ CRP (men only)</td>
<td></td>
</tr>
<tr>
<td>Healthy</td>
<td>511 (M/F)</td>
<td>21–67</td>
<td>Dietary intake of linoleic acid, αLNA, EPA and DHA</td>
<td>Linoleic acid: ↓ CRP (men only)</td>
<td>584</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>αLNA: ↓ CRP (men only)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EPA, DHA, EPA + DHA: ↓ CRP (weak)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total n-6 PUFA: ↓ CRP (men only)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total n-3 PUFA: ↓ CRP (men only)</td>
<td></td>
</tr>
</tbody>
</table>

M, male; F, female; αLNA, α-linolenic acid; = , no effect on; CRP, C-reactive protein; ↓ , decreased; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; ↑ , increased; sTNFR, soluble TNF receptor; sP-selectin, soluble P-selectin; IL-1ra, IL-1 receptor antagonist; TGF, transforming growth factor.
of CRP, IL-6, SAA, sCAM-1 or sE-selectin, but the concentration of sVCAM-1 was decreased\(^{603,604}\). In the study of Paschos et al.\(^{602}\), the control group consumed 11.2 g/d of linoleic acid on top of their normal intake, which was approximately 11 g/d. This doubling of linoleic acid intake did not affect TNF-\(\alpha\) or adiponectin concentrations. These studies did not alter any aspect of diet but required subjects to consume oil providing linoleic or \(\alpha\)-linolenic acids on top of the normal diet. Thus, these studies show that markedly increasing linoleic acid intake in those consuming on average about 10 g/d does not increase low-grade inflammation.

The study of Zhao et al.\(^{660}\) included a high linoleic acid intervention group (15\% energy) and the control group consumed what is described as an ‘average American diet’. This provided 12.7\% of energy from SFA, 7.7\% from linoleic acid and 0.8\% from \(\alpha\)-linolenic acid. The corresponding values for the linoleic and \(\alpha\)-linolenic acid rich diets were 8.5, 12.6 and 5.6 and 8.2, 10.5 and 6.5, respectively. Thus, the linoleic acid-rich diet contained more \(\alpha\)-linolenic acid than the control diet, while the \(\alpha\)-linolenic acid diet contained more linoleic acid than the control diet and almost as much linoleic acid as the linoleic acid diet. Essentially, what this means is that the linoleic acid diet is examining the effect of replacing some SFA with the combination of linoleic and \(\alpha\)-linolenic acids and that the \(\alpha\)-linolenic acid diet is examining the effect of replacing some linoleic acid with \(\alpha\)-linolenic acid.

In the linoleic acid group, the concentrations of CRP and sCAM-1 decreased by 45 and 25\%, respectively; sVCAM-1 and s-selectin also fell (by 15 and 7\%) but these changes were not significant. Thus, replacing about one-third of SFA with linoleic acid plus \(\alpha\)-linolenic acid decreases low-grade inflammation. This is consistent with the associations described above and confirms that relative to SFA, the combination of linoleic and \(\alpha\)-linolenic acids is anti-inflammatory. The changes in inflammatory markers seen with the \(\alpha\)-linolenic acid diet were greater than with the linoleic acid diet (75, 80, 37.5 and 12\% decreases in CRP, sVCAM-1, sCAM-1 and sE-selectin concentrations, respectively). Since this diet is effectively replacing some linoleic acid with \(\alpha\)-linolenic acid, relative to the amounts in the linoleic acid diet, these results suggest that \(\alpha\)-linolenic acid is more potent than linoleic acid with regard to reducing inflammation.

The studies just described have focused on increasing intake of linoleic and \(\alpha\)-linolenic acids to study their effects. The study of Liou et al.\(^{607}\) used a different approach. They kept the amount of \(\alpha\)-linolenic acid in the diet of men aged 20–45 years constant over the study period at about 1\% of energy. Linoleic acid intake was either 10.5 or 3.8\% of energy. Saturated fat was also constant across the two diets at about 8\% of energy. The manipulation of linoleic acid was at the expense of oleic acid (17 or 10\% of energy). The intervention duration was 4 weeks and a random order, cross-over design was used. CRP and IL-6 concentrations were not different after 4 weeks on either diet. This finding is in accordance with that of Turpeinen et al.\(^{597}\).

**Arachidonic acid.** Arachidonic acid intake in the diet is low relative to that of its metabolic precursor linoleic acid (approximately 500 mg/d vs. approximately 11 g/d, respectively). Nevertheless, arachidonic acid is the most prevalent \(n\)-6 PUFA and PUFA in the membranes of inflammatory cells and other cells that might be involved in low-grade inflammation such as endothelial cells and platelets. This reflects the important functional role of arachidonic acid as a precursor of the eicosanoid family of lipid mediators; this family includes the 2-series PG and the 4-series leukotrienes. Since these eicosanoids are classically associated with inflammatory processes and are targeted by common anti-inflammatory therapies, it is generally considered that arachidonic acid will enhance inflammation. However, observations that classical pro-inflammatory mediators such as PGE\(_2\) can also exert anti-inflammatory effects and that arachidonic acid gives rise to anti-inflammatory mediators such as lipoxin A\(_4\) have started to challenge the earlier view\(^{608}\). Several studies have examined the association between arachidonic acid status and markers of low-grade inflammation. There was no association between arachidonic acid in granulocytes and CRP concentration\(^{574}\). Serum free arachidonic acid was not associated with sCAM-1 or s-selectin concentrations and was actually inversely associated with sVCAM-1 concentration\(^{585}\). Ferrucci et al.\(^{578}\) reported no association between arachidonic acid in plasma and CRP, TNF-\(\alpha\), IL-1\(\beta\), IL-10 and sIL-6R concentrations, while there was an inverse association with IL-6 and IL-1ra concentrations and a positive association with TGF-\(\beta\) concentration. These observations suggest either that plasma arachidonic acid has little impact on low-grade inflammation (does not affect CRP or TNF-\(\alpha\)) or that it is anti-inflammatory (lowers IL-6; increases TGF-\(\beta\)).

There are very few intervention studies with arachidonic acid reporting on low-grade inflammation. In an uncontrolled study, Kelley et al.\(^{699}\) reported higher granulocyte numbers in the blood of a group of ten healthy men (aged 20–38 years) taking a supplement of 1.5 g/d of arachidonic acid for 100 d compared with numbers after a run-in diet providing 200 mg/d of arachidonic acid. In another small, but controlled, study, eight subjects aged 55–75 years consumed capsules providing 700 mg/d of arachidonic acid for 12 weeks\(^{603}\); there was no effect on plasma sVCAM-1, sCAM-1 or sE-selectin concentrations.

**Marine-derived long-chain \(n\)-3 PUFA.** The long-chain \(n\)-3 PUFA EPA and DHA are found in seafood, especially oily fish. They are also present in fish oils and in certain algal oils; in some preparations, the fatty acids are in a more concentrated form than in natural fish oils. In fish oils, the fatty acids are in the TAG form, but other forms of long-chain \(n\)-3 PUFA are also available, for example, as phospholipids or ethyl esters. Increased intake of long-chain \(n\)-3 PUFA results in increased proportions of those fatty acids in inflammatory cell phospholipids\(^{610–614}\). The incorporation of EPA and DHA into human inflammatory cells is partly at the expense of arachidonic acid, resulting in less substrate available for the synthesis of the classic inflammatory eicosanoids such as PGE\(_2\). Through altered eicosanoid production, \(n\)-3 PUFA could affect inflammation and inflammatory processes, although they also exert non-eicosanoid-mediated actions on cell signalling and gene expression. The effects of long-chain \(n\)-3 PUFA have been examined in many model systems and findings from
cell-culture systems and from animal models are generally consistent in identifying anti-inflammatory actions (509). Furthermore, clinical trials have demonstrated anti-inflammatory effects and clinical benefit from fish oil administration in diseases with a frank inflammatory basis including rheumatoid arthritis (615), inflammatory bowel diseases (616) and childhood asthma (617).

Data from subgroups of the Physicians’ Health Study and the Nurses’ Health Study showed inverse associations between the dietary intake of EPA + DHA and concentrations of CRP, sTNFRI and sTNFR2 (585), and CRP, sICAM-1, sVCAM-1 and sE-selectin (573). The concentration of either EPA or DHA in granulocyte membranes was inversely associated with CRP concentration in one study (574); the effect of DHA was stronger than that of EPA. Serum non-esterified EPA and DHA were both inversely associated with concentrations of sVCAM-1 and sICAM-1 in patients at risk of CHD (585). EPA was also inversely associated with s-selectin concentration. Plasma cholesteryl ester EPA was inversely associated with CRP concentration in overweight subjects (579). In an elderly Italian population, plasma EPA was inversely associated with IL-6 concentration and positively associated with the concentrations of the anti-inflammatory cytokines IL-10 and TGF-β (578). Furthermore, plasma DHA was inversely associated with IL-6 and TNF-α concentrations and was also positively associated with the concentrations of IL-10 and TGF-β (578). Thus, observational studies suggest that both EPA and DHA are anti-inflammatory.

The ready availability of fish oil capsules has facilitated numerous supplementation studies of long-chain n-3 PUFA in various subject groups; these are summarised in Table 16. Studies have shown that long-chain n-3 PUFA lower the concentrations of CRP (621,624,639), IL-6 (621,624,639), TNF-α (659), IL-18 (645), sICAM-1 (625,628,645,646), sVCAM-1 (605,645) and sE-selectin (618) in various subject/patient groups (see Table 16). For example, one study showed an increase in adiponectin concentration when a weight-loss programme and 4·2 g/d EPA + DHA were combined in overweight, insulin-resistant women (632). Thus, there is quite a lot of evidence for anti-inflammatory effects of supplemental long-chain n-3 PUFA. In a group of overweight women with type 2 diabetes, 8 weeks of a moderate dose of long-chain n-3 PUFA (1·8 g/d of EPA + DHA) decreased adiposity and reduced expression of a number of inflammation-related genes in the subcutaneous adipose tissue (630). The parallelism between the down-regulation of these genes and the reduction in adiposity and adipocyte diameter by n-3 PUFA treatment suggests a positive relationship between adipose cell size and adipose tissue inflammation, agreeing with other observations (51,60). Also these findings in type 2 diabetic women are paralleled by those from rodent studies: 6 weeks of n-3 PUFA supplementation prevented adipose tissue inflammation induced by a high-fat diet (637), and the presence of n-3 PUFA in the diet of long-term insulin-resistant, sucrose-fed rats decreased adipocyte diameter (648) and significantly reduced several inflammation-related genes (unpublished results, Guerre-Millo M, Naour N, Lombardo Y, Clement K, Rizkalla S). These studies suggest that reducing adiposity with n-3 PUFA could decrease adipose tissue inflammation and macrophage infiltration. The beneficial effects of n-3 PUFA may be linked to local blunting of adipose tissue inflammation.

Despite the large number of positive studies with long-chain n-3 PUFA, there are a number of studies that have failed to replicate these findings (see Table 16). Furthermore, two early studies showed an enhancement of selected inflammatory markers following long-chain n-3 PUFA administration (629,642). Seljeflot et al. provided 4·8 g/d of EPA + DHA in ethyl ester form to hyperlipidaemic male smokers for 6 weeks, while Johansen et al. provided 5·1 g/d of EPA + DHA in ethyl ester form to patients with CHD for 24 weeks. Both studies identified an increase in sVCAM-1 (<10%) and sE-selectin (20%) concentrations, with no effect on s-selectin and a decrease in von Willebrand factor and thrombomodulin concentrations. In both cases, the authors ascribed the effect of EPA + DHA on sVCAM-1 and sE-selectin to increased oxidant stress in these subjects.

Thus, although the overwhelming view is that EPA + DHA given at sufficient doses are anti-inflammatory, the evidence from measurements of markers of low-grade inflammation is not entirely consistent. The lack of consistency may be related to differences in: duration of treatment; sample size; characteristics of the populations studied (e.g. age, healthy v. diseased, type of disease, smokers v. non-smokers); background diet; dose of EPA + DHA used; relative contribution of EPA and DHA, since they may have different anti-inflammatory potencies; chemical formulation (e.g. TAG v. ethyl ester); degree of oxidative stress present. One other factor that has been recently identified is genetic differences among individuals, which may have an impact on the ability of n-3 PUFA to exert an anti-inflammatory effect. This was first identified by Grimble et al. (649) who showed that the ability of fish oil to lower the LPS-stimulated production of TNF-α by blood mononuclear cells was determined in part by polymorphisms within the TNF-α and TNF-β genes. Another example of such an interaction was identified by Shen et al. (650). They first identified that the IL-1β 6054 G > A SNP was significantly associated with CRP and adiponectin concentrations and with the prevalence of the metabolic syndrome among a group of 1120 men and women with a mean age of 49 years. There was also a significant interaction between this polymorphism and erythrocyte membrane n-3 PUFA content. Among subjects with low erythrocyte n-3 PUFA content (below the median), the 6054 G allele was associated with increased risk of the metabolic syndrome (OR 3-29, 95% CI 1-49, 7-26 for GG and OR 1-95, 95% CI 0-85, 4-46 for GA) compared with the AA genotype, but there were no significant genotype associations among subjects with high erythrocyte n-3 PUFA content (above the median). The results suggest that IL-1β genetic variants are associated with measures of chronic low-grade inflammation and the risk of the metabolic syndrome, and that genetic influences were more evident among subjects with low erythrocyte n-3 PUFA status and so, most probably low n-3 PUFA intake.
### Intervention studies investigating the effect of conjugated linoleic acid intake on markers of low-grade inflammation

**Table 14.**

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Intake (source; duration)</th>
<th>Effect on low-grade inflammation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy 49 (M)</td>
<td>20–47</td>
<td>0.6 g CLA (50:50 c9,t11 and t10,c12), 2.2 g/d CLA</td>
<td>CRP, IL-6, TNF-α, sICAM-1, PGE2, LTB4, sVCAM-1, TNF-α</td>
<td>CRP, IL-6, TNF-α, sICAM-1, PGE2, LTB4, sVCAM-1, TNF-α</td>
</tr>
<tr>
<td>Healthy 55 (M/F)</td>
<td>Mean 30</td>
<td>0.24 g CLA (50:50 c9,t11 and t10,c12), 0.24 g CLA (50:50 c9,t11 and t10,c12), 0.24 g CLA (50:50 c9,t11 and t10,c12)</td>
<td>CRP, IL-6, TNF-α, sICAM-1, PGE2, LTB4, sVCAM-1, TNF-α</td>
<td>CRP, IL-6, TNF-α, sICAM-1, PGE2, LTB4, sVCAM-1, TNF-α</td>
</tr>
<tr>
<td>Healthy 42 (M/F)</td>
<td>Mean 30</td>
<td>0.24 g CLA (50:50 c9,t11 and t10,c12), 0.24 g CLA (50:50 c9,t11 and t10,c12), 0.24 g CLA (50:50 c9,t11 and t10,c12)</td>
<td>CRP, IL-6, TNF-α, sICAM-1, PGE2, LTB4, sVCAM-1, TNF-α</td>
<td>CRP, IL-6, TNF-α, sICAM-1, PGE2, LTB4, sVCAM-1, TNF-α</td>
</tr>
<tr>
<td>Healthy 30 (M)</td>
<td>Mean 40</td>
<td>0.24 g CLA (50:50 c9,t11 and t10,c12), 0.24 g CLA (50:50 c9,t11 and t10,c12), 0.24 g CLA (50:50 c9,t11 and t10,c12)</td>
<td>CRP, IL-6, TNF-α, sICAM-1, PGE2, LTB4, sVCAM-1, TNF-α</td>
<td>CRP, IL-6, TNF-α, sICAM-1, PGE2, LTB4, sVCAM-1, TNF-α</td>
</tr>
</tbody>
</table>

**Carbohydrates**

**Acute postprandial effects of hyperglycaemia.** Hyperglycaemia, elevated TAG/NEFA and hyperinsulinaemia are events that are mutually inherent to the initial development of a diabetic state. The effects of the individual events are difficult to study since they always present together. However, some observations have suggested that hyperglycaemia and hypertriglyceridaemia/elevated NEFA levels induce independent effects and, when present together, act synergistically to generate oxidative stress, inflammation, impaired endothelial function and vascular disease. Oxidative stress is known to induce damage to cell membranes, internal cell structures and DNA as well as to induce inflammatory responses. Ceriello et al. observed that after meals LDL oxidation increases and that this phenomenon is correlated with the degree of hyperglycaemia. This clearly points to hyperglycaemia-induced free radical production that has an impact on a broad range of metabolic events. NO, a potent vasodilator, is assumed to play a key role in this respect. It has been suggested that hyperglycaemia leads to an increased oxidation of NO, thereby reducing NO levels which leads to impairment in vasodilatation. Indeed, alloxan diabetic rats are observed to have reduced NO levels in blood, and in human subjects, acute hyperglycaemia attenuated endothelium-dependent vasodilation. Postprandial hyperglycaemia is also correlated with impaired myocardial perfusion in diabetic patients. The fact that such a decrease can be prevented by supplying various antioxidants such as vitamin C, vitamin E and α-lipoic acid or l-arginine, the precursor of NO, suggests that increased NO oxidation and the related NO drain have an impact on cells of the vasculature. This is supported by other evidence. Restoration of NO availability results in normalisation of endothelial function as well as insulin sensitivity. During an oral glucose tolerance test, plasma antioxidant status, measured as total plasma radical trapping capacity, significantly decreased in normal as well as in diabetic individuals. The consumption of a hyperglycaemic meal increases oxidative stress and reduces antioxidant defences, with the increase being significantly greater with higher levels of hyperglycaemia. Acute post-prandial hyperglycaemia was observed to induce the formation of nitrotyrosine, a marker of oxidative stress, in healthy, non-overweight individuals. It has been hypothesised that acute hyperglycaemia may induce a drain of vitamin C from cells because vitamin C and glucose share a common transport system and oxidative stress leads to a use of intracellular vitamin C. Accordingly, Chen et al. provided evidence in vitro that acute hyperglycaemia leads to a significant decrease in leucocyte vitamin C content. Evans et al. developed a unique oxidative stress hypothesis suggesting that chronic elevation of hyperglycaemia (and NEFA) induces an activation of the NF-κB, p38 MAPK and NH2-terminal Jun kinase/stress-activated protein kinase pathways. This happens along with the activation of the RAGE, protein kinase C and sorbitol stress pathways. The authors suggest that these events play a key role in causing late complications.
Table 15. Intervention studies investigating the effect of α-linolenic acid (αLNA) intake on markers of low-grade inflammation

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Intake (source; duration)</th>
<th>Effect on low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy</td>
<td>58 (MF) in three groups</td>
<td>Mean ~ 27</td>
<td>Three diets including one with foods rich in αLNA (4 weeks)</td>
<td>= CRP, sL-selectin, sP-selectin, fibrinogen, PAI-1 activity, tissue plasminogen activator activity</td>
<td>600</td>
</tr>
<tr>
<td>Healthy</td>
<td>16 (MF) in two groups</td>
<td>56-74</td>
<td>0.2 g/d αLNA (flaxseed oil capsules; 12 weeks)</td>
<td>= sICAM-1</td>
<td>605</td>
</tr>
<tr>
<td>Hyperlipidaemic</td>
<td>76 (M) in two groups</td>
<td>Mean 51 (SD 8)</td>
<td>0, 8 g/d αLNA (flaxseed oil; 12 weeks)</td>
<td>↓ sVCAM-1, sE-selectin</td>
<td>603, 604</td>
</tr>
<tr>
<td>High cardiovascular risk</td>
<td>103 (M/F) in two groups</td>
<td>Mean 55 (SD 10)</td>
<td>0, 6-3 g/d αLNA (spread; up to 2 years)</td>
<td>= IL-6, sICAM-1, IL-10</td>
<td>599</td>
</tr>
<tr>
<td>Hyperlipidaemic</td>
<td>23 (MF) in three groups</td>
<td>36-65</td>
<td>0, 8, 3, 6, 6 % energy from αLNA (~1.5, 8, 15 g/d αLNA) (walnuts + walnut oil + flaxseed oil; 6 weeks; cross-over)</td>
<td>= Mediterranean diet background:</td>
<td>Mediterranean diet background:</td>
</tr>
<tr>
<td>Hyperlipidaemic</td>
<td>40 (M) in two groups</td>
<td>35-67</td>
<td>Mediterranean diet + 8-1 g/d αLNA, Westernised Greek diet + 8-1 g/d αLNA (flaxseed oil; 12 weeks)</td>
<td>↓ CRP, IL-6, SAA, sICAM-1, sE-selectin</td>
<td>601</td>
</tr>
<tr>
<td>Hyperlipidaemic</td>
<td>40 (M) in two groups</td>
<td>38-71</td>
<td>0, 8, 1 g/d αLNA (flaxseed oil; 12 weeks)</td>
<td>Mediterranean diet background:</td>
<td>Mediterranean diet background:</td>
</tr>
</tbody>
</table>

M, male; F, female; ↓, no effect on; CRP, C-reactive protein; sL-selectin, soluble L-selectin; sP-selectin, soluble P-selectin; PAI, plasminogen activator inhibitor; sICAM-1, soluble intercellular adhesion molecule-1; ↓, decreased; sVCAM-1, soluble vascular cell adhesion molecule-1; SAA, serum amyloid A; M-CSF, macrophage colony-stimulating factor.
Table 16. Intervention studies investigating the effect of marine n-3 PUFA intake on markers of low-grade inflammation

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Intake (source; duration)</th>
<th>Effect on low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy</td>
<td>58 (M) in four groups</td>
<td>21–87 (mean 56)</td>
<td>0, 1,06, 2,13, 3,19 g/d EPA + DHA (FO capsules; up to 52 weeks)</td>
<td>= TNF-α, IL-1, IL-1ra</td>
<td>620</td>
</tr>
<tr>
<td>Hyperlipidaemic</td>
<td>20 Healthy (M/F) and 39 hyperlipidaemic (M/F)</td>
<td>Mean − 51</td>
<td>0, 3,6 g/d EPA + DHA (EE capsules; up to 6 weeks)</td>
<td>= sICAM-1, sVCAM-1, sE-selectin, tissue plasminogen activator antigen</td>
<td>618</td>
</tr>
<tr>
<td>Hyperlipaemic smokers</td>
<td>41 (M) in four groups (two received n-3 PUFA)</td>
<td>41–57 (mean − 48)</td>
<td>0, 4,8 g/d EPA + DHA (EE capsules; 6 weeks)</td>
<td>= sICAM-1, sE-selectin, tissue plasminogen activator antigen von Willibrand factor, thrombomodulin</td>
<td>629</td>
</tr>
<tr>
<td>Patients with CHD</td>
<td>54 (M/F) in two groups</td>
<td>43–73 (mean 57)</td>
<td>0, 5,1 g/d EPA + DHA (EE capsules; 24 weeks)</td>
<td>= sICAM-1, sE-selectin, tissue plasminogen activator antigen von Willibrand factor, thrombomodulin</td>
<td>642</td>
</tr>
<tr>
<td>Healthy and type 2 diabetics</td>
<td>21 Healthy (M) and 29 diabetics (M)</td>
<td>Mean − 55</td>
<td>2 g/d EPA + DHA (FO capsules; 3 weeks)</td>
<td>= sICAM-1, sE-selectin, tissue plasminogen activator antigen PAI-1 activity, PAI-1 antigen</td>
<td>640</td>
</tr>
<tr>
<td>Healthy</td>
<td>24 (M/F) in three groups</td>
<td>55–75 (mean 48)</td>
<td>0, 0,7 g/d DHA (DHA-rich algal oil capsules; 12 weeks), 1 g/d EPA + DHA (FO capsules; 12 weeks)</td>
<td>= sICAM-1, sVCAM-1, sE-selectin, PAI-1 activity, PAI-1 antigen</td>
<td>645</td>
</tr>
<tr>
<td>Obese</td>
<td>48 (M) in four groups (two received n-3 PUFA)</td>
<td>Mean 53</td>
<td>0, 3,5 g/d EPA + DHA (EE capsules; 6 weeks)</td>
<td>= sICAM-1, sE-selectin, tissue plasminogen activator antigen von Willibrand factor, thrombomodulin</td>
<td>623</td>
</tr>
<tr>
<td>Elderly at risk of CHD</td>
<td>171 (M) in four groups (two received n-3 PUFA)</td>
<td>Mean 70</td>
<td>0, 2,4 g/d EPA + DHA (FO capsules; 18 months)</td>
<td>= sICAM-1, sVCAM-1, sE-selectin, tissue plasminogen activator antigen von Willibrand factor, thrombomodulin</td>
<td>640</td>
</tr>
<tr>
<td>Healthy on hormone replacement therapy</td>
<td>30 (F) in three groups</td>
<td>Mean 60</td>
<td>0, 1,09, 2,18 g/d EPA + DHA (FO capsules; 5 weeks)</td>
<td>= sICAM-1, sVCAM-1, sE-selectin, tissue plasminogen activator antigen von Willibrand factor, thrombomodulin</td>
<td>629</td>
</tr>
<tr>
<td>Healthy</td>
<td>60 (M/F) in three groups</td>
<td>21–57 (mean 38)</td>
<td>0, 2,0, 6,6 g/d EPA + DHA (FO capsules; 12 weeks)</td>
<td>= CRP</td>
<td>624</td>
</tr>
<tr>
<td>Myocardial infarction survivors Type 2 diabetics</td>
<td>300 (M/F) in two groups</td>
<td>28–87 (mean 65)</td>
<td>0, 3,5 g/d EPA + DHA (EE capsules; 12 months)</td>
<td>= CRP</td>
<td>625</td>
</tr>
<tr>
<td>Healthy</td>
<td>59 (M/F) in three groups</td>
<td>40–65 (mean 61)</td>
<td>0, 4,4 g/d EPA, 4 g/d DHA (EE capsules; 6 days)</td>
<td>= CRP</td>
<td>626</td>
</tr>
<tr>
<td>Healthy</td>
<td>60 (M/F) in three groups</td>
<td>Mean − 38</td>
<td>0, 1,6, 5,8 g/d EPA + DHA (combined FO capsules; 3 years)</td>
<td>= CRP</td>
<td>627</td>
</tr>
<tr>
<td>Obese</td>
<td>11 (M) in four groups</td>
<td>Not given</td>
<td>1,1 g/d EPA + DHA (FO capsules; 6 weeks)</td>
<td>Low dose: = sICAM-1, sP-selectin</td>
<td>625</td>
</tr>
<tr>
<td>Hyperlipaemia</td>
<td>563 (M) in four groups (two received n-3 PUFA)</td>
<td>64–76 (mean 70)</td>
<td>0, 2,4 g/d EPA + DHA (FO capsules; 3 years)</td>
<td>High dose: = sICAM-1, sP-selectin, tissue plasminogen activator antigen von Willibrand factor, thrombomodulin</td>
<td>628</td>
</tr>
<tr>
<td>Healthy</td>
<td>93 young (M) and 62 older (M) in four groups</td>
<td>Mean 25–70 (mean 10)</td>
<td>0, 1,35, 2,7, 4,05 g/d EPA + DHA (EPA-rich oil; 12 weeks)</td>
<td>= CRP, IL-6, sTNFR1, sTNFR2, PAI-1</td>
<td>636</td>
</tr>
<tr>
<td>Healthy</td>
<td>141 (M/F) in two groups</td>
<td>Mean − 47</td>
<td>0, 0,96 g/d EPA + DHA (FO in soya milk; 12 weeks)</td>
<td>= sICAM-1, sE-selectin, von Willibrand factor, tissue plasminogen activator antigen</td>
<td>639</td>
</tr>
<tr>
<td>Overweight and insulin resistant</td>
<td>116 (F) in three groups</td>
<td>Mean 21–69 (mean 45)</td>
<td>0, 0,4 + weight-loss programme, 4,2 g/d EPA + DHA + weight-loss programme (combined FO capsules; 24 weeks)</td>
<td>= CRP</td>
<td>640</td>
</tr>
<tr>
<td>Healthy</td>
<td>80 (M/F) in two groups</td>
<td>Mean − 30</td>
<td>0, 1,5 g/d DHA (DHA-rich algal oil; 4 weeks)</td>
<td>= CRP, fibrinogen, PAI-1 activity, inflammatory gene expression in adipose tissue</td>
<td>641</td>
</tr>
<tr>
<td>Overweight type 2 diabetics</td>
<td>27 (F) in two groups</td>
<td>Mean 55</td>
<td>0, 1,8 g/d EPA + DHA (FO capsules; 8 weeks)</td>
<td>= IL-6, sICAM-1, sVCAM-1, sE-selectin, tissue plasminogen activator antigen von Willibrand factor, thrombomodulin</td>
<td>630</td>
</tr>
<tr>
<td>Overweight and obese</td>
<td>30 (F) in two groups</td>
<td>Not given</td>
<td>0, 4,2 g/d EPA + DHA (DHA-rich TAG capsules; 12 weeks; cross-over)</td>
<td>= IL-6, sICAM-1, sVCAM-1, sE-selectin, tissue plasminogen activator antigen von Willibrand factor, thrombomodulin</td>
<td>621</td>
</tr>
</tbody>
</table>
### Table 16. Continued

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n (sex)</th>
<th>Age (years)</th>
<th>Intake (source; duration)</th>
<th>Effect on low-grade inflammation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin resistant with chronic renal failure and on haemodialysis (two received n-3 PUFA)</td>
<td>35 (M/F in four groups) Mean 55(±10)</td>
<td>2.4 g/d EPA + DHA (FO capsules; 8 weeks)</td>
<td>CRP, IL-6, TNF-α</td>
<td>639</td>
<td></td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>46 (M/F in two groups) Mean 59(±11)</td>
<td>0, 2.4 g/d EPA + DHA (FO capsules; 8 weeks)</td>
<td>CRP</td>
<td>643</td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction survivors</td>
<td>41 (M/F in two groups) Mean 63(±7)</td>
<td>0, 5.2 g/d EPA + DHA (EPA-rich TAG capsules; 12 weeks)</td>
<td>CRP</td>
<td>635</td>
<td></td>
</tr>
<tr>
<td>Overweight</td>
<td>86 (M/F in two groups) Mean 50</td>
<td>0, 1 g/d EPA + DHA (enriched foods; 6 months)</td>
<td>CRP</td>
<td>637</td>
<td></td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>23 (M/F in two groups) Mean 36–50 (mean 45)</td>
<td>0, 1.8 g/d EPA + DHA (EPA-rich oil; 8 weeks)</td>
<td>CRP, IL-6, sVCAM-1, sE-selectin, sP-selectin</td>
<td>646</td>
<td></td>
</tr>
<tr>
<td>Healthy</td>
<td>20 (M) in two groups Mean 50</td>
<td>0, 1.8 g/d EPA + DHA (EPA-rich oil; 8 weeks)</td>
<td>CRP, IL-6, sVCAM-1, sE-selectin, sP-selectin</td>
<td>646</td>
<td></td>
</tr>
<tr>
<td>Moderately hyperlipidaemic</td>
<td>34 (M) in two groups Mean 50–70</td>
<td>0, 3 g/d DHA (DHA-rich algal oil; ~90 d)</td>
<td>CRP, IL-6, TNF-α, IL-8</td>
<td>631</td>
<td></td>
</tr>
<tr>
<td>Healthy</td>
<td>77 (M/F in two groups) Mean 70</td>
<td>0, 1.5 g/d EPA + DHA (FO capsules; 12 weeks)</td>
<td>CRP, IL-6, TNF-α, IL-18</td>
<td>643</td>
<td></td>
</tr>
<tr>
<td>Elderly at risk of CHD</td>
<td>563 (M) in four groups Mean 70</td>
<td>0, 2.4 g/d EPA + DHA (FO capsules; 3 years)</td>
<td>CRP, IL-6, TNF-α, adiponectin</td>
<td>631</td>
<td></td>
</tr>
</tbody>
</table>

M, male; FO, fish oil; =, no effect on; IL-1ra, IL-1 receptor antagonist; F, female; EE, ethyl ester; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; |, decreased; sE-selectin, soluble E-selectin; |, increased; sP-selectin, soluble P-selectin; PAI-1, plasminogen activator inhibitor-1; CRP, C-reactive protein; stNF-κB, soluble TNF receptor; SAA, serum amyloid A.

Iron supplementation is complex. Part of the complexity is related to the fact that dietary iron intake is associated with reduced low-grade inflammation.
that Fe status assessment is confounded in the presence of inflammation (690–692). Fe status assessment relies on a battery of laboratory tests spanning various stages of Fe deficiency. These tests include: serum ferritin, which generally indicates body Fe stores; soluble receptor of transferrin in serum (transferrin receptor) reflecting tissue Fe; serum transferrin, total Fe-binding capacity and transferrin saturation, which indicate Fe-deficient erythropoiesis; finally, red cell indices namely mean cell volume, Hb and haematocrit, which are considered functional Fe indices. Others have suggested the ratio of transferrin receptor:serum ferritin as an index of total body Fe stores (693). Most tests of Fe status, however, are affected in response to subclinical inflammation and infections (690–692). Thus, it becomes difficult to study the relationship of Fe with any outcome of interest when inflammation is present. Recent studies have suggested that serum transferrin receptor remains unaffected in the presence of inflammation or infectious disease (reviewed in Ahluwalia (690)).

Deficiency v. excess. Fe has been called a double-edged sword, as both Fe deficiency and excess can have deleterious effects (693). Fe is important in immune/inflammatory responses including neutrophil activation, macrophage effector functions, and T-helper cell type-1 and -2 (Th1/Th2) responses including neutrophil activation, macrophage effector functions, and T-helper cell type-1 and -2 (Th1/Th2) component.

Iron status and low-grade inflammation. There is some epidemiological evidence that higher Fe intake, particularly that of haem Fe, and higher Fe status are associated with increased risk of type 2 diabetes, atherosclerosis and CHD (702–714), although not all of the literature is consistent. It is not clear whether the association of Fe intake and status with diabetes or CVD is mediated through the effects of Fe on inflammatory pathways. In a small study with thirty-one carbohydrate-intolerant patients, quantitative phlebotomy was used to induce Fe depletion to near-deficiency levels (715). The induced Fe deficiency was associated with reductions in several CVD risk factors as well as in the inflammatory marker fibrinogen. While uncertainty exists as to whether Fe plays a causative role in the aetiology of low-grade inflammation and its associated pathologies, past and emerging evidence indicates that chronic low-grade inflammation is associated with poor Fe status in obese persons (716–721). A concomitant improvement in Fe status (as measured by transferrin saturation) and decrease in inflammation (CRP and orosomucoid concentrations) has been observed after bariatric surgery intervention in morbidly obese women (722). In total, emerging evidence indicates that the low-grade inflammation of obesity may be associated with low Fe status; however, further investigation of this relationship is warranted.

A small number of studies have investigated the effects of increasing total Fe or haem Fe intake on markers of inflammation (723–725). In a small study involving three healthy volunteers who received 120 mg Fe/d for a week, there were no changes in circulating CRP concentration or leucocyte counts, or in urinary neopterin concentration (725). Furthermore, postpartum Fe supplementation (80 mg/d) for 12 weeks in non-anaemic Fe-deficient women did not significantly alter CRP concentration or leucocyte counts (726). In a small study in 8–11-year-old Guatemalan children who received twice the recommended daily amounts of Fe for 8 weeks (n 20) or placebo (n 20), no differences in CRP or orosomucoid concentrations were noted, although α-1 antichymotrypsin levels were increased with the Fe supplement (724). In another study examining the effect of increasing lean red meat intake, participants were either
assigned to a control group (maintain their usual diet) or to partially replace energy from carbohydrate-rich foods with 200 g/d of lean red meat for 8 weeks. In this short intervention, increased red meat intake was not associated with increased oxidative stress or inflammation. Taken together, the evidence from these limited studies examining the effect of Fe supplementation or increased red meat intake on inflammatory markers suggests no major effect on inflammation; however, there is a need for further larger well-designed studies to clarify this effect.

Vitamin D

Various immune cells including monocytes/macrophages, dendritic cells, T-cells and B-cells can convert inactive vitamin D$_3$ to its active form (1,25(OH)$_2$D$_3$), and these cells can also respond to the active vitamin D via its receptor which they express. It seems likely that vitamin D plays a paracrine modulatory role in the immune/inflammatory system. Although a pro-inflammatory role of vitamin D has also been suggested, epidemiological data show an association between vitamin D deficiency and increased risk of several inflammatory diseases including type 1 diabetes and atherosclerosis. Vitamin D has several anti-inflammatory actions. It blunts the pro-inflammatory effects of AGE on endothelial cells, suggesting that it acts as an endogenous vascular protector counteracting the possible deleterious effects of AGE. Vitamin D inhibits the proliferation of lymphocytes and induces their apoptosis. In addition, vitamin D affects the expression of ICAM-1 on mononuclear cells and on endothelial cells, suggesting that it suppresses the recruitment of leucocytes to sites of inflammation. In vitro, vitamin D modulates the pro-inflammatory profile of monocytes/macrophages from type 2 diabetic patients. Vitamin D also suppresses TNF-α expression in monocytes/macrophages and down-regulates the expression of TLR2 and TLR4 in human monocytes. Indeed, vitamin D primes monocytes to respond less effectively to bacterial cell wall components, most probably due to the aforementioned suppression of TLR. Vitamin D analogues selectively inhibit the inducible cyclooxygenase-2, which could be viewed as an anti-inflammatory action. Exposure to vitamin D increases the rate of the de-phosphorylation of activated extracellular signal-regulated kinases, a subset of the mammalian MAPK family involved in inflammatory processes. Serum vitamin D concentration was associated with leucocyte telomere length in 2160 women aged 18–79 years (mean age 49 years) and was inversely associated with CRP concentrations but was inversely correlated with leptin concentration. Among 261 healthy men and women, plasma 25(OH)D$_3$ was not correlated with adiponectin or IL-18 concentrations but was inversely correlated with leptin concentration. Among forty-four morbidly obese subjects, 25(OH)D$_3$ did not correlate with leptin, resistin, adiponectin or IL-18. Jablonski et al. examined the inflammatory phenotype of endothelial cells collected from the antecubital vein of middle-aged and older subjects: endothelial cell expression of NF-κB and of IL-6 were both higher in vitamin D-deficient subjects, and IL-6 expression was inversely related to serum 25(OH)D$_3$ concentration. Using data pooled from thirty-six healthy subjects, twenty-four type 1 diabetics and twenty-six type 1 diabetics with microvascular complications, Devraj et al. found significant inverse relationships between serum 25(OH)D$_3$ and CRP concentration, monocyte NF-κB activation and TLR4 expression. Most recently, NHANES data for 5867 adolescents aged 12–19 years showed no relationship between serum 25(OH)D$_3$ and CRP concentrations.

Thus, association studies have consistently found little, if any, association between vitamin D status and circulating markers of inflammation. However, two studies that investigated cellular markers of inflammation both reported an anti-inflammatory effect of vitamin D.

Most intervention studies with vitamin D have failed to identify a reduction in markers of low-grade inflammation. These studies each had a different design. Pittas et al. provided 700IU (17.5 μg) vitamin D$_3$ plus 500mg calcium citrate daily to adult non-diabetics for 3 years in a double-blind, randomised, controlled trial and found no effect on plasma CRP or IL-6. Witham et al. provided 10000IU (2500 μg) vitamin D$_2$ or placebo to elderly patients with systolic heart failure at study entry (week 0) and after 10 weeks and found no effect on plasma TNF-α at 10 or 20 weeks. Jorde et al. provided 40 000 or 20 000IU (1000 or 500 μg) vitamin D$_3$ per week or placebo to overweight subjects for 1 year; there was no difference between groups in the changes in concentrations of CRP, sICAM-1, MCP-1, IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13 or IL-17 over the course of the study. Thus, these intervention studies suggest little anti-inflammatory action of vitamin D in the sorts of subjects studied. However, compared with placebo, vitamin D (3300IU (82.5 μg)/d for 12 months) resulted in a decrease (by 10%) in TNF-α concentration in overweight subjects on a weight-reduction programme. This finding suggests that vitamin D dose, the nature of the supplementation regimen and the health status of the individuals under study, as well as starting vitamin D status, may all be important factors in determining the effect of supplemental vitamin D.
Antioxidant vitamins (vitamin C, vitamin E and carotenoids)

Vitamin C is a potent water-soluble antioxidant. Ascorbate is the active form of vitamin C and exerts antioxidant function. Upon its action as an antioxidant, ascorbate is oxidised to dehydroascorbate which can be reduced back to ascorbate by the oxidation of reduced glutathione to glutathione disulfide. Ascorbate is present at high concentrations in leucocytes, suggesting a significant role in inflammation and in protection against oxidative damage. Patients with the metabolic syndrome or diabetes showed decreased vitamin C status and increased lipid peroxidation. These findings could be explained by increased oxidative stress as a result of diabetes leading to consumption of ascorbate or a role of low vitamin C status as a risk factor for the development of diabetes. Obese subjects have lower plasma vitamin C concentrations than non-obese, and obesity was associated with moderately elevated CRP concentrations. In another study, low plasma vitamin C concentrations were related to central fat distribution, independent of BMI.

Vitamin E is an umbrella term for a number of tocopherols and tocotrienols, although dietary vitamin E mainly consists of α- and γ-tocopherols. Vitamin E is a potent chain-breaking antioxidant that acts mainly in the lipid phase and interrupts the chain reaction of lipid peroxidation and, consequently, prevents the propagation of free radical-initiated reactions. There are differences in the antioxidant activity between α- and γ-tocopherols. In vitro, vitamin E exerts a range of anti-inflammatory actions with regard to the production of pro-inflammatory cytokines and eicosanoids and adhesive interactions of monocytes with endothelial cells. There is growing evidence that γ-tocopherol, in contrast to α-tocopherol, exerts anti-inflammatory properties which can be explained by an unsubstituted position on the chromanol ring providing γ-tocopherol with the ability to trap reactive N species and subsequent formation of 5-nitro-pherol. Supplementation with α-tocopherol decreases γ-tocopherol concentrations due to a preference of the α-tocopherol transfer protein in the liver for α-tocopherol. This results in increased metabolism to carboxyethyl-hydroxychroman derivatives and excretion of the metabolites in the urine. γ-Tocopherol and γ-carboxyethyl-hydroxychroman exert actions that are not shared by α-tocopherol and α-carboxyethyl-hydroxychroman.

Carotenoids include, among others, α-carotene, β-carotene, lycopene, β-cryptoxanthin, lutein and zeaxanthin. They are highly prevalent in red, yellow and green vegetables and fruits. Carotenoids exert antioxidant properties and some of them serve as provitamin A. Among 3258 healthy men (age 68 (SD 5) years; BMI 26·7 (SD 3·6) kg/m²), dietary intakes of vitamin C, vitamin E and β-carotene did not correlate significantly with plasma CRP concentrations. Among 704 70-year-old Swedish men, dietary intakes of vitamin C and β-carotene, but not lycopene, were inversely correlated with plasma CRP concentrations. Among 379 Japanese subjects, serum β-carotene concentrations were inversely associated with adiponectin concentrations. Other associations among α- and β-carotene and CRP and IL-6 concentrations were lost after adjustment for confounding factors. A larger Japanese study (n 778 men and 1404 women) reported an inverse association between serum vitamin C and CRP concentrations after adjustment for confounders. The association was strongest in non-smokers, in non-overweight women and in postmenopausal women. Recently, plasma vitamin C concentrations have been reported to be inversely associated with plasma CRP concentrations in a small number of lean and obese men (n 8 per group) with a mean age of 21 years. Plasma concentrations of β-carotene, but not lycopene, were inversely correlated with plasma CRP concentrations in 704 70-year-old Swedish men, dietary intakes of vitamin C and β-carotene, but not of β-carotene, were inversely associated with CRP and IL-6 concentrations measured 7 years after the dietary information was collected. Thus, overall, cross-sectional and prospective studies fairly consistently demonstrate that a higher intake and status of vitamin C, vitamin E and carotenoids is associated with lower levels of low-grade inflammation.

Taking 1 g of vitamin C or 533 mg of α-tocopherol before consuming a high-fat test meal blunted the acute CRP response to the meal. Plasma 8-iso PGF2α and MCP-1 concentrations decreased after consumption of 72 mg/d of vitamin C from a vegetable soup, concentrations of TNF-α, IL-1β and IL-6 did not change. Vitamin C (1 g/d for
14 d) did not alter sICAM-1 concentrations or markers of monocyte and neutrophil activation (neopterin and elastase, respectively) in smokers or non-smokers (n 20 of each)\(^{782}\). Likewise, vitamin C supplements (250 mg three times per week for 2 months) did not alter plasma CRP concentrations in thirty-three chronic haemodialysis patients\(^{783}\). Tomato juice (delivering 20·6 mg lycopene/d) was compared with tomato juice fortified with vitamin C (delivering 435 mg vitamin C/d) over a 2-week intervention period: the vitamin C-enriched juice did not affect plasma CRP, TNF-α or IL-1β concentrations in healthy volunteers\(^{784}\). Vitamin C (1 g/d for 6 months) lowered sP-selectin, but not sVCAM-1, sICAM-1 or sE-selectin concentrations in patients with chronic degenerative aortic stenosis\(^{785}\); combining vitamin C with α-tocopherol (267 mg/d) lowered sICAM-1 concentrations. Smokers given 515 mg vitamin C/d for 2 months had a 24% reduction in plasma CRP concentrations\(^{786}\). A mixture of vitamin C with α-tocopherol (371 mg/d), γ-tocopherol (171 mg/d), mixed tocotrienols (252 mg/d) and α-lipoic acid (95 mg/d) resulted in a smaller effect (4·7% reduction that was not significant), suggesting that tocotrienols, tocopherols or α-lipoic acid, or the combination, prevents the anti-inflammatory effect of vitamin C. Vitamin C (2 g/d for 4 weeks) did not affect serum IL-6, IL-1β, sVCAM-1 or sICAM-1 concentrations in smokers, but combining 533 mg/d α-tocopherol with the vitamin C decreased the concentrations of all four inflammatory mediators; the combination of vitamin C and 267 mg/d α-tocopherol was without effect\(^{787}\).

α-Tocopherol (800 mg/d for 3 months) decreased plasma CRP concentrations in type 2 diabetics\(^{788}\). Dalgaard et al.\(^{789}\) examined the effect of a 28 d intervention with orange and blackcurrant juice (500 ml/d), vitamin E (15 mg RRR-α-tocopherol/d) or the combination of the two in patients with peripheral vascular disease. The juice but not vitamin E decreased CRP (by 11%) and fibrinogen, but there was no effect on IL-6 or PAI-1. In a randomised, placebo-controlled, double-blind trial, subjects with the metabolic syndrome received 800 mg/d α-tocopherol, 800 mg/d γ-tocopherol, a combination of both (800 mg/d each) or placebo; there was a decrease in CRP concentrations only in the combined α- and γ-tocopherol supplementation group, while TNF-α decreased with α-tocopherol alone or in combination with γ-tocopherol\(^{790}\). Biomarkers of oxidative stress decreased with α-tocopherol, γ-tocopherol or the combination, while nitrotyrosine, a biomarker of nitrative stress, decreased with γ-tocopherol alone or in combination with α-tocopherol\(^{646-648}\). In another randomised, placebo-controlled, double-blind trial, overweight and obese and normal-weight young adults completed a standardised 30 min cycle exercise bout before and after 8 weeks of supplementation with 800 IU/d of vitamin E (form not stated), 500 mg/d of vitamin C and 10 mg/d of β-carotene\(^{791}\). Adiponectin concentrations were increased by 22% in the overweight and by 3% in the normal-weight group receiving the supplement, but was reduced in the placebo group. Changes in circulating IL-6 concentrations during exercise were lower in the supplemented groups, as were the changes in lipid hydroperoxides\(^{791}\). In contrast, a double-blind, placebo-controlled trial, in which type 2 diabetics received 500 mg/d α-tocopherol or mixed tocopherols containing 315 mg/d γ-tocopherol, reported no effect on CRP, IL-6, TNF-α or MCP-1 concentrations, although there was a decrease in plasma F2-isoprostane concentrations, a biomarker of lipid peroxidation, in the mixed tocopherol group\(^{792}\). A small study conducted in healthy subjects (n 12) and patients with CHD (n 12) investigated the effect of increasing intake of α-tocopherol (100, 200 and 400 mg/d each for 3 weeks sequentially)\(^{793}\). At 200 mg/d, plasma CRP, IL-6 and fibrinogen concentrations were decreased in the CHD patients. A long-term (3 years) intervention with the combination of vitamin C (500 mg/d) and α-tocopherol (182 mg/d) in 45–69-year-old men did not alter CRP, TNF-α or IL-6 concentrations\(^{794}\). In one study, fifteen children with familial hyperlipidaemia given vitamins C plus E (500 mg/d and 400 IU/d, respectively) for 6 weeks showed no changes in CRP concentration\(^{795}\). In another study, six weeks’ supplementation with vitamin C (1 g/d) plus vitamin E (300 mg/d RRR-α-tocopherol) did not alter the magnitude of the increase in circulating CRP, TNF-α and IL-6 concentrations seen after running a marathon\(^{796}\). Older men given 1 g/d of vitamin C plus 1000 mg/d vitamin E for 4 weeks showed a decrease in plasma TNF-α concentrations\(^{797}\). Recently, a mixture of fruit-derived antioxidants has been found not to alter CRP or IL-6 concentrations over 12 weeks in type 2 diabetics\(^{798}\). In an intervention study with carotenoid-rich vegetables and fruits, plasma concentrations of α- and β-carotene, but not other carotenoids, were inversely associated with plasma CRP concentrations in healthy normal-weight men\(^{345}\). Lycopene (80 mg/d for 1 week) did not affect plasma CRP, sVCAM-1 or sICAM-1 concentrations in men and women with a mean age of 23 years\(^{799}\).

Thus, in contrast to observational studies that provide a fairly consistent picture of an anti-inflammatory effect of vitamin C, vitamin E and carotenoids, intervention studies using supplements of these antioxidant vitamins either alone or in various combinations provide a less consistent set of observations. A number of studies do demonstrate a reduction in the concentrations of circulating inflammatory markers in a variety of subgroups of individuals, including the overweight persons and diabetics, but quite a number of studies did not find an effect. The lack of consistency may be related to differences in: dose of antioxidant used (however, typically the doses used are much greater than those that can be readily achieved in the diet and are therefore much greater than would have been present in the diets of subjects investigated in the observational studies); duration of treatment (typically a few weeks to a few months); sample size which has often been small; characteristics of the populations studied (e.g. age, healthy v. diseased, type of disease, smokers v. non-smokers); background diet; interactions among the different antioxidant vitamins used, since they may have different anti-inflammatory potencies and some may even act in a pro-inflammatory way under certain conditions; degree of oxidative stress present. One other factor that has recently been identified is genetic differences among individuals, which may have an impact on the ability of antioxidants to exert an anti-inflammatory effect. Such an effect has been
identified by Belisle et al.\(^{(803)}\) who showed that the ability of α-tocopherol to lower the LPS-stimulated production of TNF-α by whole blood was determined in part by polymorphisms within the TNF-α gene. Thus, it is possible that a greater or lesser anti-inflammatory effect of antioxidant vitamins will be observed in people with different genotypes related to inflammatory processes. Clearly, this needs greater exploration in properly designed studies.

**Flavonoids**

Polyphenols are secondary metabolites of plants involved in pigmentation, reproduction and protection against pathogens. There are more than 8000 known polyphenolic substances sharing a common chemical structure (hydroxyl group on an aromatic ring) with different constituents. Flavonoids are the most abundant polyphenols present in the human diet, and they can be divided into several classes according to different constituents such as flavanones, flavones, flavanols and flavonoids. They can be found in almost all plant foods and, among the flavonols, myricetin, kaempferol and quercetin are the most representative, while catechins are the most abundant flavonols contained in tea leaves. Flavanones are mainly represented in the diet by taxifolin, naringinin and hesperetin. The main sources of flavanones are citrus fruits. Flavones are less common. In addition to these, other classes of flavonoids are present in the diet such as proanthocyanidins and their oligomers.

The intake of flavonoids and flavones was not correlated with plasma concentrations of CRP or IL-6 in healthy women (BMI 25.8–26.2 kg/m²)\(^{(801)}\). While this study used a rather limited flavonoid database, a more recent cross-sectional study applying a comprehensive flavonoid database reported anti-inflammatory effects associated with a high flavonoid intake: total flavonoid, flavonol and anthocyanidin intakes were inversely associated with plasma CRP concentrations\(^{(525)}\). Data from the Nurses’ Health Study were used to assess the relationship between flavonoid intake and biomarkers of inflammation\(^{(802)}\): intake of six flavonoid subclasses (flavonols, flavones, flavanones, flavan-3-ols, anthocyanidins and polymeric flavonoids) was assessed using a FFQ administered in 1990 and blood samples collected in 1989–90 were used to measure concentrations of CRP, IL-6, IL-18, sTNFR2, sVCAM-1 and sE-selectin. Multivariate-adjusted mean plasma IL-18 concentrations were lower (by 9, 11 and 8%, respectively) for women in the highest intake quintile of flavonones, flavanones and total flavonoids compared with those in the lowest quintiles. Multivariate-adjusted geometric plasma sVCAM-1 concentrations were lower by 4% in women in the highest intake quintile of flavonol compared with those in the lowest quintile. Thus, the study suggests that higher intakes of selected flavonoid subclasses are associated with modestly lower concentrations of some inflammatory biomarkers.

In a randomised human intervention trial with healthy normal-weight adults, supplementation with a bilberry extract providing 300 mg anthocyanins/d (equal to 100 g of fresh bilberries) reduced plasma concentrations of several NF-κB-induced pro-inflammatory cytokines (IL-8, RANTES and IFN-α)\(^{(537)}\). In addition, NF-κB-inducing cytokines (IL-4 and IL-13) tended to differ from controls, while plasma CRP concentrations did not change\(^{(537)}\). In subjects who had survived myocardial infarction and had received statin therapy for at least 6 months, supplementation with a chokeberry flavonoid extract for 6 weeks significantly decreased CRP and MCP-1 concentrations, while adiponectin was significantly increased\(^{(803)}\). In contrast, although the consumption of black tea resulted in increased plasma catechin concentrations, these were not associated with changes in plasma CRP concentrations in healthy overweight and obese adults\(^{(805)}\). A similar negative effect on CRP was observed in a double-blind, placebo-controlled, cross-over study with healthy adults (mean BMI 25.8 kg/m²) who were supplemented with a sea buckthorn flavonol extract during 4 weeks\(^{(804)}\). Quercetin (50, 100 or 150 mg/d for 2 weeks) did not affect serum concentrations of TNF-α in healthy adults\(^{(805)}\). Overweight or obese subjects aged 25–65 years with metabolic syndrome traits received 150 mg quercetin/d in a double-blind, placebo-controlled, cross-over trial with 6-week treatment periods separated by a 5-week washout period: quercetin did not affect CRP or TNF-α concentrations compared with placebo\(^{(806)}\). Quercetin (1 g/d for 21 d) failed to attenuate muscle inflammation in ultramarathon runners\(^{(807)}\) and in trained cyclists\(^{(808,809)}\). However, leucocyte IL-8 and IL-10 mRNA were significantly reduced, indicating that a high dose of quercetin may target blood cells but not the muscle tissue.

**Phyto-oestrogens**

Genistein is an isoflavone and a phyto-oestrogen which primarily occurs in soyabees. Native phyto-oestrogens exist as glycosides, while in experimental studies, mostly the aglycones have been used. In two intervention studies with healthy postmenopausal women, the intake of genistein (54 or 40 mg/d) for 6 months did not significantly affect plasma CRP concentrations\(^{(810,811)}\). The intake of soya either high or low in isoflavones for 1, 2 or 4 months had also no effect on CRP, SAA or TNF-α concentrations in hypercholesterolaemic men or in postmenopausal women\(^{(556,559,562)}\). In obese postmenopausal women, the combination of exercise with a soya isoflavone supplement (duration 6 months) did not decrease plasma CRP concentration compared with exercise + placebo\(^{(812)}\). Consumption of a soya isoflavone-enriched cereal bar (50 mg/d) for 8 weeks by postmenopausal women had no effect on CRP or other plasma markers of inflammation\(^{(813)}\). A higher intake of soya isoflavones (114 mg/d) for 3 months also did not reduce serum CRP or sE-selectin concentrations in postmenopausal women\(^{(814)}\). In another study, isoflavone-rich soya (107 mg/d as aglycone; 50% as genistein) for 6 weeks did not affect sVCAM-1, sICAM-1 or sE-selectin concentrations in healthy postmenopausal women compared with isoflavone-poor soya\(^{(815)}\). In contrast, a randomised, controlled study providing pasta naturally enriched with isoflavone aglycones (35 mg/d) to overweight hypercholesterolaemic subjects reported significantly
reduced plasma CRP concentrations, which returned to baseline when subjects were switched to conventional pasta\(^{816}\). Overall, the majority of the studies with soy-derived isolavones did not observe a significant effect on inflammatory processes in human subjects. In contrast, a lignan complex (500 mg/d) isolated from flax given to healthy postmenopausal women significantly reduced plasma CRP concentration during the 6-week placebo-controlled intervention. No significant differences were found for IL-6, TNF-α, sICAM-1, sVCAM-1 or MCP-1 concentrations\(^{817}\). A recent study, flaxseed-derived lignans (360 mg/d) lowered CRP concentrations in type 2 diabetic women but not in men over 12 weeks compared with placebo, with no effect on IL-6 concentrations\(^{818}\). A cross-sectional study in 242 men and postmenopausal women in Northern Italy revealed inverse associations between dietary intake of the lignans matairesinol and secoisolariciresinol and plasma concentrations of sICAM-1\(^{819}\).

### Other factors

**Gut microbiota and probiotics**

Probiotics are ‘live micro-organisms which, when consumed in adequate quantities, confer a health benefit on the host’\(^{820,821}\). One differential characteristic of probiotics compared with other micro-organisms is their ability to survive during gastrointestinal transit\(^{822}\). This allows them to interact with commensal microbiota and/or intestinal epithelial cells and also with gut-associated lymphoid cells, which results in the induction or modulation of a number of biological activities that can provide beneficial effects for health. The capacity of probiotics to modulate the mucosal immune system is regarded as one of the most obvious beneficial properties. The microbiota composition and the related local intestinal metabolism undergoes significant changes in various disease states that are characterised by chronic inflammation, such as inflammatory bowel disease\(^{823}\), colorectal cancer and obesity\(^{824,825}\). Mice raised under germ-free conditions fail to develop experimental colitis, suggesting an important modulating role of intestinal microbiota on local inflammatory processes\(^{826}\). Thus, there seems to be a strong association between the nature of the gut microbiota and inflammation.

A number of studies have investigated the effects of various probiotics on aspects of inflammation in a variety of subject and patient groups, as reviewed elsewhere\(^{827}\). However, relatively few studies have focused on circulating markers of inflammation in persons without an established inflammatory disease. In a small study in institutionalised elderly subjects (mean age 76 years), there was no effect of the combination of *Bifidobacterium longum* and *Lactobacillus acidophilus* (8 × 10\(^{10}\) colony forming units (CFU) of each/d for 28 d) on serum TNF-α concentration\(^{828}\). *L. salivarius* UCC118 (10\(^{10}\) CFU/d for 21 d) did not affect serum IL-1α, IL-1β, IL-4, IL-6R, TNF-α or IFN-γ concentrations in healthy adults aged 20–65 years\(^{829}\). Likewise, the combination of *L. gasseri* CECT5714 and *L. coryniformis* CECT5711 (2 × 10\(^{10}\) CFU of each/d) with *Staphylococcus thermophilus* (10\(^{6}\) CFU/d) for 2 or 4 weeks had no effect on serum TNF-α or IL-12 concentrations in healthy adults aged 23–43 years\(^{830,831}\). Kekkonen *et al.*\(^{832}\) compared *L. rhamnosus* GG ATCC53103 (1 × 10\(^{10}\) CFU/d) with *Bifidobacterium animalis* ssp. lactis Bb12 (3.5 × 10\(^{10}\) CFU/d) and *Propionibacterium freudenreichii* ssp. Sherman JS (3.3 × 10\(^{10}\) CFU/d) for 3 weeks in healthy subjects with a mean age of 44 years (range 23–58 years). There was no effect of serum TNF-α, IL-6, IL-10 or IFN-γ concentrations, but serum CRP concentration decreased in the *L. rhamnosus* group. Ouwehand *et al.*\(^{833}\) conducted a 6-month placebo-controlled trial with *B. animalis* ssp. lactis Bb12 (10\(^9\) CFU/d) or the combination of *B. longum* 2C and *B. longum* 46 (10\(^9\) CFU of each/d) in institutionalised elderly subjects (mean age 84 years). Although there were some changes over time, the groups did not differ in serum TNF-α, IL-10 or TGF-β concentrations. Thus, although there is the potential for probiotics to lower markers of chronic low-grade inflammation, intervention studies performed to date in human volunteers rarely demonstrate this effect.

### Prebiotics

There are two recent definitions of prebiotics: ‘a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora that confers benefits upon host well-being and health’\(^{834}\), and ‘a non-viable food component that confers a health benefit on the host associated with modulation of the microbiota’\(^{835}\). Typically, though not exclusively, prebiotics are carbohydrates including inulin-type fructans (including oligofructose, fructo-oligosaccharides), lactulose, galacto-oligosaccharides, xylo-oligosaccharides, d-tagatose, resistant starch, soyabean oligosaccharides, pectin, guar, carrageenan, konjac glucomannans, alginates and β-glucans from oat, barley and mushroom. Prebiotics escape digestion in the upper gastrointestinal tract and reach the large intestine virtually intact, where they are fermented by the microbiota and express their prebiotic activity\(^{836}\). The latter is most probably mediated through a quantitative increase in commensal bacteria (e.g. bifidobacteria and lactobacilli), which interact with other members of the gut microbiota. Further, changes in the microbiota enzyme activities, leading to a reduction of unfavourable substances that have an impact on disease risk, such as secondary bile acids, and the production of metabolites such as SCFA and vitamins also contribute to their impact on health and disease\(^{837}\). In high-fat-fed mice, oligofructose restored gut bifidobacteria, and normalised systemic endotoxin levels and the inflammatory state\(^{838}\). Institutionalised elderly individuals (mean age 85 years) supplemented with oligofructose (8 g/d for 3 weeks) showed increased faecal bifidobacteria counts and decreased expression of IL-6 mRNA in blood monocytes\(^{837}\). In another study, in poorly nourished elderly subjects (age >70 years), oligofructose (1.95–3.9 g/d for 12 weeks as part of a nutritional supplement) had no effect on plasma TNF-α or sIL-6R concentrations\(^{838}\). Prebiotics have been studied in the context of inflammatory conditions, especially those involving the gastrointestinal tract, as reviewed elsewhere\(^{839}\). There is
some evidence of beneficial effects but results are inconsistent. There are few studies of prebiotics and circulating inflammatory markers in the context of chronic low-grade inflammation. Thus, it is premature to draw conclusions about this relationship.

**Hydration**

When fluids are consumed, water distributes between intracellular and extracellular compartments according to osmotic load. When water enters the cells, they swell and when water is lost from the cells, for example, during dehydration, the cells will shrink. The maintenance of adequate cell volume can have a profound effect on protein function and cellular performance. Cells employ an array of mechanisms to maintain cell volume constancy, including altered transport across the cell membrane and metabolism. Hormones and mediators may modify the activity of these cell volume regulatory mechanisms and thus influence cell volume-sensitive functions. Cell volume regulatory mechanisms, therefore, participate in the signalling of those hormones and mediators. Many metabolic pathways are sensitive to cell volume, as a result of activation, inhibition or altered expression of enzymes. Cellular volume has the potential to have an impact directly or indirectly on inflammation, but the effect of hydration status on low-grade inflammation is not well documented.

**Summary, conclusions and research gaps**

Inflammation is part of the normal host defence mechanism against infections. However, inflammatory mediators and the inflammatory response can be damaging to the host if not regulated appropriately and numerous diseases and conditions have an overt chronic inflammatory basis. It is now recognised that a lower level of inflammation, here termed chronic low-grade inflammation, can also persist and may be a cause of, or result from, the obese state. Adipose tissue releases many of the characteristic mediators of inflammation including some of the classic pro-inflammatory cytokines and chemokines, as well as adiponectin which is considered to be anti-inflammatory. The source of these mediators within adipose tissue is not clear, but infiltrating macrophages seem to be especially important in this regard, although adipocytes themselves express some of the inflammatory mediators. Obese people have higher circulating concentrations of many inflammatory markers (measured in the ‘resting’ state, i.e. in fasted blood), and these are believed to play a role in causing insulin resistance and in other metabolic disturbances of the metabolic syndrome and type 2 diabetes. Blood concentrations of inflammatory markers are lowered following weight loss, whether this is induced by diet or surgery, which most probably reflects the decrease in adipose tissue mass. In the hours following the consumption of a meal, there is an elevation in the concentrations of several inflammatory mediators in the bloodstream. This postprandial inflammatory response is greater in obese subjects and type 2 diabetics. Both high-glucose and high-fat meals induce postprandial inflammation, and it is exaggerated by a high meal content of AGE and partly ablated by the inclusion of certain antioxidants or antioxidant-containing foods within the meal. These latter observations link postprandial inflammation to oxidative stress. Physical activity decreases low-grade inflammation. Exercise itself is associated with transient and local inflammation (e.g. in muscle) that may, in fact, be important in inducing a protective and ultimately healthy anti-inflammatory response. In addition to the direct effect of foods and their constituents on postprandial inflammation, diet has an impact on chronic low-grade inflammation, manifested as the basal (i.e. fasting state) concentrations of inflammatory markers in the bloodstream, including cytokines, chemokines, acute-phase proteins, soluble adhesion molecules and cytokine receptors, etc. Effects of diet and dietary components on low-grade inflammation have been identified through cross-sectional, prospective and intervention studies. The former two study designs frequently involve large numbers of subjects, while the intervention studies often have a small sample size and a limited duration which might limit their ability to identify effects; compliance may also be a limitation of intervention studies. Healthy eating patterns such as the Mediterranean diet, vegetarian diets and adherence to the Food Guide Pyramid are associated with lower concentrations of inflammatory markers; this is observed mainly from cross-sectional and prospective studies, although intervention studies with the Mediterranean diet have been positive. Among the components of healthy diets, whole grains, vegetables and fruits, and fish are all seen to be associated with lower inflammation. Strong evidence in favour of an anti-inflammatory effect of tea (black or green), coffee (caffeinated or decaffeinated) and cocoa is lacking, despite positive effects on oxidative stress and the anti-inflammatory effects, mainly demonstrated in model systems (e.g. cell cultures), of components of these foods. Alcohol appears to have a ‘U-shaped’ effect on low-grade inflammation, with the most protective action (i.e. the lowest inflammatory marker concentrations) corresponding to one or two alcoholic drinks per d. Heated meals high in AGE and ALE enhance oxidative stress and inflammation; intervention studies with low- and high-AGE meals either acutely or chronically have associated AGE with increased inflammatory marker concentrations and show that these are decreased by meals low in AGE. However, AGE and ALE are also generated in vivo and also as a result of other, non-food-related, environmental exposures (e.g. smoking), and so the overall impact of foods on the burden of AGE and ALE is not currently clear; this is compounded by technical difficulties in measuring these complex chemical entities in foods and in body fluids. Dietary fatty acids also influence low-grade inflammation; best studied are PUFA. Available data indicate that SFA and trans-MUFA are pro-inflammatory, and that one isomer of conjugated linoleic acid may also be. Relative to SFA, PUFA are anti-inflammatory. Marine n-3 PUFA have the greatest anti-inflammatory potential. Hyperglycaemia induces both postprandial and chronic low-grade inflammation, acting in part through oxidative stress. Dietary fibre decreases low-grade inflammation. There may also be a role for milk peptides, but these have not been sufficiently evaluated. Vitamin D has the potential to reduce low-grade
inflammation, with plausible mechanistic actions demonstrated in model systems. There is good evidence from both model systems and from human observational and intervention studies that vitamin C, vitamin E and carotenoids decrease the concentrations of inflammatory markers. α- and γ-Tocopherols and the different carotenoids may have different anti-inflammatory properties and potencies. The majority of available evidence indicates that soya phyto-oestrogens and soya protein do not affect low-grade inflammation. There are likely to be many plant-derived substances that influence low-grade inflammation and which may have a role as part of a healthy ‘anti-inflammatory diet’. Several studies of various probiotic bacteria have failed to demonstrate any consistent effects on markers of chronic low-grade inflammation, despite their apparent effectiveness in higher-grade inflammatory states. The effect of prebiotics on chronic low-grade inflammation is not clear and is underexplored.

The key conclusions are as follows:

(1) A state of chronic low-grade inflammation exists and this is exaggerated in obese and type 2 diabetic individuals.
(2) Adipose tissue plays a role in establishing the chronic low-grade inflammatory state because cells within that tissue can produce and release the mediators involved.
(3) Chronic low-grade inflammation is believed to increase the risk of insulin resistance, type 2 diabetes and CVD.
(4) Following consumption of a meal, there is a transient state of inflammation that is linked with oxidative stress.
(5) Hyperglycaemia or a high-fat meal promote postprandial inflammation.
(6) A healthy diet is associated with decreased low-grade inflammation.
(7) Important protective factors in the diet are whole grains, fibre, vegetables, fruits, fish, PUFA, especially marine n-3 PUFA, vitamin C, vitamin E and carotenoids.
(8) Plant-derived flavonoids are likely to be protective.
(9) Moderate alcohol consumption decreases low-grade inflammation.
(10) Dietary factors that promote inflammation are oxidised lipids, SPA and trans-fatty acids.
(11) Underexplored dietary factors include milk peptides, vitamin D, probiotics and prebiotics.

A number of important research gaps were identified. Perhaps the most important is that there is no consensus regarding the inflammatory mediators which best represent chronic low-grade inflammation. Most studies have measured CRP, perhaps because it is long established, is linked to the risk of CVD and is routinely measured in clinical laboratories. However, it is not clear whether CRP is a ‘better’ marker of low-grade inflammation than any of the other mediators measured, which include a variety of cytokines, soluble cytokine receptors, chemokines, soluble adhesion molecules and so on. Furthermore, there has been little emphasis on anti-inflammatory mediators. An expert review of the area of inflammatory markers addressing the most valid and robust markers and including a consideration of anti-inflammatory factors is warranted. Identification of dietary components that promote or prevent postprandial inflammation and the underlying mechanisms involved is a further gap. The impact of many dietary components on chronic low-grade inflammation is underexplored in human intervention studies; such components include flavonoids and other phytochemicals, milk peptides, vitamin D, probiotics and prebiotics. Further, even where dietary components have been fairly well explored through intervention studies, many of the studies have been small in size and they have reported on different inflammatory outcomes at different time points. For these components (whole grains, fibre, vegetables, fruits, fish, PUFA, especially marine n-3 PUFA, vitamin C, vitamin E and carotenoids), a better knowledge of the dose–response effect, the threshold dose (if any) and the time required for an effect to occur would all be valuable information. Such variations in study design may also explain the discordant findings of studies with tea, coffee and cocoa, and these dietary components require further investigation in the context of robust markers of inflammation, appropriate sample size and duration of exposure, and exploration of dose–response relationships. Oxidative stress and inflammation are strongly interlinked and effects of dietary components appear to frequently involve increased or decreased oxidative stress. In this regard, modified food components such as AGE and ALE may be very potent markers of oxidative and inflammatory stress, although their causal impact remains elusive. However, further exploration and greater understanding of this area is impeded by lack of agreed analytical methods for quantifying AGE in foods and in biological fluids, with inter-laboratory cross-validation, and by lack of discrimination between protein-bound and free AGE. Finally, the emerging area of the role of gene polymorphisms in influencing or even determining the effect of nutrients on markers of low-grade inflammation requires much greater exploration. Until these gaps are filled, our understanding of the interaction between diet and postprandial and chronic low-grade inflammation will remain incomplete.

Acknowledgements

This work was commissioned by the Metabolic Syndrome and Diabetes Task Force of the European Branch of the International Life Sciences Institute (ILSI Europe). Industry members of this task force are Ajinomoto Europe, Coca-Cola Europe, Danisco, Danone, Kellog Europe, Kraft Foods Europe and Schwabegroup. For further information about ILSI Europe, please email info@ilsieurope.be or call +32 2 771 00 14. The opinions expressed herein and the conclusions of this publication are those of the authors and do not necessarily represent the views of ILSI Europe nor those of its member companies. Conflict of interest statement: P. C. C. has research funding from Beneo-Orafi, Beghin-Meiji, Abbott Nutrition and Vifor Pharma and is a consultant to Danone. P. B. was an employee of Cargill. T. B. was and J. O. is an employee of Nestlé. K. C. is an employee of Coca-Cola Europe. L. S. J. is an employee of ILSI Europe. M. L. is an employee of Danone. N. M. is an employee of Kraft Foods Europe. H. N. is an employee of Ajinomoto Europe. P. C. C., N. A., F. B., K. Cl., K. E., H. K., As. M.,
Diet and low-grade chronic inflammation

An. M., G. P., S. R., C. S., J. T., J. W. and B. M. W-R received an honorarium from ILSI Europe for their participation in this publication and/or reimbursement of their travel and accommodation costs for attending the related meetings. The remaining authors have no conflicts of interest. All authors contributed to discussions and had input into writing the article. P. C. C. and L. S. J. had responsibility for producing the final version of the article.

References


Diet and low-grade chronic inflammation


Diet and low-grade chronic inflammation


363. Teede HJ, Dalais FS & McGrath BP (2004) Dietary soy containing phytoestrogens does not have detectable estrogenic


658. Heizmann CW (2007) The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: arguing against the notion. Mol Nutr Food Res 51, 1111–1115.
682. Finot PA, Bujard E, Mott F, et al. (1977) Availability of the true Schiff’s bases of lysine. Chemical evaluation of the


Diet and low-grade chronic inflammation


Diet and low-grade chronic inflammation


P. C. Calder et al.


gasseri CECT 5714 and Lactobacillus corynformis CECT 5711, boosts the immune system of healthy humans. *Int Microbiol* 9, 47–52.


